

Telaprevir for Previously Untreated Chronic Hepatitis C

New England Journal of Medicine

364, 2405-2416

DOI: [10.1056/nejmoa1012912](https://doi.org/10.1056/nejmoa1012912)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Dilantin in the treatment of lightning pains. <i>Neurology</i> , 1961, 11, 257-257. | 1.5 | 10 |
| 2 | Will direct-acting antivirals make a difference in HIV/HCV coinfecting patients?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 699-701. | 2.0 | 0 |
| 3 | Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428. | 13.9 | 1,466 |
| 4 | Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1009-1026. | 1.4 | 203 |
| 5 | A true revolution: Enhanced motivation of the patient with rapid loss of virus (or rapid negatvation) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 and <i>Gastroenterology</i> , 2011, 35, S43-S45. | 0.7 | 0 |
| 6 | Antiviral Activity of the new DAAs for the Treatment of Hepatitis C Virus Infection: Virology and Resistance. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S46-S51. | 0.7 | 9 |
| 7 | Direct-acting antiviral (DAA) actions in treatment-naïve patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S52-S58. | 0.7 | 2 |
| 8 | Management of treatment with direct-acting antiviral (DAA) in clinical practice. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S64-S68. | 0.7 | 0 |
| 9 | Management of side-effects. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S69-S74. | 0.7 | 8 |
| 10 | Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S75-S83. | 0.7 | 7 |
| 11 | Chronic hepatitis C: Treatments of the future. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S84-S95. | 0.7 | 20 |
| 12 | Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?. <i>Gastroenterology</i> , 2011, 141, 1963-1967. | 0.6 | 13 |
| 13 | Resistance to anti-HCV protease inhibitors. <i>Current Opinion in Virology</i> , 2011, 1, 599-606. | 2.6 | 36 |
| 14 | Antiviral drugs and antiviral drug resistance. <i>Current Opinion in Virology</i> , 2011, 1, 545-547. | 2.6 | 15 |
| 15 | Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2429-2438. | 13.9 | 403 |
| 16 | Telaprevir User's Guide. <i>Clinics in Liver Disease</i> , 2011, 15, 555-571. | 1.0 | 14 |
| 17 | Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 365, 1014-1024. | 13.9 | 716 |
| 18 | Hepatitis C therapy in 2011: is less more, is more less?. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 508-512. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon- α -2a in HIV/HCV-coinfected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 859-862. | 2.0 | 1 |
| 20 | Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. <i>Journal of Clinical Virology</i> , 2011, 52, 321-327. | 1.6 | 110 |
| 21 | A sprint to increase response to HCV treatment: Expectancies but caution. <i>Journal of Hepatology</i> , 2011, 55, 1154-1158. | 1.8 | 8 |
| 22 | Realize the advance in HCV treatment, but remain cautious. <i>Journal of Hepatology</i> , 2011, 55, 1457-1460. | 1.8 | 7 |
| 23 | What's fueling the biotech engine? 2010 to 2011. <i>Nature Biotechnology</i> , 2011, 29, 1083-1089. | 9.4 | 67 |
| 25 | Tratamiento de las hepatitis virales. <i>Medicine</i> , 2011, 10, 6249-6254. | 0.0 | 0 |
| 26 | Toll Like Receptors in Chronic Viral Hepatitis – Friend and Foe. , 2011, , . | | 0 |
| 27 | Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 685-694. | 2.2 | 31 |
| 28 | Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. <i>Patient Preference and Adherence</i> , 2011, 5, 587. | 0.8 | 5 |
| 29 | Directly acting antivirals for hepatitis C and antiretrovirals. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 514-526. | 1.5 | 35 |
| 30 | Future of hepatitis C therapy. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 508-513. | 1.5 | 28 |
| 31 | Diagnosis and Management of Hepatitis C Virus-infected Children. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 983-985. | 1.1 | 21 |
| 32 | Management of HCV and HIV infections among people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 501-507. | 1.5 | 68 |
| 33 | Industry Update: The latest developments in therapeutic delivery. <i>Therapeutic Delivery</i> , 2011, 2, 1527-1533. | 1.2 | 0 |
| 34 | Boceprevir in the treatment of hepatitis C infection: rationale and clinical data. <i>Clinical Investigation</i> , 2011, 1, 1717-1729. | 0.0 | 1 |
| 35 | Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011, 6, 1179-1186. | 0.9 | 2 |
| 36 | Impact of HCV Protease-Inhibitor-Based Triple Therapy for Chronic HCV Genotype 1 Infection. <i>Antiviral Therapy</i> , 2011, 16, 1187-1201. | 0.6 | 30 |
| 37 | Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial. <i>Antiviral Therapy</i> , 2011, 16, 1021-1033. | 0.6 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 38 | Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1348-1353. | 1.4 | 6 |
| 39 | Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 951-974. | 1.2 | 8 |
| 40 | Telaprevir: new specific protease inhibitor for chronic hepatitis C. <i>Future Prescriber</i> , 2011, 12, 19-23. | 0.1 | 0 |
| 41 | Hepatitis C virus and non-Hodgkin's lymphoma: biology, epidemiology and therapy. <i>Oncology Reviews</i> , 2011, 5, 249-260. | 0.8 | 2 |
| 42 | Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. <i>Nature Biotechnology</i> , 2011, 29, 993-1003. | 9.4 | 246 |
| 43 | Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3032-3037. | 1.1 | 3 |
| 45 | Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. <i>BMC Infectious Diseases</i> , 2011, 11, 315. | 1.3 | 18 |
| 46 | Mixed results from combination therapy. <i>Reviews in Medical Virology</i> , 2011, 21, 333-335. | 3.9 | 0 |
| 47 | An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2011, 54, 1433-1444. | 3.6 | 961 |
| 48 | Boceprevir (Victrelis) for HCV: V is for victory and very complex. <i>Hepatology</i> , 2011, 54, 1882-1886. | 3.6 | 5 |
| 49 | Drug therapy: Telaprevir. <i>Hepatology</i> , 2011, 54, 1463-1469. | 3.6 | 6 |
| 50 | Boceprevir. <i>Hepatology</i> , 2011, 54, 2254-2258. | 3.6 | 7 |
| 51 | Drugs in development for chronic hepatitis C: a promising future. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1611-1622. | 1.4 | 31 |
| 52 | The Impact of Human Gene Polymorphisms on HCV Infection and Disease Outcome. <i>Seminars in Liver Disease</i> , 2011, 31, 375-386. | 1.8 | 19 |
| 53 | The Conundrum of Relapse in STAT-C Therapy: Does HCV Play the Red Queen or Rip Van Winkle?. <i>Seminars in Liver Disease</i> , 2011, 31, 410-419. | 1.8 | 8 |
| 54 | The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?. <i>Seminars in Liver Disease</i> , 2011, 31, 399-409. | 1.8 | 30 |
| 55 | Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. <i>BMJ: British Medical Journal</i> , 2011, 343, d6972-d6972. | 2.4 | 10 |
| 56 | Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1111-1114. | 2.9 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 57 | Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4569-4574. | 1.4 | 63 |
| 58 | Challenges and opportunities for hepatitis C drug development in HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2011, 25, 2197-2208. | 1.0 | 33 |
| 59 | Telaprevir for the treatment of chronic hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1105-1114. | 2.0 | 12 |
| 60 | Assessments of intra- and inter-host diversity of hepatitis C virus using Next Generation Sequencing and Mass spectrometry. , 2011, , . | | 0 |
| 61 | Staging Liver Fibrosis in Hepatitis C: A Challenge for This Decade. <i>American Journal of Gastroenterology</i> , 2011, 106, 2121-2122. | 0.2 | 14 |
| 62 | It Is Time to Change the Paradigm for Hepatitis C Virus Testing. <i>Clinical Infectious Diseases</i> , 2012, 54, 1272-1274. | 2.9 | 6 |
| 63 | Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 370-8. | 3.8 | 180 |
| 64 | Telaprevir triple combination therapy, and dual peginterferon α -2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection. <i>Evidence-Based Medicine</i> , 2012, 17, 143-144. | 0.6 | 1 |
| 65 | Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9. | 3.3 | 20 |
| 66 | Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. <i>Hepatitis Monthly</i> , 2012, 12, 361-368. | 0.1 | 9 |
| 67 | Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. <i>PLoS Pathogens</i> , 2012, 8, e1002880. | 2.1 | 74 |
| 68 | Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2. | 3.3 | 4 |
| 70 | The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9. | 3.3 | 26 |
| 71 | Biochemical Study of the Comparative Inhibition of Hepatitis C Virus RNA Polymerase by VX-222 and Filibuvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 830-837. | 1.4 | 56 |
| 72 | Therapeutic Approach to the Treatment-Naive Patient With Hepatitis C Virus Genotype 1 Infection: A Step-by-Step Approach. <i>Clinical Infectious Diseases</i> , 2012, 55, 1236-1241. | 2.9 | 4 |
| 73 | Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 274. | 3.8 | 134 |
| 74 | Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5365-5373. | 1.4 | 117 |
| 75 | New Protease Inhibitors for the Treatment of Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2012, 156, 279. | 2.0 | 176 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 76 | HIV and viral hepatitis C coinfection in people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 339-344. | 1.5 | 20 |
| 77 | Hepatitis C therapy update. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 188-192. | 1.0 | 27 |
| 78 | Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 216-224. | 0.8 | 23 |
| 79 | Performance of the Abbott RealTime HCV Genotype II RUO Assay. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3099-3101. | 1.8 | 16 |
| 80 | The Liver Partition Coefficient-Corrected Inhibitory Quotient and the Pharmacokinetic-Pharmacodynamic Relationship of Directly Acting Anti-Hepatitis C Virus Agents in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5381-5386. | 1.4 | 20 |
| 81 | Interferon Responsiveness Does Not Change in Treatment-Experienced Hepatitis C Subjects: Implications for Drug Development and Clinical Decisions. <i>Clinical Infectious Diseases</i> , 2012, 55, 639-644. | 2.9 | 8 |
| 82 | Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 139-151. | 1.4 | 28 |
| 83 | Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5494-5502. | 1.4 | 27 |
| 84 | Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naïve Infected Individuals. <i>Journal of Clinical Microbiology</i> , 2012, 50, 281-287. | 1.8 | 48 |
| 86 | <i>In Vitro</i> Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 569-572. | 1.4 | 45 |
| 87 | Telaprevir for the treatment of hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 593-606. | 0.9 | 18 |
| 88 | A Watershed Moment in the Treatment of Hepatitis C. <i>New England Journal of Medicine</i> , 2012, 366, 273-275. | 13.9 | 51 |
| 89 | Therapeutic vaccination to treat chronic infectious diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1746-1757. | 1.4 | 26 |
| 90 | Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 2062-2065. | 0.5 | 6 |
| 91 | New challenges in viral hepatitis. <i>Gut</i> , 2012, 61, i1-i5. | 6.1 | 24 |
| 92 | Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 269-279. | 2.0 | 6 |
| 93 | Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 335-343. | 0.7 | 32 |
| 94 | Drug resistance testing in hepatitis C therapy. <i>Future Virology</i> , 2012, 7, 309-321. | 0.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 95 | Genomic variation-guided management in chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 497-506. | 1.4 | 9 |
| 96 | Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 1025-1031. | 2.2 | 26 |
| 97 | Evaluation of Phosphatidylinositol-4-Kinase III β as a Hepatitis C Virus Drug Target. <i>Journal of Virology</i> , 2012, 86, 11595-11607. | 1.5 | 53 |
| 98 | Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19757-19762. | 3.3 | 109 |
| 99 | New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye: <i>Tablet Gut</i> , 2012, 61, 1647-1652. | 6.1 | 23 |
| 100 | Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 271-279. | 1.4 | 37 |
| 101 | Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1115-1119. | 0.6 | 3 |
| 102 | Vitamins? The magic bullet against hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1273-1277. | 2.0 | 2 |
| 103 | Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 259-261. | 1.4 | 0 |
| 104 | Significant publications on infectious diseases pharmacotherapy in 2011. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1671-1681. | 0.5 | 11 |
| 106 | Anti-Hepatitis C Virus Activity and Toxicity of Type III Phosphatidylinositol-4-Kinase Beta Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5149-5156. | 1.4 | 61 |
| 107 | The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors. <i>PLoS Pathogens</i> , 2012, 8, e1002832. | 2.1 | 179 |
| 108 | SASLT practice guidelines: Management of hepatitis C virus infection. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 1. | 0.5 | 8 |
| 109 | Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. <i>Biologics: Targets and Therapy</i> , 2012, 6, 363. | 3.0 | 1 |
| 110 | Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-21. | 2.0 | 4 |
| 111 | Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 454-467. | 0.9 | 14 |
| 112 | Host Factors in Viral Life Cycles. <i>Mathematical Modelling of Natural Phenomena</i> , 2012, 7, 123-132. | 0.9 | 3 |
| 113 | Management of chronic hepatitis C infection in children. <i>Current Opinion in Pediatrics</i> , 2012, 24, 113-120. | 1.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 114 | Centers for Disease Control and Prevention Initiatives to Prevent Hepatitis C Virus Infection: A Selective Update. <i>Clinical Infectious Diseases</i> , 2012, 55, S49-S53. | 2.9 | 38 |
| 115 | Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2012, 54, 979-983. | 2.9 | 27 |
| 116 | Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2584. | 3.8 | 1,327 |
| 117 | HIV protease inhibitors in combination with boceprevir. <i>Aids</i> , 2012, 26, 1845-1846. | 1.0 | 5 |
| 118 | Limitations of proposed novel trial design. <i>Aids</i> , 2012, 26, 1846-1847. | 1.0 | 1 |
| 119 | A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study. <i>HIV Clinical Trials</i> , 2012, 13, 179-188. | 2.0 | 4 |
| 120 | New Antiviral Therapies in the Management of HCV Infection. <i>Antiviral Therapy</i> , 2012, 17, 771-783. | 0.6 | 24 |
| 122 | Telaprevir: Pharmacokinetics and Drug Interactions. <i>Antiviral Therapy</i> , 2012, 17, 1211-1221. | 0.6 | 41 |
| 123 | Differences in Virological Response to Peginterferon- α ± Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 117-123. | 0.9 | 12 |
| 124 | The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of chronic Hepatitis C. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S6792. | 0.4 | 0 |
| 125 | Future perspectives: towards interferon-free regimens for HCV. <i>Antiviral Therapy</i> , 2012, 17, 1201-1210. | 0.6 | 16 |
| 126 | Alisporivir for the treatment of chronic HCV. <i>Future Virology</i> , 2012, 7, 9-18. | 0.9 | 1 |
| 128 | NASPGHAN Practice Guidelines. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 838-855. | 0.9 | 176 |
| 129 | Safe Coadministration of Raltegravir-Based HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving Triple Therapy With Telaprevir or Boceprevir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, e47-e49. | 0.9 | 12 |
| 130 | Acute congestive heart failure and death secondary to itraconazole therapy. <i>Aids</i> , 2012, 26, 1848-1850. | 1.0 | 4 |
| 131 | Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067. | 0.6 | 23 |
| 132 | Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?. <i>Antiviral Therapy</i> , 2012, 17, 1163-1170. | 0.6 | 7 |
| 133 | Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA Polymerase. <i>Antiviral Therapy</i> , 2012, 17, 411-423. | 0.6 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 134 | The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. <i>Antiviral Therapy</i> , 2012, 17, 1119-1131. | 0.6 | 28 |
| 135 | Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals. <i>Antiviral Therapy</i> , 2012, 17, 1397-1401. | 0.6 | 12 |
| 136 | A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 311-319. | 0.6 | 11 |
| 137 | Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?. <i>Antiviral Therapy</i> , 2012, 17, 1171-1182. | 0.6 | 58 |
| 138 | The science of direct-acting antiviral and host-targeted agent therapy. <i>Antiviral Therapy</i> , 2012, 17, 1109-1117. | 0.6 | 26 |
| 139 | Direct-acting antiviral agents for the treatment of HCV. <i>Antiviral Therapy</i> , 2012, 17, 1105-1107. | 0.6 | 3 |
| 140 | Predictors of response to chronic hepatitis C treatment. <i>Future Virology</i> , 2012, 7, 1089-1101. | 0.9 | 7 |
| 141 | HEPATOLOGY: Triple therapy for hepatitis C. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 59-61. | 0.1 | 0 |
| 142 | Novel clinical trial designs for the development of new antiretroviral agents. <i>Aids</i> , 2012, 26, 1847-1848. | 1.0 | 2 |
| 143 | The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings. <i>Annals of Internal Medicine</i> , 2012, 156, 263. | 2.0 | 278 |
| 144 | Escitalopram for the Prevention of Peginterferon- α 2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease. <i>Annals of Internal Medicine</i> , 2012, 157, 94. | 2.0 | 59 |
| 145 | Hepatitis C Virus Testing of Persons Born During 1945-1965: Recommendations From the Centers for Disease Control and Prevention. <i>Annals of Internal Medicine</i> , 2012, 157, 817. | 2.0 | 263 |
| 146 | Telaprevir for retreatment of HCV infection: review of the REALIZE trial. <i>Future Virology</i> , 2012, 7, 435-440. | 0.9 | 0 |
| 147 | Telaprevir in the treatment of hepatitis C infection: evidence from the ADVANCE, ILLUMINATE and REALIZE studies. <i>Clinical Investigation</i> , 2012, 2, 189-198. | 0.0 | 0 |
| 148 | HCV protease inhibitors: using the evidence to guide clinical practice. <i>Clinical Investigation</i> , 2012, 2, 923-937. | 0.0 | 2 |
| 150 | Therapeutic vaccination against chronic hepatitis C virus infection. <i>Antiviral Research</i> , 2012, 96, 36-50. | 1.9 | 26 |
| 151 | Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. <i>Liver International</i> , 2012, 32, 1477-1492. | 1.9 | 45 |
| 152 | Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 677-684. | 1.0 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 153 | Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C. Expert Opinion on Investigational Drugs, 2012, 21, 111-118. | 1.9 | 8 |
| 154 | Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. Alimentary Pharmacology and Therapeutics, 2012, 36, 670-679. | 1.9 | 5 |
| 155 | Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of Viral Hepatitis, 2012, 19, 623-634. | 1.0 | 9 |
| 168 | Antiviral strategies in hepatitis C virus infection. Journal of Hepatology, 2012, 56, S88-S100. | 1.8 | 261 |
| 169 | Natural killer cells in hepatitis C virus infection. Expert Review of Clinical Immunology, 2012, 8, 775-788. | 1.3 | 9 |
| 170 | The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 2012, 142, 1592-1609. | 0.6 | 1,486 |
| 171 | Hepatitis C virus host cell entry. Current Opinion in Virology, 2012, 2, 14-19. | 2.6 | 79 |
| 172 | UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology and Therapeutics, 2012, 35, 647-662. | 1.9 | 76 |
| 173 | Anti-Hepatitis C Virus Drugs in Development. Gastroenterology, 2012, 142, 1340-1350.e1. | 0.6 | 83 |
| 174 | Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology, 2012, 56, 1641-1650. | 3.6 | 60 |
| 175 | Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology, 2012, 56, 2398-2403. | 3.6 | 31 |
| 176 | Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology, 2012, 56, 1591-1592. | 3.6 | 24 |
| 177 | Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial. Hepatology, 2012, 56, 2106-2115. | 3.6 | 41 |
| 178 | Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data. Liver Transplantation, 2012, 18, 1464-1470. | 1.3 | 76 |
| 180 | Safety of Telaprevir for Chronic Hepatitis C Virus Infection. Clinical Drug Investigation, 2012, 32, 665-672. | 1.1 | 14 |
| 181 | Liver Transplantation: From Inception to Clinical Practice. Cell, 2012, 150, 1096-1099. | 13.5 | 21 |
| 182 | Integration of substance use treatment and medical care: A special issue of JSAT. Journal of Substance Abuse Treatment, 2012, 43, 377-381. | 1.5 | 9 |
| 183 | Treating hepatitis C infection by targeting the host. Translational Research, 2012, 159, 421-429. | 2.2 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 184 | Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. <i>Virus Research</i> , 2012, 170, 1-14. | 1.1 | 76 |
| 185 | Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 717-728. | 4.6 | 95 |
| 186 | Recomendações para a terapêutica da hepatite C. <i>GE Jornal Português De Gastreenterologia</i> , 2012, 19, 133-139. | 0.0 | 2 |
| 187 | The Importance of Rapid Viral Suppression in the Era of Directly Acting Antiviral Therapy for Hepatitis C Virus. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 879-891. | 1.9 | 0 |
| 188 | Stratégies antivirales dans l'hépatite chronique C. <i>Journal Des Anti-infectieux</i> , 2012, 14, 78-88. | 0.1 | 0 |
| 189 | NS5A inhibitors to treat hepatitis C virus infection. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 648-649. | 4.6 | 0 |
| 190 | Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1270-1277.e3. | 2.4 | 16 |
| 191 | An orally available, small-molecule interferon inhibits viral replication. <i>Scientific Reports</i> , 2012, 2, 259. | 1.6 | 42 |
| 193 | Update on alisporivir in treatment of viral hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 375-382. | 1.9 | 44 |
| 194 | TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4676-4684. | 1.4 | 40 |
| 195 | Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2327-2337. | 1.3 | 12 |
| 196 | Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 502-521. | 1.5 | 13 |
| 198 | Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 313-323. | 0.9 | 30 |
| 199 | Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1101-10. | 3.3 | 78 |
| 200 | Care of the Cirrhotic Patient. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 979-994. | 1.9 | 5 |
| 201 | Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 893-901. | 1.9 | 0 |
| 202 | GS-7977: a promising nucleotide analog NS5B polymerase inhibitor of HCV. <i>Future Virology</i> , 2012, 7, 537-546. | 0.9 | 7 |
| 203 | Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1. <i>Gut</i> , 2012, 61, 1473-1480. | 6.1 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 204 | Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1838-1844. | 1.4 | 50 |
| 205 | Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5230-5239. | 1.4 | 68 |
| 206 | New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. <i>Cut</i> , 2012, 61, i36-i46. | 6.1 | 168 |
| 207 | The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment. <i>Biomarkers in Medicine</i> , 2012, 6, 141-150. | 0.6 | 7 |
| 208 | Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. <i>Liver International</i> , 2012, 32, 712-731. | 1.9 | 19 |
| 209 | <sc>HIV</sc> co-infection facing <sc>HCV</sc> protease inhibitor licensing: implications for clinicians. <i>Liver International</i> , 2012, 32, 1194-1199. | 1.9 | 18 |
| 210 | Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. <i>Liver International</i> , 2012, 32, 1270-1277. | 1.9 | 10 |
| 211 | Peripheral blood cytopenia before treatment in <sc>HCV</sc> patients: is it a limitation for <sc>HCV</sc> treatment in the era of <sc>DAA</sc>?. <i>Liver International</i> , 2012, 32, 1033-1036. | 1.9 | 2 |
| 212 | Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5387-5396. | 1.4 | 173 |
| 213 | Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 105. | 0.9 | 20 |
| 214 | Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. <i>Current Medical Research and Opinion</i> , 2012, 28, 1841-1856. | 0.9 | 14 |
| 215 | Basic answers to complicated questions for the course of chronic hepatitis C treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 371-382. | 1.4 | 3 |
| 216 | Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. <i>Journal of Hepatology</i> , 2012, 56, 455-463. | 1.8 | 135 |
| 217 | The invaders and the barrier. <i>Journal of Hepatology</i> , 2012, 56, 11-13. | 1.8 | 4 |
| 218 | A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 24-31. | 1.8 | 147 |
| 219 | Severe cutaneous eruptions on telaprevir. <i>Journal of Hepatology</i> , 2012, 57, 470-472. | 1.8 | 17 |
| 220 | Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. <i>Journal of Hepatology</i> , 2012, 57, 946-952. | 1.8 | 56 |
| 221 | Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. <i>Journal of Virological Methods</i> , 2012, 185, 94-100. | 1.0 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 227 | Elevated D-Dimer is Independently Associated with Endothelial Dysfunction: A Cross-Sectional Study in HIV-Infected Adults on Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2012, 17, 1345-1349. | 0.6 | 32 |
| 228 | High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHEYSYS cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012, 56, 2039-2050. | 3.6 | 92 |
| 229 | A great time to invest in baby Boomer's hepatitis C!. <i>Hepatology</i> , 2012, 56, 1575-1577. | 3.6 | 0 |
| 230 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. <i>Liver Transplantation</i> , 2012, 18, 1053-1059. | 1.3 | 66 |
| 231 | The race for interferon-free HCV therapies: a snapshot by the spring of 2012. <i>Reviews in Medical Virology</i> , 2012, 22, 392-411. | 3.9 | 18 |
| 232 | Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment. <i>Virology Journal</i> , 2012, 9, 147. | 1.4 | 2 |
| 233 | Hepatitis C Virus Drug Resistance. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 967-978. | 1.9 | 1 |
| 234 | To Market, To Market—2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569. | 0.5 | 23 |
| 235 | HCV virologic response—new nomenclature recommendations. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 619-620. | 8.2 | 0 |
| 236 | A new standard of care and the race towards IFN-free therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 67-68. | 8.2 | 6 |
| 237 | Telaprevir. <i>Drugs</i> , 2012, 72, 619-641. | 4.9 | 40 |
| 238 | Interferon-Free Hepatitis C Therapy. <i>Drugs</i> , 2012, 72, 1825-1831. | 4.9 | 20 |
| 239 | New Pharmacotherapy for Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 294-305. | 2.3 | 24 |
| 240 | Systems Biology Analyses to Define Host Responses to HCV Infection and Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2012, 363, 143-167. | 0.7 | 3 |
| 241 | Telaprevir: An oral protease inhibitor for hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 19-33. | 0.5 | 18 |
| 242 | Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. <i>American Journal of Gastroenterology</i> , 2012, 107, 669-689. | 0.2 | 84 |
| 243 | Genetic Factors and Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2012, 142, 1335-1339. | 0.6 | 16 |
| 244 | Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals. <i>Gastroenterology</i> , 2012, 142, 1324-1334.e3. | 0.6 | 78 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 245 | Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus. <i>Gastroenterology</i> , 2012, 142, 1314-1323.e1. | 0.6 | 50 |
| 246 | Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14. | 0.6 | 107 |
| 247 | Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus-Infected Patients Following TMC435 Monotherapy. <i>Gastroenterology</i> , 2012, 143, 1176-1178.e6. | 0.6 | 37 |
| 248 | Data to Guide the "Test and Treat Era" of Hepatitis C. <i>Gastroenterology</i> , 2012, 143, 887-889. | 0.6 | 8 |
| 249 | Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 1886-1892. | 1.1 | 8 |
| 250 | Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 445-453. | 1.0 | 14 |
| 251 | Response guided therapy in patients with chronic hepatitis C "Yesterday, today and tomorrow. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 463-469. | 1.0 | 12 |
| 252 | The role of viral and host genetics in natural history and treatment of chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 413-427. | 1.0 | 24 |
| 253 | Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530. | 1.0 | 14 |
| 254 | Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 471-485. | 1.0 | 11 |
| 255 | The role of resistance in HCV treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 487-503. | 1.0 | 108 |
| 256 | Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2012, 34, 1883-1891. | 1.1 | 6 |
| 257 | Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor. <i>Clinical Therapeutics</i> , 2012, 34, 1857-1882. | 1.1 | 34 |
| 258 | Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). <i>Current Opinion in Pharmacology</i> , 2012, 12, 556-561. | 1.7 | 19 |
| 259 | Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2012, 44, 438-441. | 0.4 | 15 |
| 260 | Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. <i>Digestive and Liver Disease</i> , 2012, 44, 497-503. | 0.4 | 72 |
| 262 | Genomics and HCV infection: Progression of fibrosis and treatment response. <i>Journal of Hepatology</i> , 2012, 57, 1110-1125. | 1.8 | 89 |
| 263 | Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1. <i>American Journal of Gastroenterology</i> , 2012, 107, 1675-1683. | 0.2 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 264 | Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection. <i>MedChemComm</i> , 2012, 3, 944-949. | 3.5 | 23 |
| 266 | HCV Inhibition Mediated Through the Nonstructural Protein 5A (NS5A) Replication Complex. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 331-345. | 0.5 | 8 |
| 267 | Impact of Ethnicity and Race on Treatment Response: Past, Present and Future. <i>Current Hepatitis Reports</i> , 2012, 11, 128-135. | 0.3 | 1 |
| 268 | IL28B: Current and Future Use. <i>Current Hepatitis Reports</i> , 2012, 11, 136-145. | 0.3 | 0 |
| 269 | Cyclophilin Inhibitors. <i>Current Hepatitis Reports</i> , 2012, 11, 153-159. | 0.3 | 4 |
| 270 | Telaprevir and Boceprevir: The Future Is Now. <i>Current Hepatitis Reports</i> , 2012, 11, 160-171. | 0.3 | 2 |
| 271 | Hepatitis C Therapy: Lessons of the Last Two Decades. <i>Current Hepatitis Reports</i> , 2012, 11, 119-127. | 0.3 | 1 |
| 272 | Acute Hepatitis C Infection: New Approaches to Surveillance, Treatment and Prevention. <i>Current Hepatitis Reports</i> , 2012, 11, 221-230. | 0.3 | 3 |
| 273 | Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. <i>Gut</i> , 2012, 61, 290-296. | 6.1 | 17 |
| 274 | Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 671-677. | 4.6 | 139 |
| 275 | Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1566-1573. | 1.0 | 50 |
| 276 | Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline. <i>Current HIV/AIDS Reports</i> , 2012, 9, 231-237. | 1.1 | 10 |
| 277 | IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 863-877. | 1.9 | 12 |
| 278 | New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. <i>Gut</i> , 2012, 61, i25-i35. | 6.1 | 67 |
| 279 | Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2355-2367. | 0.9 | 2 |
| 280 | Hepatitis C virus: current concepts and future challenges. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 29-32. | 0.2 | 19 |
| 281 | Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2012, 54, 96-104. | 2.9 | 86 |
| 282 | Chronic Hepatitis C Virus. , 2012, , . | | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 283 | Future Classes of Hepatitis C Virus Therapeutic Agents. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 949-966. | 1.9 | 2 |
| 284 | TMC435 for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1193-1209. | 1.9 | 22 |
| 285 | The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , 2012, 107, 811-826. | 0.2 | 359 |
| 286 | Viral Hepatitis in the Elderly. <i>American Journal of Gastroenterology</i> , 2012, 107, 691-697. | 0.2 | 40 |
| 287 | Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?. <i>BMC Infectious Diseases</i> , 2012, 12, S3. | 1.3 | 9 |
| 288 | Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. <i>BMC Infectious Diseases</i> , 2012, 12, 324. | 1.3 | 7 |
| 289 | Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 931-948. | 1.9 | 7 |
| 290 | A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection. <i>PLoS Computational Biology</i> , 2012, 8, e1002339. | 1.5 | 31 |
| 291 | ARF1 and GBF1 Generate a PI4P-Enriched Environment Supportive of Hepatitis C Virus Replication. <i>PLoS ONE</i> , 2012, 7, e32135. | 1.1 | 57 |
| 292 | Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials. <i>PLoS ONE</i> , 2012, 7, e34372. | 1.1 | 80 |
| 293 | Novel Small-Molecule Inhibitors of Hepatitis C Virus Entry Block Viral Spread and Promote Viral Clearance in Cell Culture. <i>PLoS ONE</i> , 2012, 7, e35351. | 1.1 | 12 |
| 294 | A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alpha-Based Therapy of Chronic Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e40159. | 1.1 | 60 |
| 295 | Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir. <i>PLoS ONE</i> , 2012, 7, e41191. | 1.1 | 23 |
| 296 | High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. <i>PLoS ONE</i> , 2012, 7, e41206. | 1.1 | 43 |
| 297 | Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 205-210. | 1.8 | 50 |
| 298 | Hepatitis C Variability, Patterns of Resistance, and Impact on Therapy. <i>Advances in Virology</i> , 2012, 2012, 1-10. | 0.5 | 17 |
| 299 | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 359-375. | 1.8 | 101 |
| 301 | Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-293. | 0.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 302 | A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. <i>Annals of Hepatology</i> , 2012, 11, 179-185. | 0.6 | 67 |
| 304 | Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 349. | 0.7 | 9 |
| 305 | Hepatitis C treatment outcomes in Australian clinics. <i>Medical Journal of Australia</i> , 2012, 196, 633-637. | 0.8 | 27 |
| 306 | Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon- α 2a (40 KD) plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 927-932. | 0.6 | 3 |
| 307 | Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 11. | 1.0 | 16 |
| 308 | Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. <i>Patient Preference and Adherence</i> , 2012, 6, 285. | 0.8 | 17 |
| 309 | Interferon-alpha inhibits airway eosinophilia and hyperresponsiveness in an animal asthma model. <i>Asia Pacific Allergy</i> , 2012, 2, 256-263. | 0.6 | 16 |
| 310 | Telaprevir and Boceprevir in African Americans with Genotype 1 Chronic Hepatitis C. <i>Southern Medical Journal</i> , 2012, 105, 431-436. | 0.3 | 5 |
| 311 | New agents for the treatment of hepatitis C virus – focus on telaprevir. <i>Virus Adaptation and Treatment</i> , 0, , 75. | 1.5 | 1 |
| 312 | Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3670-3681. | 1.4 | 103 |
| 313 | 3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 300-304. | 1.0 | 18 |
| 314 | Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 387-402. | 3.8 | 1,239 |
| 315 | Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. <i>Hepatology</i> , 2012, 55, 1038-1047. | 3.6 | 36 |
| 316 | Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. <i>Hepatology</i> , 2012, 55, 1048-1057. | 3.6 | 62 |
| 317 | Economic model of a birth cohort screening program for hepatitis C virus. <i>Hepatology</i> , 2012, 55, 1344-1355. | 3.6 | 102 |
| 318 | Safety of the hepatitis E vaccine for pregnant women: A preliminary analysis. <i>Hepatology</i> , 2012, 55, 2038-2038. | 3.6 | 70 |
| 319 | Clinical trials and their translation in hepatology: Past, present, and future. <i>Hepatology</i> , 2012, 56, 399-410. | 3.6 | 1 |
| 320 | Severe skin rash in case of readministration of telaprevir in a patient who previously experienced a non severe rash. <i>Hepatology</i> , 2012, 55, 2042-2043. | 3.6 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 321 | Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052. <i>Hepatology</i> , 2012, 55, 1692-1699. | 3.6 | 46 |
| 323 | Mucin-producing cholangiocarcinoma might derive from biliary tree stem/progenitor cells located in peribiliary glands. <i>Hepatology</i> , 2012, 55, 2041-2042. | 3.6 | 60 |
| 324 | Informed consent in surveillance for hepatocellular carcinoma in patients with cirrhosis. <i>Hepatology</i> , 2012, 55, 2039-2039. | 3.6 | 0 |
| 325 | Cystic and papillary neoplasm involving peribiliary glands: A biliary counterpart of branch-type intraductal papillary mucinous cystic neoplasm?. <i>Hepatology</i> , 2012, 55, 2040-2041. | 3.6 | 39 |
| 326 | Review and management of drug interactions with boceprevir and telaprevir. <i>Hepatology</i> , 2012, 55, 1620-1628. | 3.6 | 123 |
| 327 | Is the M probe really necessary to measure liver stiffness by FibroScan?. <i>Hepatology</i> , 2012, 55, 2043-2044. | 3.6 | 2 |
| 329 | Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 850-860. | 3.6 | 97 |
| 330 | Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. <i>Hepatology</i> , 2012, 56, 884-893. | 3.6 | 52 |
| 331 | The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023. | 3.6 | 2,935 |
| 332 | Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. <i>Hepatology</i> , 2012, 56, 567-575. | 3.6 | 47 |
| 333 | Predicting the response to the treatment of hepatitis C virus infection. <i>Clinical Liver Disease</i> , 2012, 1, 46-48. | 1.0 | 1 |
| 334 | Issues in selecting HCV-infected candidates for anti-viral treatment. <i>Clinical Liver Disease</i> , 2012, 1, 29-31. | 1.0 | 0 |
| 335 | The horizon: New targets and new agents. <i>Clinical Liver Disease</i> , 2012, 1, 24-27. | 1.0 | 1 |
| 336 | Demographics of hepatitis C virus today. <i>Clinical Liver Disease</i> , 2012, 1, 2-5. | 1.0 | 1 |
| 337 | Is there still a role for liver biopsy in managing hepatitis C virus infections?. <i>Clinical Liver Disease</i> , 2012, 1, 32-35. | 1.0 | 0 |
| 338 | Management of adverse events during the treatment of chronic hepatitis C infection. <i>Clinical Liver Disease</i> , 2012, 1, 54-57. | 1.0 | 5 |
| 339 | HCV infection on-treatment viral kinetics: Do they still have a role?. <i>Clinical Liver Disease</i> , 2012, 1, 51-53. | 1.0 | 0 |
| 340 | The new standard of HCV therapy: Retreatment in experienced patients. <i>Clinical Liver Disease</i> , 2012, 1, 16-19. | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 341 | Hepatitis C viral infection in patients with cirrhosis. <i>Clinical Liver Disease</i> , 2012, 1, 65-68. | 1.0 | 0 |
| 342 | Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapy. <i>Clinical Liver Disease</i> , 2012, 1, 69-72. | 1.0 | 0 |
| 343 | Hepatitis C viral infection in patients with chronic kidney disease. <i>Clinical Liver Disease</i> , 2012, 1, 91-94. | 1.0 | 0 |
| 344 | The new standard of HCV therapy: Treatment in therapy-naive patients. <i>Clinical Liver Disease</i> , 2012, 1, 12-15. | 1.0 | 0 |
| 345 | Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2012, 55, S16-S24. | 2.9 | 24 |
| 346 | Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice. <i>Clinical Infectious Diseases</i> , 2012, 55, S58-S63. | 2.9 | 36 |
| 347 | Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1469-1474. | 1.1 | 33 |
| 349 | APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435. | 1.9 | 152 |
| 350 | Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. <i>Archives of Virology</i> , 2012, 157, 1113-1121. | 0.9 | 4 |
| 351 | Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. <i>Liver International</i> , 2012, 32, 88-102. | 1.9 | 119 |
| 352 | Future treatment of patients with HCV cirrhosis. <i>Liver International</i> , 2012, 32, 113-119. | 1.9 | 23 |
| 353 | Treatment of chronic hepatitis C – are interferons really necessary?. <i>Liver International</i> , 2012, 32, 108-112. | 1.9 | 20 |
| 354 | Barriers to hepatitis C treatment. <i>Liver International</i> , 2012, 32, 151-156. | 1.9 | 141 |
| 355 | Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. <i>Liver International</i> , 2012, 32, 32-38. | 1.9 | 53 |
| 356 | Telaprevir user's guide. <i>Liver International</i> , 2012, 32, 17-25. | 1.9 | 7 |
| 357 | Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. <i>Liver International</i> , 2012, 32, 39-43. | 1.9 | 21 |
| 358 | What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012, 32, 135-140. | 1.9 | 14 |
| 359 | IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?. <i>Liver International</i> , 2012, 32, 74-78. | 1.9 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 360 | Response to guided and unguided treatment of chronic hepatitis C. Liver International, 2012, 32, 64-73. | 1.9 | 12 |
| 361 | Hepatitis C virus treatment pre and post liver transplantation. Liver International, 2012, 32, 120-128. | 1.9 | 62 |
| 362 | Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: Lead in or no lead in? Liver International, 2012, 32, 61-63. | 1.9 | 2 |
| 363 | Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver International, 2012, 32, 54-60. | 1.9 | 24 |
| 364 | Host genomics and HCV treatment response. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 212-222. | 1.4 | 29 |
| 365 | Implications of rapid virological response in hepatitis C therapy in the US veteran population. Alimentary Pharmacology and Therapeutics, 2012, 35, 105-115. | 1.9 | 10 |
| 366 | 5-Acetyl-2-arylbenzimidazoles as antiviral agents. Part 4. European Journal of Medicinal Chemistry, 2012, 53, 83-97. | 2.6 | 24 |
| 367 | Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1095-1098. | 1.0 | 9 |
| 368 | Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1394-1396. | 1.0 | 45 |
| 369 | Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2629-2634. | 1.0 | 42 |
| 370 | Discovery of 4-azido-2-deoxy-2-C-methyl cytidine and prodrugs thereof: A potent inhibitor of Hepatitis C virus replication. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3265-3268. | 1.0 | 15 |
| 371 | Response to guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatology Research, 2012, 42, 549-557. | 1.8 | 10 |
| 372 | Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53. | | 143 |
| 373 | Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology, 2012, 422, 174-184. | 1.1 | 29 |
| 374 | Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Virology, 2012, 429, 57-62. | 1.1 | 21 |
| 375 | The pharmacokinetics of peginterferon alfa-2a and ribavirin in African, Hispanic and Caucasian patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2012, 35, 1209-1220. | 1.9 | 7 |
| 376 | Randomised clinical trial: pre dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment naïve patients with chronic hepatitis C genotype 1. Alimentary Pharmacology and Therapeutics, 2012, 36, 370-378. | 1.9 | 3 |
| 377 | Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV and B patients. Alimentary Pharmacology and Therapeutics, 2012, 36, 353-362. | 1.9 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 378 | Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. <i>Journal of Viral Hepatitis</i> , 2012, 19, 236-243. | 1.0 | 13 |
| 379 | High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. <i>Journal of Viral Hepatitis</i> , 2012, 19, 547-553. | 1.0 | 23 |
| 380 | A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-26. | 1.0 | 71 |
| 381 | Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2012, 19, 449-464. | 1.0 | 160 |
| 382 | Hepatitis C therapy in non-genotype 1 patients: the near future. <i>Journal of Viral Hepatitis</i> , 2012, 19, 525-536. | 1.0 | 23 |
| 383 | Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. <i>Transplant International</i> , 2012, 25, 825-829. | 0.8 | 15 |
| 384 | Current status and future directions in the management of chronic hepatitis C. <i>Virology Journal</i> , 2012, 9, 57. | 1.4 | 36 |
| 385 | Treatment of chronic hepatitis C genotype 1 patients at an academic center in europe involved in prospective, controlled trials: Is there a selection bias?. <i>Hepatology</i> , 2012, 55, 30-38. | 3.6 | 18 |
| 386 | Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. <i>Hepatology</i> , 2012, 55, 742-748. | 3.6 | 318 |
| 387 | The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. <i>Hepatology</i> , 2012, 55, 749-758. | 3.6 | 108 |
| 389 | An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments. <i>Hepatology</i> , 2012, 55, 979-980. | 3.6 | 7 |
| 391 | Rapid virological response: Is it four or eight weeks?. <i>Hepatology</i> , 2012, 55, 979. | 3.6 | 0 |
| 392 | Yttrium 90 therapy for hepatocellular carcinoma: Is it any better than conventional external beam radiotherapy?. <i>Hepatology</i> , 2012, 55, 981-981. | 3.6 | 1 |
| 394 | Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era. <i>Current Gastroenterology Reports</i> , 2012, 14, 74-77. | 1.1 | 8 |
| 395 | Treatment of Non-Genotype 1 Hepatitis C Virus Patients. <i>Current Gastroenterology Reports</i> , 2012, 14, 87-93. | 1.1 | 8 |
| 396 | Resistance-Associated Variants in Chronic Hepatitis C Patients Treated with Protease Inhibitors. <i>Current Gastroenterology Reports</i> , 2012, 14, 47-54. | 1.1 | 11 |
| 397 | Management of Hepatitis C in Patients with Chronic Kidney Disease. <i>Current Gastroenterology Reports</i> , 2012, 14, 78-86. | 1.1 | 12 |
| 398 | HCV and Chemotherapy: Does Infection Change Management?. <i>Current Hepatitis Reports</i> , 2012, 11, 34-40. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 399 | HCV In At Risk Populations: Who Can be Treated and How?. Current Hepatitis Reports, 2012, 11, 1-9. | 0.3 | 0 |
| 400 | HCV Therapy in 2011: Development of New Treatment Paradigms for Na ⁻ ve and Non-Responder Patients. Current Hepatitis Reports, 2012, 11, 48-54. | 0.3 | 0 |
| 401 | Boceprevir versus Telaprevir: A New Era of Directly Acting Antiviral Therapy. Current Hepatitis Reports, 2012, 11, 23-33. | 0.3 | 1 |
| 402 | Induction and exacerbation of psoriasis with Interferon α therapy for hepatitis C: A review and analysis of 36 cases. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 771-778. | 1.3 | 65 |
| 403 | The effects of hepatitis C virus core protein on the expression of miR-122 in vitro. Virology Journal, 2013, 10, 98. | 1.4 | 11 |
| 404 | Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples. Virology Journal, 2013, 10, 53. | 1.4 | 21 |
| 405 | Approved and experimental countermeasures against pestiviral diseases: Bovine viral diarrhea, classical swine fever and border disease. Antiviral Research, 2013, 100, 133-150. | 1.9 | 28 |
| 406 | Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Infection, 2013, 41, 21-26. | 2.3 | 6 |
| 407 | Hepatitis C Virus Viral Assays in the Direct-Acting Antiviral Era. Clinics in Liver Disease, 2013, 17, 27-45. | 1.0 | 7 |
| 408 | Novel therapies for hepatitis C – one pill fits all?. Nature Reviews Drug Discovery, 2013, 12, 595-610. | 21.5 | 174 |
| 409 | Global control of hepatitis C: where challenge meets opportunity. Nature Medicine, 2013, 19, 850-858. | 15.2 | 250 |
| 410 | The presence of resistance mutations to protease and polymerase inhibitors in HCV hepatitis C virus sequences from the Los Alamos databank. Journal of Viral Hepatitis, 2013, 20, 414-421. | 1.0 | 42 |
| 411 | Viral Hepatitis in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 147-168. | 2.6 | 72 |
| 412 | A new era in the treatment of chronic hepatitis C infection. Indian Journal of Gastroenterology, 2013, 32, 71-79. | 0.7 | 4 |
| 413 | Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterology, 2013, 13, 86. | 0.8 | 18 |
| 414 | Multicenter comparison of PEG-IFN α 2a or α 2b plus ribavirin for treatment-na ⁻ ve HCV patient in Korean population. BMC Gastroenterology, 2013, 13, 74. | 0.8 | 16 |
| 415 | Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infectious Diseases, 2013, 13, 190. | 1.3 | 48 |
| 416 | Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. Hepatology International, 2013, 7, 153-161. | 1.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 417 | HCV Therapy: Treat now or wait?. Current Hepatitis Reports, 2013, 12, 7-12. | 0.3 | 1 |
| 418 | Hepatitis C: Management of Side Effects in the Era of Direct-Acting Antivirals. Current Gastroenterology Reports, 2013, 15, 305. | 1.1 | 11 |
| 419 | IL28B Genotype on HCV Infection in Asia. Current Hepatitis Reports, 2013, 12, 149-156. | 0.3 | 3 |
| 420 | Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents. Current Hepatitis Reports, 2013, 12, 13-19. | 0.3 | 0 |
| 421 | Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. Cytokine, 2013, 63, 145-150. | 1.4 | 6 |
| 422 | Impact of host and virus genome variability on HCV replication and response to interferon. Current Opinion in Virology, 2013, 3, 501-507. | 2.6 | 5 |
| 423 | Durability of SVR in chronic hepatitis C patients treated with peginterferon-2a/ribavirin in combination with a direct-acting antiviral. Alimentary Pharmacology and Therapeutics, 2013, 38, 118-123. | 1.9 | 28 |
| 424 | Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Alimentary Pharmacology and Therapeutics, 2013, 38, 16-27. | 1.9 | 19 |
| 425 | Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine, 2013, 2, 9. | 1.7 | 27 |
| 426 | Faldaprevir and Deleobuvir for HCV Genotype 1 Infection. New England Journal of Medicine, 2013, 369, 630-639. | 13.9 | 215 |
| 427 | Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials. Clinical Therapeutics, 2013, 35, 190-197. | 1.1 | 26 |
| 428 | NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opinion on Investigational Drugs, 2013, 22, 1337-1346. | 1.9 | 34 |
| 429 | Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surgery Today, 2013, 43, 1347-1354. | 0.7 | 18 |
| 430 | Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. JAMA - Journal of the American Medical Association, 2013, 310, 804. | 3.8 | 265 |
| 431 | A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. Journal of Hepatology, 2013, 59, 926-933. | 1.8 | 33 |
| 432 | Hypersensibilit  aux nouveaux traitements de lâ™h patite C. Revue Francaise D'allergologie, 2013, 53, 171-173. | 0.1 | 0 |
| 433 | Optimizing DAA management in daily practice. Digestive and Liver Disease, 2013, 45, S318-S322. | 0.4 | 6 |
| 435 | Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Brazilian Journal of Infectious Diseases, 2013, 17, 194-204. | 0.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 436 | IL28B testing in a rapidly changing world: Still relevant?. <i>Journal of Hepatology</i> , 2013, 58, 847-849. | 1.8 | 5 |
| 437 | 50 IS ADDING HCV SCREENING TO THE ANTENATAL NATIONAL SCREENING PROGRAM IN AMSTERDAM, THE NETHERLANDS COST-EFFECTIVE?. <i>Journal of Hepatology</i> , 2013, 58, S22. | 1.8 | 0 |
| 439 | Evolutionary dynamics of hepatitis C virus <scp>NS</scp>3 protease domain during and following treatment with narlaprevir, a potent <scp>NS</scp>3 protease inhibitor. <i>Journal of Viral Hepatitis</i> , 2013, 20, 779-789. | 1.0 | 0 |
| 441 | Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 124-133. | 1.9 | 41 |
| 442 | Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330. | 1.8 | 35 |
| 443 | Genotype impact on HCV RNA levels determined with the VERSANT HCV RNA 1.0 Assay (kPCR). <i>Journal of Clinical Virology</i> , 2013, 58, 522-527. | 1.6 | 16 |
| 444 | Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection. <i>Gastroenterology</i> , 2013, 145, 790-800.e3. | 0.6 | 27 |
| 445 | The importance of HCV RNA measurement for tailoring treatment duration. <i>Digestive and Liver Disease</i> , 2013, 45, S323-S331. | 0.4 | 14 |
| 446 | Hepatitis C Patients on Maintenance Hemodialysis Show Complex Immune Disturbances in the Peripheral Blood. <i>Viral Immunology</i> , 2013, 26, 351-356. | 0.6 | 2 |
| 447 | Safety of direct antiviral agents in real life. <i>Digestive and Liver Disease</i> , 2013, 45, S363-S366. | 0.4 | 14 |
| 448 | Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8163-8182. | 2.9 | 29 |
| 449 | Novel Therapeutic Approaches for Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 95, 78-88. | 2.3 | 74 |
| 450 | Determining the Cellular Diversity of Hepatitis C Virus Quasispecies by Single-Cell Viral Sequencing. <i>Journal of Virology</i> , 2013, 87, 12648-12655. | 1.5 | 21 |
| 451 | The Impact of Ethnicity on Hepatitis C Virus Treatment Decisions and Outcomes. <i>Digestive Diseases and Sciences</i> , 2013, 58, 621-629. | 1.1 | 4 |
| 452 | Perspectives and challenges of interferon-free therapy for chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 58, 583-592. | 1.8 | 87 |
| 453 | Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 10-16. | 0.7 | 24 |
| 454 | Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1427-1435. | 1.3 | 10 |
| 455 | Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. <i>Hepatology</i> , 2013, 57, 2143-2154. | 3.6 | 102 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 456 | Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 479-487. | 1.8 | 52 |
| 457 | Cost-effectiveness of viral hepatitis B & C treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 973-985. | 1.0 | 12 |
| 458 | A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir. <i>Journal of Virological Methods</i> , 2013, 193, 68-76. | 1.0 | 4 |
| 459 | Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. <i>Journal of Hepatology</i> , 2013, 58, 646-654. | 1.8 | 160 |
| 460 | Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis. <i>Virology</i> , 2013, 443, 278-284. | 1.1 | 19 |
| 461 | Virologic response and characterisation of HCV genotype 2 in patients receiving TMC435 monotherapy (study TMC435-C202). <i>Journal of Hepatology</i> , 2013, 58, 445-451. | 1.8 | 82 |
| 462 | NS5A inhibitors in the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 375-382. | 1.8 | 172 |
| 463 | No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfecting patients using deep sequencing. <i>Journal of Clinical Virology</i> , 2013, 58, 726-729. | 1.6 | 17 |
| 464 | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. <i>Journal of Hepatology</i> , 2013, 59, 667-674. | 1.8 | 49 |
| 465 | Anemia Management in Patients with Chronic Viral Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2013, 47, 228-236. | 0.9 | 12 |
| 466 | Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2013, 57, 221-229. | 2.9 | 144 |
| 467 | Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. <i>Virology</i> , 2013, 444, 384-393. | 1.1 | 2 |
| 468 | Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64. | 1.7 | 10 |
| 469 | Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. <i>Journal of Hepatology</i> , 2013, 58, 655-662. | 1.8 | 225 |
| 470 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. <i>Lancet</i> , The, 2013, 381, 2100-2107. | 6.3 | 265 |
| 471 | Simeprevir for the treatment of chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2581-2589. | 0.9 | 41 |
| 472 | <i>In Vitro</i> Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6236-6245. | 1.4 | 26 |
| 473 | Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1076-1085. | 1.9 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 474 | Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1000-1007. | 1.9 | 27 |
| 475 | Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 932, 100-110. | 1.2 | 8 |
| 476 | Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays. <i>Antiviral Research</i> , 2013, 99, 119-124. | 1.9 | 23 |
| 477 | Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 690-700. | 1.3 | 99 |
| 478 | Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. <i>Journal of Viral Hepatitis</i> , 2013, 20, 395-403. | 1.0 | 18 |
| 479 | Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2013, 33, 325-331. | 1.1 | 28 |
| 480 | Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. <i>Journal of Hepatology</i> , 2013, 59, 31-37. | 1.8 | 46 |
| 481 | Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1021-1027. | 2.4 | 25 |
| 482 | Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494. | 1.8 | 19 |
| 483 | IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. <i>Journal of General Virology</i> , 2013, 94, 1259-1265. | 1.3 | 19 |
| 484 | Emerging treatments for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 461-475. | 1.0 | 30 |
| 485 | Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S26-S32. | 1.9 | 48 |
| 486 | Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. <i>Hepatology</i> , 2013, 58, 1918-1929. | 3.6 | 255 |
| 487 | Hepatitis C virus: Antiviral therapy in wait-listed patients. <i>Clinical Liver Disease</i> , 2013, 2, 173-176. | 1.0 | 0 |
| 488 | Study of hepatitis C virus entry in genetically humanized mice. <i>Methods</i> , 2013, 59, 249-257. | 1.9 | 16 |
| 489 | Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3348-3358. | 1.1 | 10 |
| 490 | Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and experienced patients. <i>BMC Gastroenterology</i> , 2013, 13, 148. | 0.8 | 3 |
| 491 | Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1371-1382. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 492 | Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein. <i>BMC Research Notes</i> , 2013, 6, 445. | 0.6 | 21 |
| 493 | Direct-Acting Antiviral-Associated Dermatitis During Chronic Hepatitis C Virus Treatment. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 497-502. | 3.3 | 13 |
| 494 | Recent Therapeutic Advances in Gastroenterology and Hepatology. <i>Advances in Therapy</i> , 2013, 30, 855-857. | 1.3 | 0 |
| 495 | Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients. <i>American Journal of Medicine</i> , 2013, 126, 718-722. | 0.6 | 36 |
| 496 | Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5. | 0.6 | 51 |
| 497 | Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection. <i>Hepatology</i> , 2013, 58, 822-826. | 3.6 | 2 |
| 498 | Therapy for Hepatitis C Virus—Related Cryoglobulinemic Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 1035-1045. | 13.9 | 159 |
| 499 | Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients. <i>Pharmacoeconomics</i> , 2013, 31, 919-931. | 1.7 | 36 |
| 500 | Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPLIC) — NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441. | 1.8 | 407 |
| 501 | Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?. <i>Journal of Clinical Virology</i> , 2013, 56, 146-149. | 1.6 | 64 |
| 502 | Treatment decisions and contemporary versus pending treatments for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 713-728. | 8.2 | 17 |
| 503 | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 401-408. | 4.6 | 313 |
| 504 | Hepatitis C Virus. <i>Advances in Pharmacology</i> , 2013, 67, 169-215. | 1.2 | 46 |
| 505 | Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase. <i>Current Opinion in Virology</i> , 2013, 3, 508-513. | 2.6 | 14 |
| 506 | HCV, Ribavirin, and Anemia: A New Dawn. <i>Gastroenterology</i> , 2013, 145, 930-933. | 0.6 | 1 |
| 507 | Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis. <i>Current Hepatitis Reports</i> , 2013, 12, 236-245. | 0.3 | 1 |
| 508 | The Role of Public Health in an Era of All-Oral Therapy for Hepatitis C Infection. <i>Current Hepatitis Reports</i> , 2013, 12, 220-226. | 0.3 | 0 |
| 509 | Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection — What Technology do we Really Need in Clinical Practice?. <i>Current Hepatitis Reports</i> , 2013, 12, 195-199. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 510 | Real World Experience in the Era of First Generation Protease Inhibitors in the Treatment of Hepatitis C. Current Hepatitis Reports, 2013, 12, 189-194. | 0.3 | 0 |
| 511 | Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. Current Hepatitis Reports, 2013, 12, 261-268. | 0.3 | 0 |
| 513 | HCV NS3/4a Protease Inhibitors: Simeprevir (TMC435350), Vaniprevir (MK7009) and MK5172. RSC Drug Discovery Series, 2013, , 189-247. | 0.2 | 1 |
| 514 | Meloxicam as an adjuvant to peginterferon α 2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. Hepatology Research, 2013, 43, 925-932. | 1.8 | 0 |
| 515 | Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 153-163. | 0.2 | 30 |
| 516 | A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing. American Journal of Gastroenterology, 2013, 108, 1464-1472. | 0.2 | 16 |
| 517 | Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell'epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi FO \leq F2. Pharmacoconomics Italian Research Articles, 2013, 15, 111-122. | 0.2 | 1 |
| 518 | Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine, 2013, 19, 837-849. | 15.2 | 497 |
| 519 | Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan. Journal of Dermatology, 2013, 40, 587-595. | 0.6 | 13 |
| 520 | Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014. Current HIV/AIDS Reports, 2013, 10, 408-419. | 1.1 | 17 |
| 521 | Hepatitis C Virus-Specific Cell-Mediated Immune Responses in Children Born to Mothers Infected with Hepatitis C Virus. Journal of Pediatrics, 2013, 162, 148-154. | 0.9 | 24 |
| 522 | Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. Journal of Substance Abuse Treatment, 2013, 44, 115-119. | 1.5 | 10 |
| 523 | Barriers of hepatitis C virus interspecies transmission. Virology, 2013, 435, 70-80. | 1.1 | 19 |
| 524 | Guidelines for the Management of Hepatitis C Virus Infection. Hepatology Research, 2013, 43, 1-34. | 1.8 | 56 |
| 525 | Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 311-317.e1. | 2.4 | 30 |
| 526 | A Synthetic Codon-Optimized Hepatitis C Virus Nonstructural 5A DNA Vaccine Primes Polyfunctional CD8 $^{+}$ T Cell Responses in Wild-Type and NS5A-Transgenic Mice. Journal of Immunology, 2013, 190, 1113-1124. | 0.4 | 11 |
| 527 | Innate immunity and HCV. Journal of Hepatology, 2013, 58, 564-574. | 1.8 | 124 |
| 528 | Cyclophilin Inhibitors for Hepatitis C Therapy. Clinics in Liver Disease, 2013, 17, 129-139. | 1.0 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 529 | Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013, 56, 293-298. | 1.6 | 20 |
| 530 | Host factors determining the efficacy of hepatitis C treatment. <i>Journal of Gastroenterology</i> , 2013, 48, 22-30. | 2.3 | 28 |
| 531 | Revisiting the Predictors of a Sustained Virologic Response in the Era of Direct-Acting Antiviral Therapy for Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2013, 56, 118-122. | 2.9 | 19 |
| 532 | Antivirals: Past, present and future. <i>Biochemical Pharmacology</i> , 2013, 85, 727-744. | 2.0 | 115 |
| 533 | The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States. <i>Clinics in Liver Disease</i> , 2013, 17, 1-11. | 1.0 | 52 |
| 534 | Management of the Transplant Recipient with Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2013, 17, 73-91. | 1.0 | 28 |
| 536 | Screening and Rational Design of Hepatitis C Virus Entry Inhibitory Peptides Derived from GB Virus A NS5A. <i>Journal of Virology</i> , 2013, 87, 1649-1657. | 1.5 | 18 |
| 537 | Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. <i>Journal of Gastroenterology</i> , 2013, 48, 1-12. | 2.3 | 40 |
| 538 | Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients. <i>AIDS and Behavior</i> , 2013, 17, 94-103. | 1.4 | 6 |
| 540 | Viral infections and their management in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1602-1613. | 0.6 | 32 |
| 541 | Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. <i>Journal of Infectious Diseases</i> , 2013, 207, S33-S39. | 1.9 | 90 |
| 542 | Future therapies for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 268-276. | 8.2 | 36 |
| 543 | Mathematical modeling: A tool for selecting agents with complementary modes of action?. <i>Journal of Hepatology</i> , 2013, 59, 1346-1348. | 1.8 | 1 |
| 544 | Hepatitis C infection and presence of advanced fibrosis: Wait or treat? Why wait? There is no time to lose, is there?. <i>Journal of Hepatology</i> , 2013, 58, 412-414. | 1.8 | 4 |
| 545 | Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?. <i>Journal of Hepatology</i> , 2013, 58, 391-394. | 1.8 | 8 |
| 547 | High Incidence of Telaprevir-associated Severe Rash Leading to Discontinuation. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 86. | 0.4 | 1 |
| 548 | Emerging Therapeutic Targets for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 612-619.e1. | 2.4 | 14 |
| 550 | Ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis/Peg-IFN α . <i>Presse Medicale</i> , 2013, 42, 694-695. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 551 | Preparing the patient for success: Treat or wait?. Digestive and Liver Disease, 2013, 45, S332-S336. | 0.4 | 1 |
| 552 | Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2013, 11, 193-195. | 2.4 | 8 |
| 555 | Management of Recurrent Hepatitis C in Orthotopic Liver Transplant Recipients. Infectious Disease Clinics of North America, 2013, 27, 285-304. | 1.9 | 2 |
| 556 | Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Review of Anti-Infective Therapy, 2013, 11, 1269-1279. | 2.0 | 35 |
| 559 | HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4428-4435. | 1.0 | 17 |
| 560 | Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. Experimental and Molecular Pathology, 2013, 95, 18-22. | 0.9 | 19 |
| 561 | Hepatitis C Virusâ€“Infected Resident: End of Residency, End of Career?. Annals of Thoracic Surgery, 2013, 95, 779-786. | 0.7 | 1 |
| 563 | Serotonin and interleukin-6: The role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology, 2013, 38, 1803-1813. | 1.3 | 53 |
| 564 | The effect of stimulant use on antiviral treatment in an integrated hepatitis clinic. General Hospital Psychiatry, 2013, 35, 387-392. | 1.2 | 2 |
| 566 | Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era. Digestive and Liver Disease, 2013, 45, 356-361. | 0.4 | 8 |
| 567 | Identification of proteins that mediate the pro-viral functions of the interferon stimulated gene 15 in hepatitis C virus replication. Antiviral Research, 2013, 100, 654-661. | 1.9 | 23 |
| 568 | Management of anaemia and other treatment complications. Digestive and Liver Disease, 2013, 45, S337-S342. | 0.4 | 7 |
| 570 | Is the HCV Pipeline Heading in the Right Direction?. Gastroenterology, 2013, 144, 482-485. | 0.6 | 4 |
| 572 | HCV Enters the Twenty-First Century. Current Infectious Disease Reports, 2013, 15, 52-60. | 1.3 | 0 |
| 573 | â€“Makes you wanna do treatmentâ€™: Benefits of a hepatitis C specialist clinic to clients in Christchurch, New Zealand. Health and Social Care in the Community, 2013, 21, 216-223. | 0.7 | 10 |
| 574 | The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. British Journal of Clinical Pharmacology, 2013, 75, 431-439. | 1.1 | 35 |
| 575 | Effect of peginterferon alfaâ€“2a (40<sc>KD</sc>) on cytochrome <sc>P</sc>450 isoenzyme activity. British Journal of Clinical Pharmacology, 2013, 75, 497-506. | 1.1 | 22 |
| 576 | Role of ILâ€“28B and inosine triphosphatase polymorphisms in efficacy and safety of Pegâ€“interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. Journal of Viral Hepatitis, 2013, 20, 113-121. | 1.0 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 577 | Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. <i>Journal of Viral Hepatitis</i> , 2013, 20, 167-173. | 1.0 | 12 |
| 578 | Hepatitis C virus vaccines in the era of new direct-acting antivirals. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 171-185. | 1.4 | 12 |
| 579 | Interplay between Hepatitis C Virus and Redox Cell Signaling. <i>International Journal of Molecular Sciences</i> , 2013, 14, 4705-4721. | 1.8 | 24 |
| 580 | Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. <i>The Cochrane Library</i> , 2013, , CD003617. | 1.5 | 23 |
| 581 | Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 659-671. | 1.9 | 13 |
| 582 | Current prospects for interferon-free treatment of hepatitis C in 2012. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 38-45. | 1.4 | 70 |
| 583 | How to optimize HCV therapy in genotype 1 patients: predictors of response. <i>Liver International</i> , 2013, 33, 23-29. | 1.9 | 19 |
| 584 | New therapeutic strategies in HCV: second-generation protease inhibitors. <i>Liver International</i> , 2013, 33, 80-84. | 1.9 | 43 |
| 585 | Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. <i>Liver International</i> , 2013, 33, 105-110. | 1.9 | 26 |
| 586 | How to optimize HCV therapy in genotype 1 patients with cirrhosis. <i>Liver International</i> , 2013, 33, 46-55. | 1.9 | 28 |
| 587 | New therapeutic strategies in HCV: polymerase inhibitors. <i>Liver International</i> , 2013, 33, 85-92. | 1.9 | 51 |
| 588 | Optimal treatment with boceprevir for chronic HCV infection. <i>Liver International</i> , 2013, 33, 14-22. | 1.9 | 9 |
| 589 | Optimal treatment with telaprevir for chronic HCV infection. <i>Liver International</i> , 2013, 33, 3-13. | 1.9 | 11 |
| 590 | How to optimize HCV therapy in genotype 1 patients: management of side effects. <i>Liver International</i> , 2013, 33, 30-34. | 1.9 | 41 |
| 591 | HCV therapy in HIV-infected patients. <i>Liver International</i> , 2013, 33, 63-67. | 1.9 | 30 |
| 592 | Treatment of viral hepatitis: a new era. <i>Liver International</i> , 2013, 33, 1-2. | 1.9 | 2 |
| 593 | Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects. <i>Hepatology</i> , 2013, 57, 897-902. | 3.6 | 13 |
| 594 | The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. <i>Hepatology</i> , 2013, 58, 54-64. | 3.6 | 71 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 595 | Hepatitis C Virus Proteins: From Structure to Function. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 113-142. | 0.7 | 227 |
| 596 | Treatment of Chronic Hepatitis C: Current and Future. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 321-342. | 0.7 | 79 |
| 597 | A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. <i>Hepatology</i> , 2013, 57, 1325-1332. | 3.6 | 89 |
| 598 | Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. <i>New England Journal of Medicine</i> , 2013, 368, 45-53. | 13.9 | 271 |
| 599 | Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance. <i>Journal of Biological Chemistry</i> , 2013, 288, 5673-5681. | 1.6 | 16 |
| 600 | Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 487-495. | 0.6 | 38 |
| 601 | HCV infection: an enigma, recent advances and new paradigms for its treatment. <i>Future Virology</i> , 2013, 8, 381-389. | 0.9 | 0 |
| 602 | Prise en charge de lâ€™hÃ©patite C chroniqueÂ: les derniÃ©res avancÃ©es thÃ©rapeutiques. <i>Pharmacien Hospitalier Et Clinicien</i> , 2013, 48, 131-143. | 0.3 | 0 |
| 603 | Direct-Acting Antiviral Agents for Hepatitis C Virus Infection. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 427-449. | 4.2 | 84 |
| 604 | Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 527-536. | 1.9 | 71 |
| 605 | Sofosbuvir: the final nail in the coffin for hepatitis C?. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 378-379. | 4.6 | 33 |
| 606 | Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894. | 1.9 | 44 |
| 607 | Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984. | 3.6 | 67 |
| 608 | Systematic review: Asian patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 921-936. | 1.9 | 105 |
| 609 | Hepatitis C virus vaccines â€œ Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72. | 1.3 | 34 |
| 610 | PegIFN-Î±2a for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 459-474. | 2.0 | 15 |
| 611 | Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance. <i>ACS Chemical Biology</i> , 2013, 8, 1469-1478. | 1.6 | 58 |
| 612 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889. | 1.8 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 613 | Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906. | 3.6 | 21 |
| 614 | HCV NS5A Inhibitors in Development. <i>Clinics in Liver Disease</i> , 2013, 17, 111-121. | 1.0 | 38 |
| 615 | Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. <i>Hepatology</i> , 2013, 58, 1236-1244. | 3.6 | 26 |
| 616 | Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887. | 13.9 | 1,605 |
| 617 | Different Molecular Mechanisms of Inhibition of Bovine Viral Diarrhea Virus and Hepatitis C Virus RNA-Dependent RNA Polymerases by a Novel Benzimidazole. <i>Biochemistry</i> , 2013, 52, 3752-3764. | 1.2 | 37 |
| 618 | HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2013, 108, 471-475. | 0.2 | 26 |
| 619 | Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2013, 52, 487-510. | 1.6 | 27 |
| 620 | Telaprevir for Chronic Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2013, 17, 47-62. | 1.0 | 3 |
| 621 | Cost Effectiveness of Direct-Acting Antiviral Therapy for Treatment-Naive Patients With Chronic HCV Genotype 1 Infection in the Veterans Health Administration. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1503-1510. | 2.4 | 60 |
| 622 | Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 707-716. | 1.4 | 24 |
| 623 | Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. <i>Transplant International</i> , 2013, 26, 527-534. | 0.8 | 8 |
| 624 | Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1907-1917. | 13.9 | 418 |
| 625 | Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies. <i>Gastroenterology</i> , 2013, 144, 1450-1455.e2. | 0.6 | 153 |
| 626 | The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. <i>Nature Reviews Microbiology</i> , 2013, 11, 482-496. | 13.6 | 336 |
| 627 | Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1107-1121. | 1.9 | 67 |
| 628 | 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. <i>Nature Reviews Immunology</i> , 2013, 13, 535-542. | 10.6 | 134 |
| 629 | Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. <i>Digestive and Liver Disease</i> , 2013, 45, 1-7. | 0.4 | 26 |
| 630 | Hepatitis C Virus-Associated Glomerulonephritis. <i>Contributions To Nephrology</i> , 2013, 181, 194-206. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 631 | Advances in the management of hepatitis <sc>C</sc>. Internal Medicine Journal, 2013, 43, 1265-1271. | 0.5 | 3 |
| 632 | Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication. Antimicrobial Agents and Chemotherapy, 2013, 57, 1312-1322. | 1.4 | 49 |
| 633 | Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment. Journal of Virology, 2013, 87, 1544-1553. | 1.5 | 137 |
| 634 | The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. Clinical Infectious Diseases, 2013, 56, 228-235. | 2.9 | 24 |
| 635 | Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. Clinical Infectious Diseases, 2013, 56, 806-816. | 2.9 | 127 |
| 636 | Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy. Clinical Infectious Diseases, 2013, 56, 1466-1470. | 2.9 | 10 |
| 637 | Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates. Antiviral Research, 2013, 100, 328-336. | 1.9 | 2 |
| 638 | Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. Antimicrobial Agents and Chemotherapy, 2013, 57, 3147-3158. | 1.4 | 22 |
| 639 | Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. Value in Health, 2013, 16, 973-986. | 0.1 | 63 |
| 640 | Protease Inhibitors for Hepatitis C: Economic Implications. Pharmacoeconomics, 2013, 31, 739-751. | 1.7 | 4 |
| 641 | Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. Clinical Infectious Diseases, 2013, 56, 1382-1393. | 2.9 | 80 |
| 642 | Affinity Labeling of Hepatitis C Virus Replicase with a Nucleotide Analogue: Identification of Binding Site. Biochemistry, 2013, 52, 432-444. | 1.2 | 7 |
| 643 | Telaprevir and anaemia: What we learned from the first three patients. Scandinavian Journal of Infectious Diseases, 2013, 45, 575-575. | 1.5 | 2 |
| 644 | Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 596-606. | 8.2 | 117 |
| 645 | Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. Aids, 2013, 27, 2485-2488. | 1.0 | 21 |
| 646 | Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost-effectiveness. Hepatology, 2013, 57, 451-460. | 3.6 | 51 |
| 647 | The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. Aids, 2013, 27, 1941-1947. | 1.0 | 6 |
| 648 | IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 9-16. | 0.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 649 | <i>In Vitro</i> Characterization of GSK2485852, a Novel Hepatitis C Virus Polymerase Inhibitor. Antimicrobial Agents and Chemotherapy, 2013, 57, 5216-5224. | 1.4 | 19 |
| 650 | Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design. Journal of Clinical Microbiology, 2013, 51, 571-577. | 1.8 | 60 |
| 653 | Hepatic Fibrosis: Evaluation with Semiquantitative Contrast-enhanced CT. Radiology, 2013, 266, 151-158. | 3.6 | 78 |
| 654 | Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6. | 0.9 | 3 |
| 655 | Association of Biochemical Markers, Hepatitis C Virus and Diabetes Mellitus in Pakistani Males. Tropical Journal of Pharmaceutical Research, 2013, 12, . | 0.2 | 0 |
| 656 | Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis. Scandinavian Journal of Gastroenterology, 2013, 48, 1074-1081. | 0.6 | 4 |
| 657 | Temporal Analysis of Hepatitis C Virus Cell Entry with Occludin Directed Blocking Antibodies. PLoS Pathogens, 2013, 9, e1003244. | 2.1 | 67 |
| 658 | Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI) Tj ETQq1 1 0.784314 rgBT /Overlock Hepatitis C. Antimicrobial Agents and Chemotherapy, 2013, 57, 4727-4735. | 1.4 | 22 |
| 659 | Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus Coinfected Patients With Compensated Cirrhosis. Clinical Infectious Diseases, 2013, 56, 1646-1653. | 2.9 | 77 |
| 660 | A novel program for treating patients with trimorbidity. European Journal of Gastroenterology and Hepatology, 2013, 25, 1377-1384. | 0.8 | 18 |
| 661 | Hepatitis C virus therapy update 2013. Current Opinion in Gastroenterology, 2013, 29, 1. | 1.0 | 55 |
| 662 | A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors. Journal of Clinical Gastroenterology, 2013, 47, 800-806. | 1.1 | 3 |
| 663 | Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Current Opinion in Organ Transplantation, 2013, 18, 271-278. | 0.8 | 5 |
| 664 | New opportunities for control of dengue virus. Current Opinion in Infectious Diseases, 2013, 26, 567-574. | 1.3 | 7 |
| 665 | Sexually transmitted hepatitis C infection. Current Opinion in Infectious Diseases, 2013, 26, 66-72. | 1.3 | 100 |
| 666 | Measuring Ribavirin Concentrations During the Earliest Stages of Antiviral Therapy for Hepatitis C. Therapeutic Drug Monitoring, 2013, 35, 546-551. | 1.0 | 7 |
| 667 | Pharmacokinetic Interaction between Telaprevir and Methadone. Antimicrobial Agents and Chemotherapy, 2013, 57, 2304-2309. | 1.4 | 27 |
| 668 | An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials. Therapeutic Advances in Infectious Disease, 2013, 1, 191-208. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 669 | Risk of Liver Decompensation Among HIV/Hepatitis C Virus-Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 1401-1408. | 2.9 | 25 |
| 670 | Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity. <i>Clinical Infectious Diseases</i> , 2013, 56, 552-554. | 2.9 | 6 |
| 671 | The Hepatitis C Self-Management Program. <i>Health Education and Behavior</i> , 2013, 40, 730-740. | 1.3 | 12 |
| 672 | New agents for the treatment of hepatitis C in patients co-infected with HIV. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 71-80. | 1.1 | 4 |
| 673 | Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5037-5044. | 1.4 | 20 |
| 674 | What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 56, 1629-1636. | 2.9 | 23 |
| 675 | The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1078-1082. | 1.8 | 35 |
| 676 | Sigma-1 Receptor Regulates Early Steps of Viral RNA Replication at the Onset of Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2013, 87, 6377-6390. | 1.5 | 44 |
| 678 | Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon- α 2a and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1. <i>Hepatology Research</i> , 2013, 43, 1005-1012. | 1.8 | 4 |
| 679 | Evaluation of the Hepatitis C Virus-Infected Patient: The Initial Encounter. <i>Clinical Infectious Diseases</i> , 2013, 56, 853-860. | 2.9 | 6 |
| 680 | Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area. <i>Intervirology</i> , 2013, 56, 178-183. | 1.2 | 4 |
| 681 | Focus on drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 50-57. | 1.3 | 14 |
| 682 | Short Communication: Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 223-225. | 0.5 | 1 |
| 683 | Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S129-S137. | 2.9 | 99 |
| 684 | Genotypic and Phenotypic Analyses of Hepatitis C Virus from Patients Treated with JTK-853 in a Three-Day Monotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 436-444. | 1.4 | 2 |
| 685 | Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1115-1120. | 1.4 | 14 |
| 686 | Prediction of sustained virologic responses to combination therapy of pegylated interferon- α 2a and ribavirin in patients with chronic hepatitis C infection. <i>Journal of Family and Community Medicine</i> , 2013, 20, 35. | 0.5 | 21 |
| 687 | Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. <i>Hepatology Research</i> , 2013, 43, 865-875. | 1.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 688 | Viral Hepatitis C Gets Personal - The Value of Human Genomics to Public Health. Public Health Genomics, 2013, 16, 192-197. | 0.6 | 8 |
| 689 | Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discoveries and Therapeutics, 2013, , . | 0.6 | 5 |
| 690 | Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World Journal of Gastroenterology, 2013, 19, 8227. | 1.4 | 9 |
| 691 | British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Medicine, 2013, 14, 1-71. | 1.0 | 43 |
| 693 | Commentary: the effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis â€” authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 38, 1406-1407. | 1.9 | 6 |
| 694 | Si sigue desempeÃ±ando algÃºn papel la cinÃ©tica viral durante el tratamiento de la infecciÃ³n por el VHC?. Clinical Liver Disease, 2013, 2, S24Ã–S27Ã–. | 1.0 | 0 |
| 695 | Hepatitis B and C in liver transplantation: new strategies to combat the enemies. Reviews in Medical Virology, 2013, 23, 172-193. | 3.9 | 9 |
| 696 | Current approaches to the management of hepatitis C. The Prescriber, 2013, 24, 30-34. | 0.1 | 0 |
| 697 | Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2013, 20, 550-555. | 1.0 | 34 |
| 698 | Hepatitis C Co-infection and Severity of Liver Disease as Risk Factors for Osteoporotic Fractures Among HIV-Infected Patients. Journal of Bone and Mineral Research, 2013, 28, 2577-2583. | 3.1 | 40 |
| 699 | Criterios para seleccionar a los pacientes infectados por el VHC que son candidatos al tratamiento antiviral. Clinical Liver Disease, 2013, 2, S20Ã–S23Ã–. | 1.0 | 1 |
| 700 | Who is more likely to respond to dual treatment with pegylatedâ€”interferon and ribavirin for chronic hepatitis C? A genderâ€”oriented analysis. Journal of Viral Hepatitis, 2013, 20, 790-800. | 1.0 | 11 |
| 701 | The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Journal of Viral Hepatitis, 2013, 20, 745-760. | 1.0 | 78 |
| 702 | Exploratory study on telaprevir given every 8â€”h at 500â€”mg or 750â€”mg with peginterferonâ€”alphaâ€”2b and ribavirin in hepatitis <sc>C</sc> patients. Hepatology Research, 2013, 43, 691-701. | 1.8 | 19 |
| 703 | A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 915-921. | 1.3 | 4 |
| 704 | Effect of Ritonavirâ€”Boosted Danoprevir, a Potent Hepatitis <sc>C</sc> Virus Protease Inhibitor, on <sc>QTc</sc> Interval in Healthy Subjects: Results from a Thorough <sc>QT</sc> Study. Drug Development Research, 2013, 74, 306-315. | 1.4 | 1 |
| 705 | Pegylated versus standard interferon plus ribavirin in chronic hepatitis <sc>C</sc> genotype 4: A systematic review and metaâ€”analysis. Hepatology Research, 2013, 43, 1255-1263. | 1.8 | 3 |
| 706 | Knowledge and attitudes about hepatitis C virus (<sc>HCV</sc>) infection and its treatment in <sc>HCV</sc> monoâ€”infected and <sc>HCV</sc>/<sc>HIV</sc> coâ€”infected adults. Journal of Viral Hepatitis, 2013, 20, 708-714. | 1.0 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 707 | Características demográficas actuales del virus de la hepatitis C. <i>Clinical Liver Disease</i> , 2013, 2, S12-S15. | 1.0 | 0 |
| 708 | Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1407-1408. | 1.9 | 1 |
| 710 | Current and emerging antiviral treatments for hepatitis C infection. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 931-943. | 1.1 | 42 |
| 711 | Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 316-327. | 0.8 | 18 |
| 712 | Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849. | 3.3 | 57 |
| 713 | Editorial : Killing Two Birds With One Stone: Screening for Chronic Hepatitis C at the Time of Colonoscopy in the Baby Boomer Cohort. <i>American Journal of Gastroenterology</i> , 2013, 108, 990-992. | 0.2 | 3 |
| 714 | Prevalent and Incident Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men Engaged in Primary Care in a Boston Community Health Center. <i>Clinical Infectious Diseases</i> , 2013, 56, 1480-1487. | 2.9 | 38 |
| 715 | Lack of a Clinically Significant Drug-Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir. <i>Clinical Infectious Diseases</i> , 2013, 56, 300-306. | 2.9 | 29 |
| 716 | Oral antiviral therapies for chronic hepatitis C infection. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 107-116. | 1.1 | 10 |
| 717 | Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6333-6340. | 1.4 | 89 |
| 719 | Sustained and rapid virological responses in hepatitis C clinical trials. <i>Clinical Investigation</i> , 2013, 3, 1083-1093. | 0.0 | 2 |
| 720 | Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review. <i>Annals of Internal Medicine</i> , 2013, 158, 114. | 2.0 | 99 |
| 721 | Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma. <i>Annals of Internal Medicine</i> , 2013, 158, 329. | 2.0 | 734 |
| 722 | Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment rationale and clinical trials. <i>Clinical Investigation</i> , 2013, 3, 191-207. | 0.0 | 7 |
| 723 | Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life. <i>Future Virology</i> , 2013, 8, 735-743. | 0.9 | 0 |
| 724 | Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 361-374. | 1.6 | 24 |
| 725 | Telaprevir: evidence and guidance for use in clinical practice. <i>Clinical Practice (London, England)</i> , 2013, 10, 265-273. | 0.1 | 0 |
| 726 | Review of Drug Interactions with Telaprevir and Antiretrovirals. <i>Antiviral Therapy</i> , 2013, 18, 1-8. | 0.6 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 727 | Women with Chronic Hepatitis C Virus Infection. <i>Southern Medical Journal</i> , 2013, 106, 422-426. | 0.3 | 3 |
| 728 | Non-Hodgkin's Lymphomas, Version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 257-273. | 2.3 | 53 |
| 729 | Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. <i>Antiviral Therapy</i> , 2014, 19, 527-531. | 0.6 | 18 |
| 730 | JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 514-523. | 3.6 | 49 |
| 731 | Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609. | 3.6 | 431 |
| 732 | The FDA, bridging data, and hepatitis C. <i>Hepatology</i> , 2013, 57, 875-877. | 3.6 | 1 |
| 733 | Potential consequences of healthcare recommendations: A focus on the U.S. Preventive Services Task Force. <i>Hepatology</i> , 2013, 58, 422-427. | 3.6 | 2 |
| 734 | Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials. <i>Hepatology</i> , 2013, 58, 488-490. | 3.6 | 2 |
| 735 | PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 524-537. | 3.6 | 39 |
| 736 | Oral direct-acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus-related cirrhosis. <i>Liver Transplantation</i> , 2013, 19, 780-781. | 1.3 | 8 |
| 737 | Hepatitis C screening: Getting it right. <i>Hepatology</i> , 2013, 57, 1644-1650. | 3.6 | 11 |
| 738 | Potential role for statins in the treatment of chronic HCV infection. <i>Future Virology</i> , 2013, 8, 727-729. | 0.9 | 4 |
| 739 | Intensified Peginterferon α -2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 271-279. | 1.1 | 3 |
| 740 | Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2013, 27, 2541-2549. | 1.0 | 29 |
| 741 | IL28B in the Era of Direct-acting Antivirals for Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 222-227. | 1.1 | 18 |
| 742 | Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 67-73. | 0.9 | 27 |
| 743 | Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 587-593. | 0.8 | 10 |
| 744 | Telaprevir is Effective Given Every 12 H at 750 Mg with Pegylated Interferon α -2b and Ribavirin to Japanese Patients with HCV-1B IL28B Rs8099917 Tt. <i>Antiviral Therapy</i> , 2014, 19, 277-285. | 0.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 745 | Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715. | 0.6 | 12 |
| 746 | Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414. | 0.6 | 5 |
| 747 | Randomized Study of Asunaprevir plus Pegylated Interferon- α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893. | 0.6 | 44 |
| 749 | Pegylated Interferon- α 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729. | 2.0 | 91 |
| 750 | Effect of the Coadministration of Daclatasvir on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate. <i>Antiviral Therapy</i> , 2014, 19, 511-519. | 0.6 | 14 |
| 751 | Telaprevir-Related Dermatitis. <i>JAMA Dermatology</i> , 2013, 149, 152. | 2.0 | 52 |
| 752 | The Efficacy and Safety of Telaprevir-based Regimens for Treating Chronic Hepatitis C Virus Genotype 1 Infection: A Meta-analysis of Randomized Trials. <i>Internal Medicine</i> , 2013, 52, 653-660. | 0.3 | 9 |
| 753 | Long-term Combined Therapy with Very-low-dose Peginterferon and Ursodeoxycholic Acid Decreased the Spleen Size in a Patient with Hepatitis C Virus-related Cirrhosis. <i>Internal Medicine</i> , 2013, 52, 363-367. | 0.3 | 2 |
| 754 | Hepatitis C virus: virology and life cycle. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 17. | 4.5 | 134 |
| 755 | The Natural Killer Cell Response to HCV Infection. <i>Immune Network</i> , 2013, 13, 168. | 1.6 | 18 |
| 756 | Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2013, 108, 48-53. | 0.8 | 16 |
| 757 | Novel drugs in the management of difficult-to-treat hepatitis C genotypes. <i>Hepatic Medicine: Evidence and Research</i> , 2013, 5, 53. | 0.9 | 8 |
| 758 | Profound jaundice in a patient with acute hepatitis C. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200233-bcr2013200233. | 0.2 | 1 |
| 759 | Viral hepatitis and HIV: update and management. <i>Antiviral Therapy</i> , 2013, 18, 451-458. | 0.6 | 4 |
| 760 | Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 1033-1035. | 0.6 | 10 |
| 762 | Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. <i>PLoS ONE</i> , 2013, 8, e58380. | 1.1 | 1 |
| 763 | Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. <i>PLoS ONE</i> , 2013, 8, e58975. | 1.1 | 61 |
| 764 | Nonresponse to Interferon- α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e61568. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 765 | Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome. PLoS ONE, 2013, 8, e62674. | 1.1 | 8 |
| 766 | Current and Future Disease Progression of the Chronic HCV Population in the United States. PLoS ONE, 2013, 8, e63959. | 1.1 | 28 |
| 767 | Variation in Both IL28B and KIR2DS3 Genes Influence Pegylated Interferon and Ribavirin Hepatitis C Treatment Outcome in HIV-1 Co-Infection. PLoS ONE, 2013, 8, e66831. | 1.1 | 12 |
| 768 | Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients. PLoS ONE, 2013, 8, e69698. | 1.1 | 11 |
| 769 | New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication. PLoS ONE, 2013, 8, e72519. | 1.1 | 7 |
| 770 | Relevance of Baseline Viral Genetic Heterogeneity and Host Factors for Treatment Outcome Prediction in Hepatitis C Virus 1b-Infected Patients. PLoS ONE, 2013, 8, e72600. | 1.1 | 9 |
| 771 | Hepatitis C virus (HCV) infection in Africa: a review. Pan African Medical Journal, 2013, 2, 44. | 0.3 | 119 |
| 772 | Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. Annals of Internal Medicine, 2013, 159, 86-96. | 2.0 | 179 |
| 774 | Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives. Scientific World Journal, The, 2013, 2013, 1-9. | 0.8 | 28 |
| 775 | Hepatitis C Virus Infection: Looking for Interferon Free Regimens. Scientific World Journal, The, 2013, 2013, 1-11. | 0.8 | 11 |
| 776 | Epidemiology and Treatment of Hepatitis C Genotypes 5 and 6. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, e8-e12. | 1.8 | 21 |
| 777 | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian Guidelines for Management and Treatment of HIV/Hepatitis C Coinfection in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 217-238. | 0.7 | 10 |
| 778 | Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clinical Epidemiology, 2013, 5, 173. | 1.5 | 11 |
| 779 | Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Annals of Hepatology, 2013, 12, 380-391. | 0.6 | 54 |
| 781 | Syncope during boceprevir treatment in hepatitis C. Annals of Hepatology, 2013, 12, 837-838. | 0.6 | 1 |
| 782 | Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Annals of Hepatology, 2013, 12, 190-198. | 0.6 | 2 |
| 783 | An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology, 2013, 12, S3-S35. | 0.6 | 9 |
| 784 | Raloxifene hydrochloride as hepatitis C treatment. Annals of Hepatology, 2013, 12, 164-165. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 786 | Treatment of Chronic HCV Infection in the Era of Protease Inhibitors. , 2013, , . | | 0 |
| 787 | Management of HCV Infection in the Elderly. , 2013, , . | | 0 |
| 788 | The Skin and Viral Liver Disease. , 2013, , . | | 0 |
| 790 | Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy. Italian Journal of Medicine, 2014, , . | 0.2 | 0 |
| 791 | Triple antiviral therapy with telaprevir after liver transplantation: a case series. Transplant Research and Risk Management, 2014, , 73. | 0.7 | 2 |
| 792 | Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug, Healthcare and Patient Safety, 2014, 6, 37. | 1.0 | 37 |
| 793 | Hepatitis C in Argentina: epidemiology and treatment. Hepatic Medicine: Evidence and Research, 2014, 6, 35. | 0.9 | 6 |
| 794 | Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and Clinical Risk Management, 2014, 10, 493. | 0.9 | 29 |
| 795 | Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C. PLoS ONE, 2014, 9, e90295. | 1.1 | 19 |
| 796 | Hepatic HMOX1 Expression Positively Correlates with Bach-1 and miR-122 in Patients with HCV Mono and HIV/HCV Coinfection. PLoS ONE, 2014, 9, e95564. | 1.1 | 9 |
| 797 | Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin. PLoS ONE, 2014, 9, e103370. | 1.1 | 4 |
| 798 | The Dynamic Relationship between Innate Immune Biomarkers and Interferon-Based Treatment Effects and Outcome in Hepatitis C Virus Infection Is Altered by Telaprevir. PLoS ONE, 2014, 9, e105665. | 1.1 | 7 |
| 799 | Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 445-451. | 0.8 | 62 |
| 800 | Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 529-534. | 0.8 | 5 |
| 801 | Telaprevir Activity is unaffected by the Q80K Polymorphism in Hepatitis C virus Genotype 1a. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 510-510. | 0.8 | 1 |
| 802 | Chronic Hepatitis C in Western Canada: A Survey of Practice Patterns among Gastroenterologists in Alberta and British Columbia. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, e1-e4. | 0.8 | 1 |
| 803 | Hepatitis C Worldwide and in Brazil: Silent Epidemic"Data on Disease including Incidence, Transmission, Prevention, and Treatment. Scientific World Journal, The, 2014, 2014, 1-10. | 0.8 | 25 |
| 804 | Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. Reviews on Recent Clinical Trials, 2014, 9, 1-7. | 0.4 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 805 | Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 9633. | 1.4 | 135 |
| 806 | PBDE: Structure-Activity Studies for the Inhibition of Hepatitis C Virus NS3 Helicase. <i>Molecules</i> , 2014, 19, 4006-4020. | 1.7 | 7 |
| 807 | Chronic hepatitis C: future treatment. <i>Clinical Pharmacology: Advances and Applications</i> , 2014, 6, 1. | 0.8 | 45 |
| 808 | A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 533-540. | 2.2 | 15 |
| 809 | SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. <i>Clinical Epidemiology</i> , 2014, 6, 49. | 1.5 | 8 |
| 810 | Patient adherence issues in the treatment of hepatitis C. <i>Patient Preference and Adherence</i> , 2014, 8, 763. | 0.8 | 16 |
| 811 | Boceprevir in Mexico: Experience in a Series of Cases. , 2014, 05, . | | 0 |
| 812 | CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian Guidelines for the Treatment of Hepatitis C Infection in HIV-hepatitis C Coinfected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 311-320. | 0.7 | 8 |
| 813 | Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. <i>World Journal of Gastroenterology</i> , 2014, 20, 2876. | 1.4 | 26 |
| 815 | Current issues in comparative effectiveness research for hepatitis C. <i>Comparative Effectiveness Research</i> , 2014, , 13. | 0.2 | 0 |
| 816 | Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin?. <i>Journal of Infectious Disease and Therapy</i> , 2014, 02, . | 0.1 | 0 |
| 817 | A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. <i>Annals of Hepatology</i> , 2014, 13, 364-375. | 0.6 | 18 |
| 818 | Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. <i>Annals of Hepatology</i> , 2014, 13, 452-455. | 0.6 | 16 |
| 819 | Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, S4-S66. | 0.6 | 28 |
| 820 | Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment. <i>Annals of Hepatology</i> , 2014, 13, 753-761. | 0.6 | 11 |
| 821 | Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia. <i>Annals of Hepatology</i> , 2014, 13, 843-844. | 0.6 | 2 |
| 822 | The good, the bad and the ugly of the new treatments for hepatitis C virus. <i>Annals of Hepatology</i> , 2014, 13, 574-575. | 0.6 | 3 |
| 825 | Serum 25-hydroxyvitamin D ₃ levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. <i>Hepatology Research</i> , 2014, 44, 1277-1285. | 1.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 826 | Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a+Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1136-1145. | 1.4 | 19 |
| 828 | Sofosbuvir as backbone of interferon free treatments. <i>Digestive and Liver Disease</i> , 2014, 46, S212-S220. | 0.4 | 23 |
| 829 | The future of dual therapy for hepatitis C virus. <i>Future Virology</i> , 2014, 9, 905-912. | 0.9 | 1 |
| 830 | Barriers to Hepatitis C Antiviral Therapy in HIV/HCV Co-Infected Patients in the United States: A Review. <i>AIDS Patient Care and STDs</i> , 2014, 28, 228-239. | 1.1 | 24 |
| 831 | Reply. <i>Hepatology</i> , 2014, 60, 1110-1110. | 3.6 | 0 |
| 832 | Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-na+ve genotype 1b hepatitis C virus: a case report. <i>Clinical Journal of Gastroenterology</i> , 2014, 7, 465-470. | 0.4 | 4 |
| 833 | Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 38-47. | 1.4 | 25 |
| 834 | Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014, 159, 3345-3351. | 0.9 | 3 |
| 835 | National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996+2010 in the United States: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2014, 14, 536. | 1.3 | 11 |
| 836 | Hepatitis C treatment eligibility among HIV+hepatitis C virus coinfecting patients in Oregon: a population-based sample. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1178-1185. | 0.6 | 9 |
| 837 | LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. <i>Clinical Proteomics</i> , 2014, 11, 44. | 1.1 | 1 |
| 838 | Effectiveness Research in the Evolving HCV Landscape. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2845-2847. | 1.1 | 1 |
| 840 | Editorial Commentary: Management of Hepatitis C Virus in HIV-Infected Patients in the Era of Direct-Acting Antivirals. <i>Clinical Infectious Diseases</i> , 2014, 58, 880-882. | 2.9 | 9 |
| 841 | Efficacy of daclatasvir in hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1025-1031. | 2.0 | 11 |
| 842 | Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. <i>Journal of Hepatology</i> , 2014, 61, S98-S107. | 1.8 | 28 |
| 843 | National Estimates of Healthcare Utilization by Individuals With Hepatitis C Virus Infection in the United States. <i>Clinical Infectious Diseases</i> , 2014, 59, 755-764. | 2.9 | 64 |
| 844 | Incidence of virological failure and emergence of resistance with twice+daily vs every 8h administration of telaprevir in the OPTIMIZE study. <i>Journal of Viral Hepatitis</i> , 2014, 21, 835-842. | 1.0 | 5 |
| 845 | Actualizaci3n en el tratamiento de la hepatitis C. <i>Medicine</i> , 2014, 11, 4103-4111. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 846 | Optimal Management of HCV Genotype 4. <i>Current Hepatology Reports</i> , 2014, 13, 286-294. | 0.4 | 0 |
| 847 | Current and future targets of antiviral therapy in the hepatitis C virus life cycle. <i>Future Virology</i> , 2014, 9, 947-965. | 0.9 | 3 |
| 848 | A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity. <i>PLoS Pathogens</i> , 2014, 10, e1004064. | 2.1 | 66 |
| 849 | Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients. <i>Seminars in Liver Disease</i> , 2014, 34, 072-078. | 1.8 | 6 |
| 850 | Quasispecies and Drug Resistance. , 2014, , 1-22. | | 0 |
| 851 | Resistance to Cyclophilin Inhibitors. , 2014, , 1-24. | | 0 |
| 852 | Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. <i>Gut</i> , 2014, 63, 1150-1158. | 6.1 | 41 |
| 853 | Cleavage of the T Cell Protein Tyrosine Phosphatase by the Hepatitis C Virus Nonstructural 3/4A Protease Induces a Th1 to Th2 Shift Reversible by Ribavirin Therapy. <i>Journal of Immunology</i> , 2014, 192, 1671-1680. | 0.4 | 12 |
| 854 | Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment. <i>PLoS Computational Biology</i> , 2014, 10, e1003772. | 1.5 | 7 |
| 855 | Inhibition of Hepatitis C Virus Replication In Vitro by Xanthohumol, A Natural Product Present in Hops. <i>Planta Medica</i> , 2014, 80, 171-176. | 0.7 | 14 |
| 856 | Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. <i>Annals of Pharmacotherapy</i> , 2014, 48, 826-836. | 0.9 | 2 |
| 858 | Interferon-Free Regimens in the Liver-Transplant Setting. <i>Seminars in Liver Disease</i> , 2014, 34, 058-071. | 1.8 | 34 |
| 859 | Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 387. | 0.4 | 31 |
| 860 | Amphipathic Î±-Helices in Apolipoproteins Are Crucial to the Formation of Infectious Hepatitis C Virus Particles. <i>PLoS Pathogens</i> , 2014, 10, e1004534. | 2.1 | 73 |
| 861 | Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. <i>Journal of Dermatological Case Reports</i> , 2014, 8, 95-102. | 1.1 | 5 |
| 862 | Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. <i>Hepatitis Research and Treatment</i> , 2014, 2014, 1-8. | 2.0 | 4 |
| 863 | Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. <i>Drug Discoveries and Therapeutics</i> , 2014, 8, 89-95. | 0.6 | 12 |
| 864 | Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C. <i>Seminars in Liver Disease</i> , 2014, 34, 030-036. | 1.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 865 | Simeprevir for the treatment of hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 241. | 0.4 | 29 |
| 866 | Considerations on Direct Antiviral Agent Therapy in Patients Having Chronic Hepatitis C from Constanta County. <i>Acta Marisiensis - Seria Medica</i> , 2014, 60, 204-206. | 0.3 | 1 |
| 867 | The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4747-4779. | 1.8 | 23 |
| 868 | Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. <i>BMJ Open</i> , 2014, 4, e006255. | 0.8 | 2 |
| 869 | The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170. | 2.0 | 129 |
| 872 | Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. <i>Journal of Medical Economics</i> , 2014, 17, 862-871. | 1.0 | 15 |
| 873 | SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α -2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436. | 1.4 | 13 |
| 874 | Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis. <i>Gut</i> , 2014, 63, 1033-1034. | 6.1 | 5 |
| 875 | Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. <i>Digestive and Liver Disease</i> , 2014, 46, S197-S205. | 0.4 | 9 |
| 877 | Targets for Antiviral Therapy of Hepatitis C. <i>Seminars in Liver Disease</i> , 2014, 34, 009-021. | 1.8 | 40 |
| 878 | Treatment of Recurrent Genotype 1 Hepatitis C Post-Liver Transplantation: Single Center Experience with Telaprevir-Based Triple Therapy. <i>Zeitschrift Fur Gastroenterologie</i> , 2014, 52, 27-34. | 0.2 | 19 |
| 881 | Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 647-653. | 1.4 | 31 |
| 882 | Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. <i>Gene Therapy</i> , 2014, 21, 739-750. | 2.3 | 15 |
| 883 | Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses. <i>Molecular Therapy</i> , 2014, 22, 881-890. | 3.7 | 30 |
| 884 | Costs of telaprevir-based triple therapy for hepatitis C: \$189,000 per sustained virological response. <i>Hepatology</i> , 2014, 60, 1187-1195. | 3.6 | 39 |
| 885 | Is there still a role for PEG IFN + RBV therapy in patients with HCV genotype 1?. <i>Liver International</i> , 2014, 34, 11-12. | 1.9 | 1 |
| 886 | How to optimize current therapy of HCV genotype 1 infection with boceprevir. <i>Liver International</i> , 2014, 34, 4-10. | 1.9 | 0 |
| 887 | Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus. <i>Hepatology</i> , 2014, 59, 1688-1691. | 3.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 888 | Hepatitis C screening beyond <sc>CDC</sc> guidelines in an Egyptian immigrant community. <i>Liver International</i> , 2014, 34, 253-258. | 1.9 | 12 |
| 889 | Sofosbuvir. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1019-1029. | 0.9 | 52 |
| 890 | Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 984-985. | 1.9 | 0 |
| 891 | Infrequent Development of Resistance in Genotype 1 ⁶ Hepatitis C Virus ⁶ Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 1666-1674. | 2.9 | 199 |
| 892 | Treating <sc>HCV</sc> in <sc>HIV</sc> 2013: on the cusp of change. <i>Liver International</i> , 2014, 34, 53-59. | 1.9 | 7 |
| 893 | Use of first-generation <sc>HCV</sc> protease inhibitors in patients coinfecting by <sc>HIV</sc> and <sc>HCV</sc> genotype 1. <i>Liver International</i> , 2014, 34, 869-889. | 1.9 | 4 |
| 894 | Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1074-1081. | 2.8 | 12 |
| 895 | Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis <sc>C</sc>-related liver disease and costs in <sc>A</sc>ustralia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1-9. | 1.4 | 67 |
| 896 | Anti-interferon- λ neutralizing antibody induced telaprevir resistance under the interferon- λ plus telaprevir treatment in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 453-458. | 1.0 | 2 |
| 897 | Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. <i>Liver International</i> , 2014, 34, 668-671. | 1.9 | 13 |
| 898 | Potential role of oxidative DNA damage in the impact of PNPLA3 variant (rs 738409 C>G) in hepatocellular carcinoma risk. <i>Hepatology</i> , 2014, 60, 1110-1111. | 3.6 | 5 |
| 899 | Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan. <i>Journal of Medical Virology</i> , 2014, 86, 1877-1885. | 2.5 | 4 |
| 900 | Adjuvant epoetin α with peginterferon α and ribavirin in <sc>J</sc>apanese ribavirin-intolerant relapsed patients with chronic hepatitis <sc>C</sc> genotype 2. <i>Hepatology Research</i> , 2014, 44, E290-6. | 1.8 | 1 |
| 901 | In routine clinical practice, few physicians use early viral kinetics to guide <sc>HCV</sc> dual therapy treatment decisions. <i>Liver International</i> , 2014, 34, e217-28. | 1.9 | 1 |
| 902 | Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. <i>Digestive and Liver Disease</i> , 2014, 46, S179-S185. | 0.4 | 26 |
| 903 | Strategies to manage hepatitis <sc>C</sc> virus (<sc>HCV</sc>) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89. | 1.0 | 161 |
| 904 | Medical co-morbidities and practice. <i>Haemophilia</i> , 2014, 20, 130-136. | 1.0 | 8 |
| 905 | Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. <i>Liver Transplantation</i> , 2014, 20, 1106-1117. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 906 | Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment. <i>Digestive Diseases</i> , 2014, 32, 747-754. | 0.8 | 18 |
| 907 | Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 545-553. | 1.4 | 113 |
| 908 | Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. <i>Liver International</i> , 2014, 34, 707-719. | 1.9 | 15 |
| 909 | Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: Direct sequencing and pyrosequencing of the HCV regions. <i>Journal of Medical Virology</i> , 2014, 86, 1886-1897. | 2.5 | 5 |
| 910 | Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 543-544. | 1.9 | 1 |
| 911 | Management of HCV patients with cirrhosis with direct acting antivirals. <i>Liver International</i> , 2014, 34, 38-45. | 1.9 | 22 |
| 912 | A pill for HCV – “myth or foreseeable future?”. <i>Liver International</i> , 2014, 34, 6-11. | 1.9 | 20 |
| 913 | Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2609-2622. | 0.9 | 17 |
| 914 | Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 563-573. | 1.0 | 13 |
| 915 | Cost-Effectiveness of Telaprevir in Patients with Genotype 1 Hepatitis C in Australia. <i>Value in Health</i> , 2014, 17, 792-800. | 0.1 | 13 |
| 916 | Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2014, 59, 1657-1665. | 2.9 | 34 |
| 917 | Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. <i>Journal of Gastroenterology</i> , 2014, 49, 1504-1513. | 2.3 | 62 |
| 918 | Île-1 is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. <i>Journal of Medical Virology</i> , 2014, 86, 461-472. | 2.5 | 7 |
| 919 | Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-Î and ribavirin in chronic hepatitis C virus patients. <i>Liver International</i> , 2014, 34, 551-557. | 1.9 | 13 |
| 920 | Optimal Management of HCV Transplant Patients. <i>Current Hepatology Reports</i> , 2014, 13, 304-313. | 0.4 | 0 |
| 921 | A practical guide for antiviral therapy of chronic Hepatitis C. <i>GE Portuguese Journal of Gastroenterology</i> , 2014, 21, 221-230. | 0.3 | 6 |
| 922 | Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. <i>Journal of Hepatology</i> , 2014, 61, S120-S131. | 1.8 | 65 |
| 923 | Management of acute and chronic HCV infection in persons with HIV coinfection. <i>Journal of Hepatology</i> , 2014, 61, S108-S119. | 1.8 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 924 | Synthesis and Biological Applications of Phosphinates and Derivatives. <i>Topics in Current Chemistry</i> , 2014, 360, 39-114. | 4.0 | 27 |
| 925 | Daclatasvir for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 725-738. | 1.4 | 7 |
| 927 | Incidence and Management of Rash in Telaprevir-Treated Patients. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1166-1171. | 0.9 | 4 |
| 928 | HCV Triple Therapy is Equally effective in African-Americans and Non-African-Americans. <i>Journal of Racial and Ethnic Health Disparities</i> , 2014, 1, 319-325. | 1.8 | 1 |
| 929 | Advances in and the future of treatments for hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 633-647. | 1.4 | 8 |
| 930 | Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. <i>BMC Gastroenterology</i> , 2014, 14, 47. | 0.8 | 10 |
| 931 | Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. <i>BMC Health Services Research</i> , 2014, 14, 429. | 0.9 | 5 |
| 932 | Validation of the Fatigue Severity Scale in chronic hepatitis C. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 90. | 1.0 | 29 |
| 933 | In vitro blood cell responsiveness to IFN- λ predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients. <i>Journal of Translational Medicine</i> , 2014, 12, 206. | 1.8 | 4 |
| 934 | Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 80-84. | 0.7 | 8 |
| 935 | Hepatitis C Direct-acting Antiviral Agents. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 106-112. | 1.1 | 22 |
| 936 | Hepatitis C Virus-Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance. <i>Journal of Addiction Medicine</i> , 2014, 8, 249-257. | 1.4 | 37 |
| 937 | Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 548-552. | 1.1 | 0 |
| 938 | Reduced expression of Blimp-1 in memory B cells in patients with HIV-1 infection suggests distinct roles of this molecule for B and T cell regulation. <i>Aids</i> , 2014, 28, 2489-2491. | 1.0 | 2 |
| 939 | VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 761-773. | 0.8 | 11 |
| 940 | Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 65-73. | 0.8 | 3 |
| 941 | Hepatitis C genotype 1. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 535-539. | 1.3 | 0 |
| 942 | Chronic binge alcohol increases susceptibility to rectal simian immunodeficiency virus infection in macaques. <i>Aids</i> , 2014, 28, 2485-2487. | 1.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 943 | Hepatitis C and neutropenia. <i>Current Opinion in Hematology</i> , 2014, 21, 58-63. | 1.2 | 9 |
| 944 | Physician Nonadherence With a Hepatitis C Screening Program. <i>Quality Management in Health Care</i> , 2014, 23, 1-9. | 0.4 | 20 |
| 945 | Hepatitis C virus therapy in the direct acting antiviral era. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 217-222. | 1.0 | 30 |
| 946 | Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 836-845. | 0.8 | 24 |
| 947 | Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1329-1334. | 0.8 | 0 |
| 948 | Real-world outcomes in patients with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 388-395. | 0.8 | 3 |
| 949 | Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 781-787. | 0.8 | 3 |
| 950 | Delivery of treatment for hepatitis C virus infection in the primary care setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1003-1009. | 0.8 | 16 |
| 951 | Hepatitis C Virus and Liver Transplantation. , 2014, , . | | 1 |
| 952 | Predictors of hepatitis C treatment response: what's new?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 183-191. | 2.0 | 3 |
| 953 | Viral Hepatitis and Liver Transplantation: Pathogenesis, Prevention and Therapy of Recurrent Disease. <i>Digestive Diseases</i> , 2014, 32, 538-544. | 0.8 | 3 |
| 954 | Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. <i>World Journal of Hepatology</i> , 2014, 6, 870. | 0.8 | 14 |
| 955 | Treatment of Hepatitis C. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 631. | 3.8 | 390 |
| 956 | Widespread Morbilliform Eruption Associated With Telaprevir. <i>JAMA Dermatology</i> , 2014, 150, 756. | 2.0 | 7 |
| 957 | Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections. <i>Frontiers in Microbiology</i> , 2014, 5, 690. | 1.5 | 17 |
| 958 | New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development. <i>Seminars in Liver Disease</i> , 2014, 34, 022-029. | 1.8 | 89 |
| 959 | The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C. <i>JAMA Internal Medicine</i> , 2014, 174, 204. | 2.6 | 113 |
| 960 | Pegylated Interferon Pharmacokinetics and Self-Reported Depressive Symptoms During Antiviral Treatment for Chronic Hepatitis C. <i>Pharmacopsychiatry</i> , 2014, 47, 195-201. | 1.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 961 | Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus. <i>Journal of Pharmacy Technology</i> , 2014, 30, 159-167. | 0.5 | 3 |
| 962 | Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. <i>Hepatology Research</i> , 2014, 44, 1165-1171. | 1.8 | 14 |
| 963 | Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120. | 1.4 | 28 |
| 964 | Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 157-164. | 2.0 | 2 |
| 965 | Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. <i>BMC Infectious Diseases</i> , 2014, 14, S3. | 1.3 | 5 |
| 966 | Cost-Effectiveness of IL28^{A>} Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection. <i>Public Health Genomics</i> , 2014, 17, 306-319. | 0.6 | 6 |
| 967 | Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 996-1002. | 0.8 | 4 |
| 968 | Cost of treating hepatitis C in Germany. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1278-1285. | 0.8 | 9 |
| 969 | Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfecting advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir. <i>Aids</i> , 2014, 28, 2487-2489. | 1.0 | 3 |
| 970 | Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. <i>Hepatology Research</i> , 2014, 44, 1259-1264. | 1.8 | 9 |
| 971 | Pretreatment prediction of the outcome of response-guided peginterferon and ribavirin therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1996-2005. | 1.4 | 2 |
| 972 | Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. <i>Journal of Hepatology</i> , 2014, 60, 78-86. | 1.8 | 182 |
| 973 | What is the future of ribavirin therapy for hepatitis C?. <i>Antiviral Research</i> , 2014, 104, 34-39. | 1.9 | 41 |
| 974 | A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. <i>Journal of Hepatology</i> , 2014, 61, 508-514. | 1.8 | 75 |
| 975 | Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. <i>Gastroenterology & Hepatology</i> , 2014, 37, 1-8. | 0.2 | 2 |
| 976 | Hepatitis C treatment: an incipient therapeutic revolution. <i>Trends in Molecular Medicine</i> , 2014, 20, 315-321. | 3.5 | 42 |
| 977 | From the CUPIC study: Great times are not coming (?). <i>Journal of Hepatology</i> , 2014, 60, 234-235. | 1.8 | 1 |
| 978 | Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial. <i>Journal of Hepatology</i> , 2014, 60, 699-705. | 1.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 980 | Coût-efficacité et VHC: mise au point. Journal Des Anti-infectieux, 2014, 16, 50-63. | 0.1 | 0 |
| 981 | Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. Gastroenterology, 2014, 146, 744-753.e3. | 0.6 | 42 |
| 982 | Impact of New Hepatitis C Treatments in Different Regions of the World. Gastroenterology, 2014, 146, 1145-1150.e4. | 0.6 | 48 |
| 983 | Pachydermodactyly Successfully Treated With Triamcinolone Injections. Actas Dermo-sifilograficas, 2014, 105, 319-321. | 0.2 | 10 |
| 984 | Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology, 2014, 59, 71-77. | 3.6 | 37 |
| 985 | Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. Archives of Virology, 2014, 159, 831-846. | 0.9 | 15 |
| 986 | Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. Journal of Hepatology, 2014, 60, 16-21. | 1.8 | 25 |
| 987 | Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. Journal of Gastroenterology, 2014, 49, 737-747. | 2.3 | 3 |
| 988 | Safety and efficacy of faldaprevir with pegylated interferon alfa2a and ribavirin in Japanese patients with chronic genotype 1 hepatitis C infection. Liver International, 2014, 34, 78-88. | 1.9 | 21 |
| 989 | Functional Attributes of Responding T Cells in HCV Infection: The Recent Advances in Engineering Functional Antiviral T Cells. Archivum Immunologiae Et Therapiae Experimentalis, 2014, 62, 23-30. | 1.0 | 4 |
| 990 | Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. Journal of Gastroenterology, 2014, 49, 138-147. | 2.3 | 73 |
| 991 | Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. Journal of Gastroenterology, 2014, 49, 1485-1494. | 2.3 | 7 |
| 992 | Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. Hepatology Research, 2014, 44, E447-54. | 1.8 | 13 |
| 994 | Hepatitis C virus: a silent killer relevant to dentistry. Oral Diseases, 2014, 20, 425-429. | 1.5 | 4 |
| 995 | Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B. Antimicrobial Agents and Chemotherapy, 2014, 58, 3399-3410. | 1.4 | 20 |
| 996 | Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. Gastroenterology, 2014, 147, 132-142.e4. | 0.6 | 232 |
| 997 | Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure. Antiviral Research, 2014, 105, 112-117. | 1.9 | 11 |
| 998 | Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. Journal of Viral Hepatitis, 2014, 21, 229-240. | 1.0 | 65 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 999 | Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , 2014, 21, 260-263. | 1.0 | 24 |
| 1000 | Clinical significance of pretreatment serum interferon- γ inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. <i>Hepatology Research</i> , 2014, 44, E397-E407. | 1.8 | 12 |
| 1001 | Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV/HCV coinfecting subjects. <i>Antiviral Research</i> , 2014, 104, 59-61. | 1.9 | 6 |
| 1002 | PCR-Based <i>In Vitro</i> Synthesis of Hepatitis C Virus NS3 Protease for Rapid Phenotypic Resistance Testing of Protease Inhibitors. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1139-1145. | 1.8 | 1 |
| 1003 | Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. <i>Antiviral Research</i> , 2014, 104, 102-109. | 1.9 | 10 |
| 1004 | Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014, 44, E163-71. | 1.8 | 12 |
| 1005 | Serum interferon- γ inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. <i>Hepatology Research</i> , 2014, 44, 1208-1216. | 1.8 | 9 |
| 1006 | HCV F1/F2 patients: treat now or continue to wait. <i>Liver International</i> , 2014, 34, 79-84. | 1.9 | 7 |
| 1007 | Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir. <i>Hepatology</i> , 2014, 60, 1109-1110. | 3.6 | 11 |
| 1008 | Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 209-216. | 1.9 | 16 |
| 1009 | Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2014, 146, 420-429. | 0.6 | 188 |
| 1010 | Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 93-103. | 1.9 | 49 |
| 1011 | Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 14-24. | 0.7 | 22 |
| 1012 | Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 144-150. | 1.4 | 18 |
| 1013 | Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2014, 21, 341-347. | 1.0 | 38 |
| 1014 | Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP and PROPEL studies. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 533-542. | 1.1 | 2 |
| 1015 | Role of IL28B for chronic hepatitis C treatment toward personalized medicine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 241-249. | 1.4 | 49 |
| 1016 | Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. <i>Digestive and Liver Disease</i> , 2014, 46, 88-89. | 0.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1017 | Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2014, 146, 736-743.e1. | 0.6 | 201 |
| 1018 | Should we await IFN-free regimens to treat HCV genotype 1 treatment-naïve patients? A cost-effectiveness analysis (ANRS 95141). <i>Journal of Hepatology</i> , 2014, 61, 7-14. | 1.8 | 57 |
| 1019 | All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2014, 59, 872-880. | 1.1 | 42 |
| 1020 | Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 273-281. | 1.1 | 4 |
| 1021 | Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus. <i>Hepatology International</i> , 2014, 8, 112-120. | 1.9 | 7 |
| 1022 | Interferon-Free Regimens for Hepatitis C: Combine and Conquer. <i>BioDrugs</i> , 2014, 28, 161-169. | 2.2 | 2 |
| 1023 | Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. <i>Journal of Viral Hepatitis</i> , 2014, 21, e98-e107. | 1.0 | 23 |
| 1024 | All-oral combination of ledipasvir, vedoprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. <i>Hepatology</i> , 2014, 60, 56-64. | 3.6 | 43 |
| 1025 | Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1673-1693. | 2.9 | 174 |
| 1026 | Update on Recently Approved Treatments for Hepatitis C. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 211-228. | 0.3 | 7 |
| 1027 | Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naïve HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 658-667. | 1.9 | 51 |
| 1028 | Emerging therapies for the treatment of hepatitis C. <i>EMBO Molecular Medicine</i> , 2014, 6, 4-15. | 3.3 | 93 |
| 1029 | Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 137-147. | 1.9 | 74 |
| 1030 | Mass Balance and Metabolite Profiling of Steady-State Faldaprevir, a Hepatitis C Virus NS3/4 Protease Inhibitor, in Healthy Male Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2369-2376. | 1.4 | 9 |
| 1031 | Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2781-2797. | 1.4 | 55 |
| 1032 | The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010. <i>Journal of Hepatology</i> , 2014, 60, 691-698. | 1.8 | 145 |
| 1033 | Current race in the development of DAAs (direct-acting antivirals) against HCV. <i>Biochemical Pharmacology</i> , 2014, 89, 441-452. | 2.0 | 83 |
| 1034 | Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: "A Flood of Opportunity". <i>American Journal of Transplantation</i> , 2014, 14, 994-1002. | 2.6 | 72 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1035 | Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. <i>Journal of Hepatology</i> , 2014, 61, 219-227. | 1.8 | 135 |
| 1036 | Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014, 59, 1692-1705. | 3.6 | 75 |
| 1037 | Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 337-343. | 1.4 | 17 |
| 1038 | The diagnostic challenge of vulvar squamous cell carcinoma: Clinical manifestations and unusual human papillomavirus types. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 586-588. | 0.6 | 11 |
| 1039 | Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. <i>Journal of Hepatology</i> , 2014, 60, 490-499. | 1.8 | 135 |
| 1040 | Evaluation of the Abbott RealTime HCV genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing. <i>Journal of Clinical Virology</i> , 2014, 60, 22-26. | 1.6 | 28 |
| 1041 | HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2.0 in comparison with FDA-approved nucleic acid tests. <i>Journal of Clinical Virology</i> , 2014, 60, 336-340. | 1.6 | 9 |
| 1042 | Hepatitis C Virus. , 2014, , 859-877. | | 0 |
| 1043 | Antiviral drugs. <i>Side Effects of Drugs Annual</i> , 2014, , 503-550. | 0.6 | 1 |
| 1044 | Long-term stimulation of Toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I:C treatment. <i>Journal of Viral Hepatitis</i> , 2014, 21, 480-490. | 1.0 | 18 |
| 1045 | Review article: genetic factors that modify the outcome of viral hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1059-1070. | 1.9 | 50 |
| 1046 | Comparison of the QIAGEN artus HCV QS-RGQ test with the Roche COBAS Ampliprep/COBAS TaqMan HCV test v2.0 for the quantification of HCV-RNA in plasma samples. <i>Journal of Clinical Virology</i> , 2014, 60, 323-327. | 1.6 | 9 |
| 1047 | Second wave anti-HCV protease inhibitors: too little too late?. <i>Liver International</i> , 2014, 34, e168-70. | 1.9 | 3 |
| 1048 | The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 366-376.e6. | 0.6 | 38 |
| 1049 | Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1879-1888. | 13.9 | 1,080 |
| 1050 | ABT-450/Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1973-1982. | 13.9 | 834 |
| 1051 | Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue. <i>Seminars in Liver Disease</i> , 2014, 34, 047-057. | 1.8 | 14 |
| 1052 | ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. <i>Gastroenterology</i> , 2014, 147, 359-365.e1. | 0.6 | 336 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1053 | Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. <i>Journal of Hepatology</i> , 2014, 60, 530-537. | 1.8 | 118 |
| 1054 | Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232. | 13.9 | 262 |
| 1055 | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1889-1898. | 13.9 | 1,580 |
| 1056 | Direct-Acting Antiviral Agents and the Path to Interferon Independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 728-737. | 2.4 | 34 |
| 1057 | Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats. <i>Xenobiotica</i> , 2014, 44, 1014-1025. | 0.5 | 1 |
| 1058 | Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2105-2112. | 1.4 | 16 |
| 1059 | ABT-450/Ombitasvir and Dasabuvir with or without Ribavirin for HCV. <i>New England Journal of Medicine</i> , 2014, 370, 1983-1992. | 13.9 | 669 |
| 1060 | Therapy of Hepatitis C – Back to the Future. <i>New England Journal of Medicine</i> , 2014, 370, 2043-2047. | 13.9 | 102 |
| 1061 | Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 25-38. | 1.6 | 2 |
| 1062 | Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 1548-1556. | 2.3 | 21 |
| 1063 | On the History of Hepatitis C Virus Cell Culture Systems. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1627-1642. | 2.9 | 77 |
| 1064 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. <i>Lancet</i> , The, 2014, 383, 515-523. | 6.3 | 522 |
| 1065 | Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. <i>HIV Medicine</i> , 2014, 15, 108-115. | 1.0 | 28 |
| 1066 | Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. <i>Journal of Infection</i> , 2014, 68, 1-20. | 1.7 | 69 |
| 1067 | Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. <i>Liver International</i> , 2014, 34, 1018-1024. | 1.9 | 6 |
| 1068 | Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 17-25. | 1.1 | 11 |
| 1069 | Therapeutic vaccines against hepatitis C virus. <i>Infection, Genetics and Evolution</i> , 2014, 22, 120-129. | 1.0 | 19 |
| 1070 | Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. <i>Gastroenterology</i> , 2014, 146, 430-441.e6. | 0.6 | 217 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1071 | Phylogeny and molecular evolution of the hepatitis C virus. <i>Infection, Genetics and Evolution</i> , 2014, 21, 67-82. | 1.0 | 59 |
| 1072 | UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 609-612. | 1.0 | 17 |
| 1073 | Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2047-2057. | 2.9 | 120 |
| 1074 | Inference with viral quasispecies diversity indices: clonal and NGS approaches. <i>Bioinformatics</i> , 2014, 30, 1104-1111. | 1.8 | 56 |
| 1075 | Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. <i>Journal of Clinical Virology</i> , 2014, 59, 148-155. | 1.6 | 2 |
| 1076 | Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1880-1892. | 2.9 | 32 |
| 1077 | Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 1220-1227. | 1.8 | 25 |
| 1078 | Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 561-571. | 1.9 | 43 |
| 1079 | Roadblock to the Only FDA-Approved Treatment for Chronic Migraine. <i>Headache</i> , 2014, 54, 169-170. | 1.8 | 2 |
| 1080 | Headache Associated With Telaprevir Treatment. <i>Headache</i> , 2014, 54, 168-169. | 1.8 | 1 |
| 1081 | Burning Mouth Syndrome Response to High-Dose Vitamin C. <i>Headache</i> , 2014, 54, 169-169. | 1.8 | 3 |
| 1082 | Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 544-545. | 1.9 | 0 |
| 1083 | Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. <i>Clinical Therapeutics</i> , 2014, 36, 2047-2063.e3. | 1.1 | 10 |
| 1084 | The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. <i>Pharmacotherapy</i> , 2014, 34, 185-201. | 1.2 | 11 |
| 1085 | Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 960-969. | 2.9 | 8 |
| 1086 | What Is the Contribution of Protease Inhibitors to the High Mortality of Patients With Cirrhosis Receiving HCV Treatment?. <i>Gastroenterology</i> , 2014, 147, 1185. | 0.6 | 0 |
| 1087 | HCV NS5A Inhibitors Disrupt Replication Factory Formation: A Novel Mechanism of Antiviral Action. <i>Gastroenterology</i> , 2014, 147, 959-962. | 0.6 | 11 |
| 1088 | Risky Business—the Real Life of the Unresolved HCV Therapy. <i>Gastroenterology</i> , 2014, 147, 1185-1186. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1089 | Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting. <i>Digestive Diseases and Sciences</i> , 2014, 59, 3043-3052. | 1.1 | 24 |
| 1090 | Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5386-5394. | 1.4 | 32 |
| 1091 | The J6JFH1 Strain of Hepatitis C Virus Infects Human B-Cells with Low Replication Efficacy. <i>Viral Immunology</i> , 2014, 27, 285-294. | 0.6 | 5 |
| 1092 | Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1473-1479. | 0.6 | 0 |
| 1093 | Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study. <i>Molecular BioSystems</i> , 2014, 10, 767. | 2.9 | 15 |
| 1094 | The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. <i>Virology</i> , 2014, 462-463, 42-48. | 1.1 | 99 |
| 1095 | A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin. <i>Liver International</i> , 2014, 34, 1550-1559. | 1.9 | 6 |
| 1096 | Cost Utility of Telaprevir+PR (Peginterferon+Ribavirin) Versus Boceprevir+PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 647-659. | 1.0 | 13 |
| 1097 | Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 1653-1666. | 1.2 | 23 |
| 1098 | Intracellular Effects of the Hepatitis C Virus Nucleoside Polymerase Inhibitor RO5855 (Mericitabine) Tj ETQq1 1 0.784314 rgBT /Overl | 1.4 | 3 |
| 1099 | An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825. | 0.4 | 8 |
| 1100 | Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3-4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE Study. <i>Journal of Infectious Diseases</i> , 2014, 210, 1871-1880. | 1.9 | 19 |
| 1101 | Pegylated interferon ± plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014, 46, 826-832. | 0.4 | 12 |
| 1102 | Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 91-98. | 1.0 | 11 |
| 1103 | Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 Telaprevir): An Open-Label, Single-Arm, Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1768-1776. | 2.9 | 25 |
| 1104 | Efficacy and safety of telaprevir (<sc>TVR</sc>) triple therapy in a "real-life" cohort of 102 patients with <sc>HCV</sc> genotype 1: interim analysis after 24 weeks of treatment. <i>Journal of Viral Hepatitis</i> , 2014, 21, 333-340. | 1.0 | 12 |
| 1105 | Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. <i>Antiviral Research</i> , 2014, 109, 141-148. | 1.9 | 16 |
| 1106 | <i>ITPA</i> genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. <i>Hepatology</i> , 2014, 59, 2152-2160. | 3.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1107 | Telaprevir-based treatment effects on hepatitis C virus in liver and blood. <i>Hepatology</i> , 2014, 60, 1826-1837. | 3.6 | 22 |
| 1108 | Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1576-1584. | 0.2 | 33 |
| 1109 | Cross-Genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7215-7224. | 1.4 | 12 |
| 1110 | Treatment of HCV infection with the novel NS3/4A protease inhibitors. <i>Current Opinion in Pharmacology</i> , 2014, 18, 9-17. | 1.7 | 30 |
| 1111 | HCV and HIV co-infection: mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 362-371. | 8.2 | 148 |
| 1112 | Identification of the NS5B S282T Resistant Variant and Two Novel Amino Acid Substitutions That Affect Replication Capacity in Hepatitis C Virus-Infected Patients Treated with Mericitabine and Danoprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3105-3114. | 1.4 | 16 |
| 1113 | Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program. <i>Journal of Hepatology</i> , 2014, 61, 976-983. | 1.8 | 25 |
| 1114 | Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675. | 1.9 | 62 |
| 1115 | Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , 2014, 109, 7-14. | 1.9 | 12 |
| 1116 | Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 8-16. | 2.6 | 13 |
| 1117 | Recurrent HCV after liver transplantation—mechanisms, assessment and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 710-721. | 8.2 | 33 |
| 1118 | Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 85-86. | 0.4 | 16 |
| 1119 | Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 416-423. | 1.0 | 11 |
| 1120 | HCV NS5A Inhibitors: The Devil Is in the Details. <i>Gastroenterology</i> , 2014, 147, 273-277. | 0.6 | 5 |
| 1121 | Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227. | 1.1 | 11 |
| 1122 | Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 936-942. | 0.4 | 17 |
| 1123 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. <i>Lancet, The</i> , 2014, 384, 1756-1765. | 6.3 | 751 |
| 1124 | The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine. <i>Drug Development Research</i> , 2014, 75, 107-113. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1125 | Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 348-356. | 1.0 | 35 |
| 1126 | Treating hepatitis C in the elderly: the future is near?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2019-2028. | 0.9 | 3 |
| 1127 | Hepatitis C Direct-Acting Antiviral Agents in HIV/HCV Co-infected Patients. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 132-143. | 0.8 | 1 |
| 1128 | The role of interferon in the new era of hepatitis C treatments. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 649-656. | 1.4 | 7 |
| 1129 | Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. <i>Hepatology International</i> , 2014, 8, 352-364. | 1.9 | 1 |
| 1130 | German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. <i>AIDS Research and Therapy</i> , 2014, 11, 16. | 0.7 | 10 |
| 1131 | Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 257. | 0.4 | 4 |
| 1132 | Antiviral treatment of hepatitis C. <i>BMJ, The</i> , 2014, 349, g3308-g3308. | 3.0 | 175 |
| 1133 | A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. <i>Journal of Hepatology</i> , 2014, 61, 1238-1246. | 1.8 | 126 |
| 1134 | Retreatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1604-1614. | 13.9 | 536 |
| 1135 | Treatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1594-1603. | 13.9 | 816 |
| 1136 | The Efficacy of a Hansenula-Derived 20kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 727-733. | 0.5 | 3 |
| 1137 | Peg-IFN/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 831-837. | 0.5 | 62 |
| 1138 | Hepatitis C virus and interferon type III (interferon- λ 3/interleukin-28B and interferon- λ 4): genetic basis of susceptibility to infection and response to antiviral treatment. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1237-1245. | 2.8 | 16 |
| 1139 | Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 131-140. | 1.4 | 85 |
| 1140 | Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. <i>Journal of Gastroenterology</i> , 2014, 49, 941-953. | 2.3 | 96 |
| 1141 | Membranoproliferative Glomerulonephritis, Type II Cryoglobulinemia and Triple Therapy for Hepatitis C: A Case Series and Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2007-2012. | 1.1 | 12 |
| 1142 | Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. <i>Hepatology</i> , 2014, 59, 2083-2091. | 3.6 | 517 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1143 | Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. <i>Hepatology</i> , 2014, 59, 46-48. | 3.6 | 80 |
| 1145 | Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377. | 1.7 | 3 |
| 1146 | EASL Recommendations on Treatment of Hepatitis C 2014. <i>Journal of Hepatology</i> , 2014, 61, 373-395. | 1.8 | 172 |
| 1147 | The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 568-577. | 1.0 | 19 |
| 1148 | Advances in newly developing therapy for chronic hepatitis C virus infection. <i>Frontiers of Medicine</i> , 2014, 8, 166-174. | 1.5 | 8 |
| 1149 | Safety and efficacy of protease inhibitor based combination therapy in a single-center real-life cohort of 110 patients with chronic hepatitis C genotype 1 infection. <i>BMC Gastroenterology</i> , 2014, 14, 87. | 0.8 | 21 |
| 1150 | High rates of early treatment discontinuation in hepatitis C-infected US veterans. <i>BMC Research Notes</i> , 2014, 7, 266. | 0.6 | 8 |
| 1152 | Natural History and Management of Hepatitis C: Does Sex Play a Role?. <i>Journal of Infectious Diseases</i> , 2014, 209, S81-S85. | 1.9 | 101 |
| 1153 | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2014, 370, 211-221. | 13.9 | 1,065 |
| 1154 | Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1574-1581. | 1.4 | 17 |
| 1156 | Is genotype 3 of the hepatitis C virus the new villain?. <i>Hepatology</i> , 2014, 59, 2403-2412. | 3.6 | 116 |
| 1157 | Treatment of hepatitis C: Perspectives. <i>Médecine Et Maladies Infectieuses</i> , 2014, 44, 449-454. | 5.1 | 11 |
| 1158 | New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. <i>Gut</i> , 2014, 63, 207-215. | 6.1 | 29 |
| 1159 | Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6079-6092. | 1.4 | 29 |
| 1160 | Nitazoxanide for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, 2014, CD009182. | 1.5 | 11 |
| 1161 | Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 969-972. | 1.0 | 7 |
| 1162 | Hepatitis B and C in African Americans: Current Status and Continued Challenges. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 738-748. | 2.4 | 38 |
| 1163 | EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 60, 392-420. | 1.8 | 739 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1164 | Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. <i>Journal of Hepatology</i> , 2014, 60, 872-884. | 1.8 | 56 |
| 1165 | Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445. | 0.4 | 3 |
| 1166 | New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. <i>Gastroenterology</i> , 2014, 146, 1176-1192. | 0.6 | 458 |
| 1167 | Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , 2014, 89, 595-601. | 1.4 | 3 |
| 1168 | Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: A modelling approach. <i>Digestive and Liver Disease</i> , 2014, 46, 157-163. | 0.4 | 15 |
| 1169 | Skin Toxicity Due to Telaprevir: A New Drug We Should Be Familiar With. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 317-319. | 0.2 | 0 |
| 1170 | Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1381-1383. | 2.4 | 16 |
| 1171 | Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C. <i>Journal of Clinical Virology</i> , 2014, 60, 190-195. | 1.6 | 11 |
| 1172 | Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 48-52. | 0.3 | 11 |
| 1173 | Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , 2014, 60, 1100-1101. | 1.8 | 1 |
| 1174 | Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491. | 1.8 | 18 |
| 1175 | Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. <i>Gastroenterology</i> , 2014, 146, 1669-1679.e3. | 0.6 | 239 |
| 1176 | Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1029-1037.e5. | 2.4 | 20 |
| 1177 | HCV and HBV testing acceptability and knowledge among urban emergency department patients and pharmacy clients. <i>Preventive Medicine</i> , 2014, 61, 29-33. | 1.6 | 8 |
| 1178 | Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 584-586. | 0.6 | 2 |
| 1179 | Entry inhibitors and future treatment of hepatitis C. <i>Antiviral Research</i> , 2014, 104, 136-142. | 1.9 | 20 |
| 1180 | Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , 2014, 46, 67-71. | 0.4 | 9 |
| 1181 | Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. <i>Journal of Hepatology</i> , 2014, 60, 1118-1126. | 1.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1182 | Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24. | 0.4 | 9 |
| 1183 | Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. <i>Journal of Hepatology</i> , 2014, 60, 913-919. | 1.8 | 39 |
| 1184 | Interferon-free hepatitis C treatment: one pill to fit all?. <i>Lancet, The</i> , 2014, 383, 491-492. | 6.3 | 7 |
| 1185 | Toxicidad cutánea por telaprevir: un nuevo fármaco que es necesario conocer. <i>Actas Dermo-sifilográficas</i> , 2014, 105, 317-319. | 0.2 | 6 |
| 1186 | Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?. <i>Antiviral Research</i> , 2014, 105, 64-71. | 1.9 | 85 |
| 1187 | O impacto da hepatite C em Portugal. <i>GE Jornal Português De Gastrenterologia</i> , 2014, 21, 44-54. | 0.0 | 13 |
| 1188 | Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients. <i>Journal of Hepatology</i> , 2014, 60, 1112-1117. | 1.8 | 20 |
| 1189 | Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196. | 1.8 | 40 |
| 1190 | The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both?. <i>Hepatology</i> , 2014, 60, 1126-1129. | 3.6 | 19 |
| 1191 | Review article: <scp>HCV</scp> genotype 3 “ the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698. | 1.9 | 103 |
| 1192 | Safety of direct-acting antivirals in the treatment of chronic hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 307-319. | 1.0 | 10 |
| 1193 | Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1337-1349. | 0.9 | 23 |
| 1194 | Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. <i>Journal of Medical Economics</i> , 2014, 17, 65-76. | 1.0 | 29 |
| 1195 | Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 387-402. | 0.7 | 13 |
| 1196 | The cost-effectiveness of boceprevir for hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 319-334. | 0.7 | 1 |
| 1197 | Synthesis and Anti-HCV Activity of 4-Hydroxyamino $\hat{\pm}$ -Pyranone Carboxamide Analogues. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 259-263. | 1.3 | 22 |
| 1198 | Novel Quinoline-Based P2 $\hat{\pm}$ P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 264-269. | 1.3 | 22 |
| 1199 | New antiviral agents for the treatment of hepatitis C: ABT-450. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 711-716. | 0.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1200 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Review of Clinical Pharmacology, 2014, 7, 555-566. | 1.3 | 22 |
| 1201 | Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. Clinical Transplantation, 2014, 28, 722-727. | 0.8 | 9 |
| 1202 | Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics, 2014, 53, 409-427. | 1.6 | 35 |
| 1203 | MicroRNA-155 controls Toll-like receptor and hepatitis C virus-induced immune responses in the liver. Journal of Viral Hepatitis, 2014, 21, 99-110. | 1.0 | 45 |
| 1204 | Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2014, 39, 331-338. | 1.9 | 53 |
| 1205 | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2014, 384, 414-426. | 6.3 | 376 |
| 1206 | QUEST for a cure for hepatitis C virus: the end is in sight. Lancet, The, 2014, 384, 381-383. | 6.3 | 7 |
| 1207 | The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab Journal of Gastroenterology, 2014, 15, 45-52. | 0.4 | 88 |
| 1208 | Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis. Journal of Clinical Virology, 2014, 60, 431-432. | 1.6 | 8 |
| 1209 | The Current State and Future Prospects of Chronic Hepatitis C Virus Infection Treatment. Current Infectious Disease Reports, 2014, 16, 413. | 1.3 | 8 |
| 1210 | Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals. Drugs, 2014, 74, 951-961. | 4.9 | 9 |
| 1211 | Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2014, 384, 403-413. | 6.3 | 431 |
| 1212 | Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Research, 2014, 108, 181-191. | 1.9 | 172 |
| 1213 | High urine IP-10 levels associate with chronic HCV infection. Journal of Infection, 2014, 68, 591-600. | 1.7 | 26 |
| 1214 | Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 738-743. | 0.4 | 15 |
| 1215 | Resistance to hepatitis C virus protease inhibitors. Current Opinion in Virology, 2014, 8, 16-21. | 2.6 | 34 |
| 1216 | Renal impairment and anemia during triple therapy. Journal of Hepatology, 2014, 60, 1099-1100. | 1.8 | 1 |
| 1217 | Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios. Journal of Hepatology, 2014, 61, 530-537. | 1.8 | 76 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1218 | Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1753-1769. | 2.9 | 123 |
| 1219 | Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1770-1776. | 2.9 | 29 |
| 1221 | Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCVâ€“HIV Coinfection in Interferon-Naive Patients. <i>Antiviral Therapy</i> , 2014, 19, 735-745. | 0.6 | 5 |
| 1222 | A Randomized Trial of Daclatasvir with Peginterferon Alfa-2B and Ribavirin for HCV Genotype 1 Infection. <i>Antiviral Therapy</i> , 2014, 19, 491-499. | 0.6 | 31 |
| 1223 | Daclatasvir Combined with Peginterferon Alfa-2A and Ribavirin in Japanese Patients Infected with Hepatitis C Genotype 1. <i>Antiviral Therapy</i> , 2014, 19, 501-510. | 0.6 | 26 |
| 1224 | Non-Invasive Fibrosis Assessment Predicts Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 185-192. | 0.6 | 8 |
| 1225 | Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. <i>International Journal of Nanomedicine</i> , 2014, 9, 2051. | 3.3 | 19 |
| 1226 | Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. <i>Annals of Internal Medicine</i> , 2014, 161, 546. | 2.0 | 77 |
| 1227 | MicroRNAs: role and therapeutic targets in viral hepatitis. <i>Antiviral Therapy</i> , 2014, 19, 533-541. | 0.6 | 10 |
| 1228 | The clinical management of HCV in the HIV-infected patient. <i>Antiviral Therapy</i> , 2014, 20, 457-467. | 0.6 | 4 |
| 1229 | Virological Escape in HCV Genotype-1-Infected Patients Receiving Daclatasvir plus Ribavirin and Peginterferon Alfa-2A or Alfa-2B. <i>Antiviral Therapy</i> , 2014, 19, 479-490. | 0.6 | 38 |
| 1230 | Characterization and risk of blood-borne virus transmission in organ transplantation: what are the priorities?. <i>Future Virology</i> , 2014, 9, 1049-1060. | 0.9 | 1 |
| 1231 | Aminoadamantanes for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD010125. | 1.5 | 2 |
| 1232 | A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 439-448. | 0.8 | 4 |
| 1233 | IL28B genotyping and treatment of HCV infected subjects. <i>Asian Biomedicine</i> , 2014, 8, 445-452. | 0.2 | 0 |
| 1234 | Prevalence of HCV Infection Among Clients in Community-Based Health Settings in Hawaii, 2002â€“2010: Assessing Risk Factors. <i>American Journal of Public Health</i> , 2014, 104, 1534-1539. | 1.5 | 8 |
| 1235 | Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 41-51. | 0.7 | 0 |
| 1236 | Previous Exposure to HCV Among Persons Born During 1945â€“1965: Prevalence and Predictors, United States, 1999â€“2008. <i>American Journal of Public Health</i> , 2014, 104, 474-481. | 1.5 | 40 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1238 | Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. , 2014, , CD011132. | | 4 |
| 1239 | Expanding access to hepatitis C virus care: A call to deconstruct individualized therapy. <i>Hepatology</i> , 2014, 59, 13-15. | 3.6 | 13 |
| 1240 | HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. <i>Aids</i> , 2014, 28, 41-47. | 1.0 | 30 |
| 1241 | Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis. <i>Aids</i> , 2014, 28, 2491-2493. | 1.0 | 3 |
| 1243 | Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 42-46. | 0.9 | 7 |
| 1244 | HCV Kinetic Models and Their Implications in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 231-242. | 1.3 | 16 |
| 1245 | Inhibition of expression of hepatitis C virus 1b genotype core and NS4B genes in HepG2 cells using artificial microRNAs. <i>Molecular Medicine Reports</i> , 2015, 12, 1905-1913. | 1.1 | 1 |
| 1246 | UEG Week 2015 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2015, 3, 146-687. | 1.6 | 11 |
| 1247 | Telaprevir enhances ribavirin-induced anaemia through renal function impairment. <i>Antiviral Therapy</i> , 2015, 20, 479-486. | 0.6 | 5 |
| 1248 | Safety and Efficacy of Partial Splenic Embolization in Telaprevir-based Triple Therapy for Chronic Hepatitis C. <i>Internal Medicine</i> , 2015, 54, 119-126. | 0.3 | 6 |
| 1249 | Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection. <i>Internal Medicine</i> , 2015, 54, 567-572. | 0.3 | 4 |
| 1250 | Low Frequency of Drug-Resistant virus did not Affect the Therapeutic Efficacy in Daclatasvir plus Asunaprevir Therapy in Patients with Chronic HCV Genotype-1 Infection. <i>Antiviral Therapy</i> , 2016, 21, 37-44. | 0.6 | 13 |
| 1252 | The ARRIBA concept: adequate resorption of ribavirin. <i>Antiviral Therapy</i> , 2015, 20, 515-520. | 0.6 | 2 |
| 1253 | PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 465-474. | 0.7 | 0 |
| 1254 | Ribavirin Concentration Determines Treatment success of First-Generation DAA-Based Chronic HCV Therapy. <i>Antiviral Therapy</i> , 2016, 21, 153-159. | 0.6 | 5 |
| 1255 | A new era of therapy for hepatitis C virus infection. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 471-478. | 1.3 | 17 |
| 1256 | Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey. <i>Value in Health Regional Issues</i> , 2015, 7, 42-48. | 0.5 | 5 |
| 1257 | Drug Eruptions Induced by Telaprevir in Patients With Chronic Hepatitis C Virus Genotype 1 Infection: A Prospective Study. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2015, 106, 219-225. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1258 | IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. SpringerPlus, 2015, 4, 357. | 1.2 | 8 |
| 1259 | Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?. Journal of Public Health, 2015, 38, fdv178. | 1.0 | 2 |
| 1260 | Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. Journal of Medical Virology, 2015, 87, 1913-1920. | 2.5 | 73 |
| 1261 | Resistance to direct-acting antiviral agents. Current Opinion in HIV and AIDS, 2015, 10, 381-389. | 1.5 | 22 |
| 1262 | Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. Journal of Viral Hepatitis, 2015, 22, 481-488. | 1.0 | 9 |
| 1263 | Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. Liver International, 2015, 35, 1833-1844. | 1.9 | 5 |
| 1264 | Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1 coinfected patients. Liver International, 2015, 35, 2090-2099. | 1.9 | 10 |
| 1265 | IFN-free combination of sofosbuvir and simeprevir for treatment of genotype 1 hepatitis C infection. Future Virology, 2015, 10, 1133-1144. | 0.9 | 0 |
| 1266 | The role of HCV proteins on treatment outcomes. Virology Journal, 2015, 12, 217. | 1.4 | 23 |
| 1267 | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Alimentary Pharmacology and Therapeutics, 2015, 42, 829-844. | 1.9 | 34 |
| 1268 | Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1759-1767. | 1.4 | 11 |
| 1269 | Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. Journal of Viral Hepatitis, 2015, 22, 489-495. | 1.0 | 6 |
| 1270 | Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Transplant International, 2015, 28, 1011-1024. | 0.8 | 10 |
| 1272 | Alanine aminotransferase elevations during triple therapy with simeprevir, pegylated interferon plus ribavirin. Acta Hepatologica Japonica, 2015, 56, 567-574. | 0.0 | 0 |
| 1273 | Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer, 2015, 121, 2874-2882. | 2.0 | 63 |
| 1274 | Virologic response and haematologic toxicity of boceprevir and telaprevir-containing regimens in actual clinical settings. Journal of Viral Hepatitis, 2015, 22, 691-700. | 1.0 | 13 |
| 1275 | Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. Liver International, 2015, 35, 2275-2284. | 1.9 | 0 |
| 1276 | Lack of drug interaction between cyclosporine and telaprevir in a liver transplant recipient. Transplant Infectious Disease, 2015, 17, 106-110. | 0.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1277 | The hepatitis C revolution part 1. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 563-571. | 1.3 | 17 |
| 1278 | Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. <i>Hepatology Research</i> , 2015, 45, 745-754. | 1.8 | 12 |
| 1279 | Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1147-1156. | 1.0 | 3 |
| 1280 | Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, e37-e40. | 0.9 | 3 |
| 1281 | Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607. | 1.0 | 5 |
| 1282 | Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents. <i>Journal of Addiction Medicine</i> , 2015, 9, 405-410. | 1.4 | 13 |
| 1283 | Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 517-524. | 1.0 | 6 |
| 1284 | High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. <i>Liver International</i> , 2015, 35, 510-517. | 1.9 | 16 |
| 1285 | Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2015, 22, 861-870. | 1.0 | 74 |
| 1286 | Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. <i>Journal of Viral Hepatitis</i> , 2015, 22, 1020-1032. | 1.0 | 10 |
| 1287 | High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 745-750. | 1.0 | 6 |
| 1288 | Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. <i>Gastroenterology Nursing</i> , 2015, 38, 417-428. | 0.2 | 3 |
| 1289 | Kidney Transplantation Threshold in Patients With Hepatitis C. <i>Transplantation</i> , 2015, 99, 829-834. | 0.5 | 2 |
| 1290 | Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease. <i>Transplantation</i> , 2015, 99, 1644-1651. | 0.5 | 19 |
| 1291 | Automated Low Cost Method of Quantification of Hepatitis C Virus. <i>Bangladesh Journal of Medical Science</i> , 2015, 14, 247-253. | 0.1 | 0 |
| 1292 | Rate, Delay and Predictors of Hepatitis C Treatment in British Columbia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 315-320. | 0.8 | 16 |
| 1293 | Rescuing compound bioactivity in a secondary cell-based screening by using γ -cyclodextrin as a molecular carrier. <i>International Journal of Nanomedicine</i> , 2015, 10, 2249. | 3.3 | 4 |
| 1294 | Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 9163. | 1.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1295 | Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 5421. | 1.4 | 7 |
| 1296 | Hepatitis C genotype 4: The past, present, and future. <i>World Journal of Hepatology</i> , 2015, 7, 2792. | 0.8 | 41 |
| 1297 | Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 171. | 0.9 | 9 |
| 1298 | Treatment Patterns, Health Care Resource Utilization, and Costs in U.S. Patients Diagnosed with Chronic Hepatitis C Infection Who Received Telaprevir or Boceprevir. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 308-316. | 0.5 | 6 |
| 1300 | Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. <i>Vaccines</i> , 2015, 3, 203-220. | 2.1 | 29 |
| 1301 | Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0117334. | 1.1 | 21 |
| 1302 | Establishment of Hepatitis C Virus RNA-Replicating Cell Lines Possessing Ribavirin-Resistant Phenotype. <i>PLoS ONE</i> , 2015, 10, e0118313. | 1.1 | 6 |
| 1303 | Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes. <i>PLoS ONE</i> , 2015, 10, e0121734. | 1.1 | 9 |
| 1304 | Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613. | 1.1 | 2 |
| 1305 | Short and Long-Term Effects of Telaprevir on Kidney Function in Patients with Hepatitis C Virus Infection: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0124139. | 1.1 | 6 |
| 1306 | Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015, 10, e0125080. | 1.1 | 12 |
| 1307 | Prevalence of Thymine-Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. <i>PLoS ONE</i> , 2015, 10, e0125400. | 1.1 | 7 |
| 1308 | Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. <i>PLoS ONE</i> , 2015, 10, e0125846. | 1.1 | 16 |
| 1309 | Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138503. | 1.1 | 3 |
| 1310 | Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy. <i>PLoS ONE</i> , 2015, 10, e0135963. | 1.1 | 18 |
| 1311 | A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine. <i>PLoS ONE</i> , 2015, 10, e0142349. | 1.1 | 9 |
| 1312 | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. <i>Viruses</i> , 2015, 7, 6716-6729. | 1.5 | 72 |
| 1313 | Treatment Outcomes with Telaprevir-Based Therapy for HIV/Hepatitis C Coinfected Patients are Comparable with Hepatitis C Monoinfected Patients. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 293-296. | 0.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1314 | An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 19-34. | 0.8 | 67 |
| 1315 | Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. International Journal of Hepatology, 2015, 2015, 1-10. | 0.4 | 7 |
| 1316 | The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 46-48. | 0.8 | 7 |
| 1317 | Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 125-129. | 0.8 | 5 |
| 1318 | Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis. Hepatitis Monthly, 2015, 15, e32707. | 0.1 | 5 |
| 1319 | Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics. Annals of Hepatology, 2015, 14, 234-242. | 0.6 | 15 |
| 1320 | Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy. Annals of Hepatology, 2015, 14, 28-35. | 0.6 | 4 |
| 1321 | High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. Annals of Hepatology, 2015, 14, 477-486. | 0.6 | 1 |
| 1322 | Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. Annals of Hepatology, 2015, 14, 420-424. | 0.6 | 7 |
| 1325 | Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Annals of Hepatology, 2015, 14, 46-57. | 0.6 | 18 |
| 1326 | Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin. Annals of Hepatology, 2015, 14, 132-136. | 0.6 | 4 |
| 1328 | Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World Journal of Hepatology, 2015, 7, 1936. | 0.8 | 17 |
| 1329 | Hepatitis C " Overview and Update in Treatment. , 2015, , . | | 0 |
| 1330 | New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies. , 2015, , . | | 0 |
| 1331 | Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver International, 2015, 35, 11-17. | 1.9 | 16 |
| 1332 | Mass Balance, Metabolite Profile, and <i>In Vitro-In Vivo</i> Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor. Antimicrobial Agents and Chemotherapy, 2015, 59, 25-37. | 1.4 | 12 |
| 1333 | TRIPLE THERAPY IN CHRONIC HEPATITIS C: initial series in a public health program in the South of Brazil. Arquivos De Gastroenterologia, 2015, 52, 14-17. | 0.3 | 5 |
| 1334 | Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2015, 9, 9-20. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1335 | Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 545-549. | 1.1 | 5 |
| 1336 | An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTime HCV RNA Assay. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1264-1269. | 1.8 | 13 |
| 1337 | Hepatitis C virus genetic variability and evolution. <i>World Journal of Hepatology</i> , 2015, 7, 831. | 0.8 | 85 |
| 1338 | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 11. | 0.9 | 4 |
| 1339 | Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis. <i>Medicine (United States)</i> , 2015, 94, 1000-1007. | 0.4 | 10 |
| 1340 | Tratamiento de la infección crónica por los virus de la hepatitis C y B. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2015, 22, 264-273. | 0.0 | 0 |
| 1341 | Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. <i>BMC Research Notes</i> , 2015, 8, 367. | 0.6 | 21 |
| 1342 | The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 1363-1377. | 2.5 | 56 |
| 1343 | Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2835-2848. | 0.9 | 9 |
| 1344 | Hepatitis C: pay now or pay later?. <i>Future Virology</i> , 2015, 10, 1285-1290. | 0.9 | 0 |
| 1345 | Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 314-327. | 1.1 | 13 |
| 1348 | Traceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay. <i>BMC Infectious Diseases</i> , 2015, 16, 47. | 1.3 | 2 |
| 1349 | Effect of IL28B genotype on hepatitis B and C virus infection. <i>Current Opinion in Virology</i> , 2015, 14, 50-55. | 2.6 | 22 |
| 1350 | Optimal management of patients with chronic hepatitis C and comorbidities. <i>Liver International</i> , 2015, 35, 35-43. | 1.9 | 12 |
| 1351 | Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term. <i>Hepatology</i> , 2015, 61, 1503-1511. | 3.6 | 13 |
| 1352 | The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2015, 11, 116-123. | 0.4 | 1 |
| 1353 | Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. <i>Liver International</i> , 2015, 35, 27-34. | 1.9 | 29 |
| 1354 | Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. <i>Journal of Infection</i> , 2015, 70, 197-205. | 1.7 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1356 | Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2015, 42, 329-338. | 0.8 | 22 |
| 1357 | Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 233-241. | 0.4 | 4 |
| 1358 | Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. <i>Digestive and Liver Disease</i> , 2015, 47, 157-163. | 0.4 | 5 |
| 1359 | <i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 979-987. | 1.4 | 128 |
| 1360 | Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen—The ANRS CO20-CUPIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450. | 0.7 | 5 |
| 1361 | Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 671-685. | 1.9 | 24 |
| 1362 | Hepatitis C. <i>Lancet</i> , 2015, 385, 1124-1135. | 6.3 | 424 |
| 1363 | Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 729-735. | 1.9 | 10 |
| 1364 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection. <i>Annals of Pharmacotherapy</i> , 2015, 49, 566-581. | 0.9 | 44 |
| 1365 | Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 473-484. | 1.0 | 9 |
| 1366 | Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2813-2823. | 1.6 | 30 |
| 1367 | The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316. | 1.8 | 12 |
| 1368 | Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. <i>Journal of Clinical Virology</i> , 2015, 65, 50-53. | 1.6 | 24 |
| 1369 | Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. <i>Antiviral Research</i> , 2015, 116, 10-16. | 1.9 | 103 |
| 1370 | Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 656-671. | 2.6 | 36 |
| 1371 | ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 295-304. | 2.0 | 6 |
| 1372 | Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. <i>Hepatology</i> , 2015, 61, 1523-1532. | 3.6 | 78 |
| 1373 | STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255. | 1.8 | 19 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1374 | SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1155-1160. | 1.3 | 9 |
| 1375 | Population Pharmacokinetic Modeling of Plasma and Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2179-2188. | 1.4 | 28 |
| 1376 | All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. <i>Hepatology</i> , 2015, 61, 1127-1135. | 3.6 | 598 |
| 1378 | Inhibitory effects of Pycnogenol® on hepatitis C virus replication. <i>Antiviral Research</i> , 2015, 113, 93-102. | 1.9 | 19 |
| 1379 | Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis. <i>Hepatology Research</i> , 2015, 45, E89-98. | 1.8 | 9 |
| 1380 | A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 249-254. | 0.4 | 5 |
| 1381 | Is widespread screening for hepatitis C justified?. <i>BMJ</i> , The, 2015, 350, g7809-g7809. | 3.0 | 44 |
| 1382 | Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis. <i>Journal of Viral Hepatitis</i> , 2015, 22, 701-707. | 1.0 | 12 |
| 1383 | Conjugated bilirubin triggers anemia by inducing erythrocyte death. <i>Hepatology</i> , 2015, 61, 275-284. | 3.6 | 141 |
| 1384 | Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015, 212, 367-377. | 1.9 | 54 |
| 1385 | Innate and adaptive genetic pathways in HCV infection. <i>Tissue Antigens</i> , 2015, 85, 231-240. | 1.0 | 13 |
| 1386 | Revolution in hepatitis C antiviral therapy. <i>British Medical Bulletin</i> , 2015, 113, 31-44. | 2.7 | 34 |
| 1387 | Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2746-2755. | 1.4 | 13 |
| 1388 | Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246. | 1.0 | 11 |
| 1389 | Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. <i>Hepatology Research</i> , 2015, 45, E156-60. | 1.8 | 5 |
| 1390 | Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. <i>Gut</i> , 2015, 64, 483-494. | 6.1 | 83 |
| 1391 | Cost-effectiveness of screening for hepatitis C in Canada. <i>Cmaj</i> , 2015, 187, E110-E121. | 0.9 | 65 |
| 1392 | Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1197-1204. | 1.4 | 36 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1393 | Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Na ⁺ ve Patients Receiving Antiviral Therapy. <i>Pharmacoeconomics</i> , 2015, 33, 409-422. | 1.7 | 4 |
| 1394 | Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin. <i>Current Hepatology Reports</i> , 2015, 14, 53-59. | 0.4 | 0 |
| 1395 | Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir". <i>Clinical Infectious Diseases</i> , 2015, 60, 1829-1836. | 2.9 | 134 |
| 1396 | Gene Therapies for Hepatitis C Virus. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 1-29. | 0.8 | 8 |
| 1397 | Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. <i>Current Hepatology Reports</i> , 2015, 14, 32-39. | 0.4 | 0 |
| 1398 | Faldaprevir for the Treatment of Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4985-4996. | 1.8 | 16 |
| 1399 | IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. <i>Frontiers in Microbiology</i> , 2015, 6, 153. | 1.5 | 4 |
| 1400 | Regimens for Cirrhotic Patients. <i>Clinics in Liver Disease</i> , 2015, 19, 657-667. | 1.0 | 0 |
| 1401 | The New Era of Interferon-Free Treatment of Chronic Hepatitis C. <i>Visceral Medicine</i> , 2015, 31, 290-296. | 0.5 | 19 |
| 1402 | New Biomarkers for Early Detection of Hepatocellular Carcinoma. <i>EBioMedicine</i> , 2015, 2, 370-371. | 2.7 | 4 |
| 1403 | The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection. <i>Journal of Clinical Virology</i> , 2015, 69, 68-73. | 1.6 | 12 |
| 1404 | Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population. <i>Women's Health Issues</i> , 2015, 25, 289-293. | 0.9 | 6 |
| 1405 | Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. <i>Molecular Diversity</i> , 2015, 19, 829-853. | 2.1 | 8 |
| 1406 | Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations. <i>Molecular BioSystems</i> , 2015, 11, 2568-2578. | 2.9 | 17 |
| 1407 | Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. <i>Clinical Therapeutics</i> , 2015, 37, 1713-1725.e3. | 1.1 | 7 |
| 1408 | Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1015-1030. | 0.9 | 14 |
| 1409 | Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 4-14. | 1.1 | 38 |
| 1410 | HCV targeting of patients with cirrhosis. <i>Journal of Hepatology</i> , 2015, 63, 1015-1022. | 1.8 | 54 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1411 | Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1205-1222. | 1.6 | 42 |
| 1412 | Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?. <i>Journal of Hepatology</i> , 2015, 63, 1254-1262. | 1.8 | 48 |
| 1413 | Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 971-980.e1. | 0.6 | 77 |
| 1414 | Paritaprevir in patients with chronic hepatitis C genotype 1. <i>Future Virology</i> , 2015, 10, 679-690. | 0.9 | 1 |
| 1415 | Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2942-2950. | 1.8 | 11 |
| 1416 | HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. <i>Clinical Infectious Diseases</i> , 2015, 61, 1127-1134. | 2.9 | 28 |
| 1417 | Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 593-605. | 0.6 | 4 |
| 1418 | Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5. | 0.2 | 28 |
| 1419 | Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings. <i>Social Work in Public Health</i> , 2015, 30, 325-335. | 0.7 | 2 |
| 1420 | Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1157-1165. | 1.5 | 1 |
| 1421 | Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2015, 17, 443. | 1.1 | 3 |
| 1422 | Ultradeep Pyrosequencing of NS3 To Predict Response to Triple Therapy with Protease Inhibitors in Previously Treated Chronic Hepatitis C Patients. <i>Journal of Clinical Microbiology</i> , 2015, 53, 389-397. | 1.8 | 6 |
| 1423 | Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report. <i>Transplantation Proceedings</i> , 2015, 47, 809-814. | 0.3 | 4 |
| 1424 | Treatment of hepatitis C in difficult-to-treat patients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 284-292. | 8.2 | 65 |
| 1425 | From non-A, non-B hepatitis to hepatitis C virus cure. <i>Journal of Hepatology</i> , 2015, 62, S87-S99. | 1.8 | 284 |
| 1426 | Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. <i>Journal of Medical Economics</i> , 2015, 18, 502-511. | 1.0 | 13 |
| 1427 | Natural History of Hepatitis C. , 2015, , 120-130. | | 0 |
| 1428 | Transplantation for Hepatitis C. , 2015, , 131-152. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1429 | Retransplantation. , 2015, , 801-810. | | 0 |
| 1430 | Recurrent Hepatitis C After Transplantation. , 2015, , 1040-1050. | | 0 |
| 1431 | Evaluation of the COBAS [®] AmpliPrep/COBAS [®] TaqMan [®] HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. Journal of Clinical Virology, 2015, 67, 67-72. | 1.6 | 18 |
| 1432 | A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. Journal of Comparative Effectiveness Research, 2015, 4, 101-114. | 0.6 | 3 |
| 1433 | Utility of Evaluating HCV in an Uninsured Population. Digestive Diseases and Sciences, 2015, 60, 1092-1097. | 1.1 | 7 |
| 1434 | Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive Diseases and Sciences, 2015, 60, 1045-1051. | 1.1 | 21 |
| 1435 | Cure of <sc>HCV</sc> related liver disease. Liver International, 2015, 35, 71-77. | 1.9 | 24 |
| 1436 | EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology, 2015, 63, 199-236. | 1.8 | 1,052 |
| 1437 | First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virology Journal, 2015, 12, 37. | 1.4 | 11 |
| 1438 | Telaprevir Experience From Turkey. Hepatitis Monthly, 2015, 15, e25639. | 0.1 | 2 |
| 1439 | Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. Journal of Comparative Effectiveness Research, 2015, 4, 267-277. | 0.6 | 12 |
| 1440 | Encoded Library Technology Screening of Hepatitis C Virus NS4B Yields a Small-Molecule Compound Series with <i>In Vitro</i> Replicon Activity. Antimicrobial Agents and Chemotherapy, 2015, 59, 3450-3459. | 1.4 | 29 |
| 1441 | Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus. Journal of Virology, 2015, 89, 6105-6116. | 1.5 | 32 |
| 1442 | Drug Interactions With Direct-Acting Antivirals for Hepatitis C. Annals of Pharmacotherapy, 2015, 49, 674-687. | 0.9 | 73 |
| 1443 | A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon- α and ribavirin in patients infected with genotype 1 Hepatitis C virus. Journal of Medical Economics, 2015, 18, 787-796. | 1.0 | 5 |
| 1444 | Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs. Epidemiologic Reviews, 2015, 37, 131-143. | 1.3 | 53 |
| 1445 | Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatology International, 2015, 9, 486-507. | 1.9 | 18 |
| 1446 | Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. Drugs, 2015, 75, 823-834. | 4.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1447 | Impact of Provider Type on Hepatitis C Outcomes With Boceprevir-based and Telaprevir-based Regimens. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 329-335. | 1.1 | 11 |
| 1448 | Generation of improved mouse models for the study of hepatitis C virus. <i>European Journal of Pharmacology</i> , 2015, 759, 313-325. | 1.7 | 14 |
| 1449 | Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 336-344. | 1.1 | 7 |
| 1450 | Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 218-230. | 8.2 | 79 |
| 1451 | Prevalence and Management of Chronic Hepatitis C Virus Infection in Women. <i>Medical Clinics of North America</i> , 2015, 99, 575-586. | 1.1 | 6 |
| 1452 | Liver transplantation in the context of organ shortage. <i>Current Opinion in Critical Care</i> , 2015, 21, 163-170. | 1.6 | 19 |
| 1453 | Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. <i>Annals of Internal Medicine</i> , 2015, 162, 397-406. | 2.0 | 303 |
| 1455 | Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 713-731. | 1.0 | 1 |
| 1456 | Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. <i>Aids</i> , 2015, 29, 53-58. | 1.0 | 28 |
| 1457 | Management of post transplant hepatitis C in the direct antiviral agents era. <i>Hepatology International</i> , 2015, 9, 192-201. | 1.9 | 7 |
| 1458 | Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. <i>Journal of Hepatology</i> , 2015, 63, 364-369. | 1.8 | 115 |
| 1459 | Drug—drug interactions of telaprevir and boceprevir in HCV monoinfected and HIV/HCV coinfecting patients can modify the adherence. <i>Liver International</i> , 2015, 35, 1557-1565. | 1.9 | 5 |
| 1460 | Development and validation of a “capture–fusion” model to study drug sensitivity of patient-derived hepatitis C. <i>Hepatology</i> , 2015, 61, 1192-1204. | 3.6 | 5 |
| 1461 | Comparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patients. <i>Journal of Virological Methods</i> , 2015, 220, 1-4. | 1.0 | 11 |
| 1462 | <i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 988-997. | 1.4 | 108 |
| 1463 | Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 681-698. | 0.8 | 0 |
| 1465 | Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus. <i>Trends in Microbiology</i> , 2015, 23, 618-629. | 3.5 | 46 |
| 1466 | Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 699-704. | 0.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1467 | Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. <i>Journal of Clinical Virology</i> , 2015, 72, 114-118. | 1.6 | 15 |
| 1468 | Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , 2015, 14, 267-273. | 0.4 | 0 |
| 1469 | Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. <i>BMC Gastroenterology</i> , 2015, 15, 98. | 0.8 | 42 |
| 1470 | Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. <i>BMC Public Health</i> , 2015, 15, 566. | 1.2 | 11 |
| 1471 | A new role for PGA1 in inhibiting hepatitis C virus-IRES-mediated translation by targeting viral translation factors. <i>Antiviral Research</i> , 2015, 117, 1-9. | 1.9 | 7 |
| 1472 | Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6017-6025. | 1.4 | 11 |
| 1473 | Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. <i>Digestive Diseases</i> , 2015, 33, 613-623. | 0.8 | 15 |
| 1474 | Prisoners Treated for Hepatitis C with Protease Inhibitor, New York, USA, 2012. <i>Emerging Infectious Diseases</i> , 2015, 21, 186-188. | 2.0 | 7 |
| 1475 | The potency-insolubility conundrum in pharmaceuticals: Mechanism and solution for hepatitis C protease inhibitors. <i>Biophysical Chemistry</i> , 2015, 196, 100-108. | 1.5 | 14 |
| 1476 | Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1870-1882. | 2.0 | 54 |
| 1477 | Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. <i>Liver International</i> , 2015, 35, 2358-2362. | 1.9 | 15 |
| 1479 | Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 63-79. | 2.6 | 38 |
| 1480 | Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme. <i>Journal of Infection</i> , 2015, 71, 675-682. | 1.7 | 1 |
| 1481 | Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 644-654. | 0.2 | 12 |
| 1483 | Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1307-1317. | 2.0 | 7 |
| 1484 | Toxicodermias por telaprevir en el tratamiento de la infección crónica por el genotipo 1 del virus de la hepatitis C. Estudio prospectivo. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 219-225. | 0.2 | 4 |
| 1485 | Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. <i>Clinics in Liver Disease</i> , 2015, 19, 641-656. | 1.0 | 9 |
| 1486 | UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 443-449. | 1.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1487 | Alcoholic liver disease: Clinical and translational research. <i>Experimental and Molecular Pathology</i> , 2015, 99, 596-610. | 0.9 | 36 |
| 1488 | High-resolution genetic profile of viral genomes: why it matters. <i>Current Opinion in Virology</i> , 2015, 14, 62-70. | 2.6 | 13 |
| 1489 | The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 263-269. | 1.4 | 1 |
| 1490 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. <i>Current Gastroenterology Reports</i> , 2015, 17, 462. | 1.1 | 1 |
| 1491 | Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 825-843. | 1.0 | 17 |
| 1492 | Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 785-793. | 1.3 | 13 |
| 1493 | Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. <i>International Journal of Drug Policy</i> , 2015, 26, 1014-1019. | 1.6 | 21 |
| 1494 | Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1483-1494. | 1.4 | 10 |
| 1495 | The safety of daclatasvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1787-1797. | 1.0 | 3 |
| 1496 | Role of HCV-RNA decay and IP-10 levels after 48hours of standard HCV therapy as predictors of rapid virological response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 705-710. | 0.7 | 2 |
| 1497 | HPLC method for the determination of the S- and R-diastereomers of telaprevir for treatment of patients with hepatitis C. <i>Laboratoriums Medizin</i> , 2015, 39, . | 0.1 | 0 |
| 1498 | Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1815-1825. | 1.0 | 2 |
| 1499 | Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. <i>Clinical Infectious Diseases</i> , 2015, 62, civ897. | 2.9 | 31 |
| 1500 | Emerging treatments for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 204-215. | 0.8 | 32 |
| 1501 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review. <i>Journal of Advanced Research</i> , 2015, 6, 301-310. | 4.4 | 40 |
| 1502 | IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: Systematic review of its prevalence in chronic hepatitis C patients and general population frequency. <i>Pharmacological Reports</i> , 2015, 67, 260-266. | 1.5 | 3 |
| 1503 | Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C. <i>Human Genetics</i> , 2015, 134, 279-289. | 1.8 | 13 |
| 1504 | The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 15-22. | 0.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1505 | Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting. <i>Clinical Infectious Diseases</i> , 2015, 60, 108-116. | 2.9 | 46 |
| 1506 | A randomized, placebo-controlled study of the NS 5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. <i>Journal of Viral Hepatitis</i> , 2015, 22, 658-664. | 1.0 | 17 |
| 1507 | Novel Dengue Virus NS2B/NS3 Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1100-1109. | 1.4 | 108 |
| 1508 | Which therapeutic option for hepatitis C virus genotype 1?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 470-478. | 0.6 | 3 |
| 1509 | Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 27-35. | 4.6 | 60 |
| 1510 | Hepatitis C virus and lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 246-256. | 2.0 | 23 |
| 1511 | Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy. <i>Virus Research</i> , 2015, 196, 37-43. | 1.1 | 3 |
| 1512 | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331. | 6.1 | 30 |
| 1513 | Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. <i>Journal of Viral Hepatitis</i> , 2015, 22, 376-383. | 1.0 | 40 |
| 1514 | Barriers to HCV treatment in the era of triple therapy: a prospective multicentred study in clinical practice. <i>Liver International</i> , 2015, 35, 401-408. | 1.9 | 16 |
| 1515 | Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. <i>Journal of Viral Hepatitis</i> , 2015, 22, 158-165. | 1.0 | 34 |
| 1517 | Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND, a Phase 2b study. <i>Liver International</i> , 2015, 35, 417-421. | 1.9 | 18 |
| 1518 | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. <i>Journal of Viral Hepatitis</i> , 2015, 22, 366-375. | 1.0 | 17 |
| 1519 | Hepatitis C Virus-Associated Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 345-370. | 9.6 | 79 |
| 1520 | Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. <i>Journal of Viral Hepatitis</i> , 2015, 22, 8-17. | 1.0 | 15 |
| 1522 | Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1. | 0.6 | 49 |
| 1523 | Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. <i>Gut</i> , 2015, 64, 1277-1288. | 6.1 | 50 |
| 1524 | The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. <i>Journal of Viral Hepatitis</i> , 2015, 22, 254-262. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1525 | Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 299-306. | 0.2 | 8 |
| 1526 | Simeprevir (<scp>TMC435</scp>) once daily with peginterferon- and ribavirin in patients with genotype 1 hepatitis <scp>C</scp> virus infection: The <scp>CONCERTO</scp>-4 study. Hepatology Research, 2015, 45, 501-513. | 1.8 | 50 |
| 1527 | <scp>DAUPHINE</scp>: a randomized phase <scp>II</scp> study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in <scp>HCV</scp> genotypes 1 or 4. Liver International, 2015, 35, 108-119. | 1.9 | 22 |
| 1528 | Management of treatment-naïve chronic hepatitis <scp>C</scp> genotype 1 patients: a cost-effectiveness analysis of treatment options. Journal of Viral Hepatitis, 2015, 22, 175-183. | 1.0 | 19 |
| 1529 | Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 2015, 61, 77-87. | 3.6 | 1,293 |
| 1530 | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut, 2015, 64, 948-956. | 6.1 | 101 |
| 1531 | HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatology International, 2015, 9, 52-57. | 1.9 | 9 |
| 1532 | <scp>eGFR</scp> decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?. Liver International, 2015, 35, 71-78. | 1.9 | 18 |
| 1533 | Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. Digestive Diseases and Sciences, 2015, 60, 573-581. | 1.1 | 34 |
| 1534 | Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. Journal of Clinical Pharmacology, 2015, 55, 63-72. | 1.0 | 6 |
| 1535 | Ribavirin dose reduction during telaprevir/ribavirin/peginterferon therapy overcomes the effect of the <scp>ITPA</scp> gene polymorphism. Journal of Viral Hepatitis, 2015, 22, 166-174. | 1.0 | 11 |
| 1536 | A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes. Journal of Chemical Information and Modeling, 2015, 55, 362-373. | 2.5 | 39 |
| 1537 | Sofosbuvir for the treatment of hepatitis C virus infection. Cmaj, 2015, 187, 203-204. | 0.9 | 3 |
| 1538 | Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. Hepatology Research, 2015, 45, 837-845. | 1.8 | 15 |
| 1539 | Undetectable <scp>HCV</scp>-RNA at treatment-week 8 results in high-sustained virological response in <scp>HCV</scp> G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. Journal of Viral Hepatitis, 2015, 22, 469-480. | 1.0 | 9 |
| 1540 | Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. Journal of Hepatology, 2015, 62, 286-293. | 1.8 | 86 |
| 1541 | The prospective randomized study on telaprevir at 1500 or 2250mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. Journal of Gastroenterology, 2015, 50, 313-322. | 2.3 | 6 |
| 1542 | Hepatitis C Virus. , 2016, , 1313-1345. | | 61 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1543 | Viral Transmission in Organ Transplantation: The Importance of Risk Assessment. , 0, , . | | 0 |
| 1544 | Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 863-871. | 0.5 | 1 |
| 1545 | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-34. | 0.7 | 21 |
| 1546 | IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2016, 58, 37. | 0.5 | 1 |
| 1547 | Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Brazilian Journal of Medical and Biological Research, 2016, 49, . | 0.7 | 5 |
| 1548 | Conceptual framework for outcomes research studies of hepatitis C: an analytical review. Infection and Drug Resistance, 2016, 9, 101. | 1.1 | 0 |
| 1549 | Anemia and iron deficiency in gastrointestinal and liver conditions. World Journal of Gastroenterology, 2016, 22, 7908. | 1.4 | 103 |
| 1550 | New approaches in the treatment of hepatitis C. World Journal of Gastroenterology, 2016, 22, 1421. | 1.4 | 108 |
| 1551 | Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents. Brazilian Journal of Medical and Biological Research, 2016, 49, e5504. | 0.7 | 9 |
| 1552 | Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. Journal of Korean Medical Science, 2016, 31, 1431. | 1.1 | 7 |
| 1553 | Treatment of Hepatitis C with First Generation Protease Inhibitors. Advances in Pharmacoepidemiology & Drug Safety, 2016, 05, . | 0.1 | 0 |
| 1554 | Advances in hepatitis C therapy: What is the current state - what come's next?. World Journal of Hepatology, 2016, 8, 139. | 0.8 | 85 |
| 1555 | Serine protease inhibitors. , 2016, , 343-347. | | 0 |
| 1556 | Hepatitis C Treatment with Sofosbuvir and Daclatasvir in an 83 Year Old Patient with Ischemic Vasculitis and End Stage Renal Disease on Hemodialysis. Journal of Infectious Diseases and Treatment, 2016, 02, . | 0.0 | 0 |
| 1557 | Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepatitis Research and Treatment, 2016, 2016, 1-8. | 2.0 | 2 |
| 1558 | Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation, 2016, 2016, 1-11. | 1.4 | 49 |
| 1559 | Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World Journal of Gastroenterology, 2016, 22, 8050. | 1.4 | 43 |
| 1560 | Hepatitis C virus: Promising discoveries and new treatments. World Journal of Gastroenterology, 2016, 22, 6393. | 1.4 | 19 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1561 | Analysis of the Changes in Expression Levels of Sialic Acid on Influenza-Virus-Infected Cells Using Lectin-Tagged Polymeric Nanoparticles. <i>Frontiers in Microbiology</i> , 2016, 7, 1147. | 1.5 | 5 |
| 1562 | C the difference: exploring the learning strategies used by hepatology nurses in the era of new hepatitis C treatments. <i>Gastrointestinal Nursing</i> , 2016, 14, 47-57. | 0.0 | 2 |
| 1563 | Treatment of Chronic Hepatitis C in the Aged – Does It Impact Life Expectancy? A Decision Analysis. <i>PLoS ONE</i> , 2016, 11, e0157832. | 1.1 | 25 |
| 1564 | Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. <i>PLoS ONE</i> , 2016, 11, e0158989. | 1.1 | 5 |
| 1565 | Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. <i>PLoS ONE</i> , 2016, 11, e0163945. | 1.1 | 4 |
| 1566 | Anti-hepatitis C virus drugs and kidney. <i>World Journal of Hepatology</i> , 2016, 8, 1343. | 0.8 | 16 |
| 1567 | Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. <i>World Journal of Hepatology</i> , 2016, 8, 83. | 0.8 | 31 |
| 1568 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT/Overlook</i> | 0.4 | 23 |
| 1569 | New prospects for the treatment and prevention of hepatitis C in children. <i>Current Opinion in Pediatrics</i> , 2016, 28, 93-100. | 1.0 | 24 |
| 1570 | Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients. <i>Aids</i> , 2016, 30, 975-989. | 1.0 | 5 |
| 1571 | NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects. <i>Journal of Viral Hepatitis</i> , 2016, 23, 840-849. | 1.0 | 15 |
| 1572 | Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. <i>Journal of Medical Virology</i> , 2016, 88, 481-486. | 2.5 | 6 |
| 1573 | Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. <i>Hepatology Research</i> , 2016, 46, 707-712. | 1.8 | 11 |
| 1574 | Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living donor liver transplantation: A Japanese multicenter experience. <i>Hepatology Research</i> , 2016, 46, 1285-1293. | 1.8 | 7 |
| 1575 | Ledipasvir/Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. <i>Pharmacotherapy</i> , 2016, 36, 562-574. | 1.2 | 12 |
| 1576 | Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. <i>Current Infectious Disease Reports</i> , 2016, 18, 22. | 1.3 | 14 |
| 1577 | Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. <i>Journal of Medical Virology</i> , 2016, 88, 1659-1671. | 2.5 | 23 |
| 1578 | Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 635-643. | 0.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1579 | Hepatitis C-A clinical review. Journal of Medical Virology, 2016, 88, 1844-1855. | 2.5 | 38 |
| 1581 | Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1276-1292. | 1.9 | 124 |
| 1582 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naïve patients. Liver International, 2016, 36, 189-197. | 1.9 | 23 |
| 1583 | Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation. Journal of Interferon and Cytokine Research, 2016, 36, 358-366. | 0.5 | 6 |
| 1584 | Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Annals of Internal Medicine, 2016, 164, 84. | 2.0 | 137 |
| 1586 | Why is viral eradication so important in patients with HCV-related cirrhosis?. Antiviral Therapy, 2016, 22, 1-12. | 0.6 | 9 |
| 1587 | Systems Pharmacology and Pharmacodynamics. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , . | 0.2 | 9 |
| 1588 | Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C. Digestive Diseases, 2016, 34, 620-626. | 0.8 | 6 |
| 1589 | Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Scientific Reports, 2016, 6, 22995. | 1.6 | 7 |
| 1591 | Safety and Efficacy of Sofosbuvir plus Ledipasvir with and without Ribavirin for Chronic HCV Genotype-1 Infection: A Systematic Review and Meta-Analysis. Antiviral Therapy, 2017, 22, 369-379. | 0.6 | 14 |
| 1592 | Telaprevir: From Drug Discovery to the Manufacture of Drug Substance. ACS Symposium Series, 2016, , 281-323. | 0.5 | 1 |
| 1593 | Chronic Hepatitis B, C, and D. Microbiology Spectrum, 2016, 4, . | 1.2 | 2 |
| 1594 | Viral Dynamic Modeling of Hepatitis C Virus Infection: Past Successes and Future Challenges. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 403-420. | 0.2 | 0 |
| 1595 | Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals. Biomedical Reports, 2016, 4, 664-666. | 0.9 | 1 |
| 1596 | The discovery of indole derivatives as novel hepatitis C virus inhibitors. European Journal of Medicinal Chemistry, 2016, 116, 147-155. | 2.6 | 18 |
| 1597 | Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology, 2016, 63, 63-73. | 3.6 | 50 |
| 1598 | Hepatitis por el virus C. Medicine, 2016, 12, 484-493. | 0.0 | 0 |
| 1599 | New combination antiviral for the treatment of hepatitis C. American Journal of Health-System Pharmacy, 2016, 73, 1042-1050. | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1601 | Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. <i>Journal of Medical Economics</i> , 2016, 19, 983-994. | 1.0 | 12 |
| 1602 | Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 622-630. | 0.7 | 3 |
| 1603 | A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. <i>Journal of the National Medical Association</i> , 2016, 108, 24-29. | 0.6 | 30 |
| 1604 | Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1153-1164. | 0.9 | 15 |
| 1605 | Analysis, detection and quantitation of mixed cryoglobulins in HCV infection: brief review and case examples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1853-1859. | 1.4 | 10 |
| 1606 | Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. <i>Clinical Infectious Diseases</i> , 2016, 62, 1290-1296. | 2.9 | 46 |
| 1607 | A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 369-375. | 1.4 | 115 |
| 1608 | Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease. <i>Digestive Diseases</i> , 2016, 34, 317-326. | 0.8 | 9 |
| 1609 | von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199. | 0.4 | 1 |
| 1610 | Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection. <i>Gastroenterology & Hepatology (English Edition)</i> , 2016, 39, 377-384. | 0.0 | 0 |
| 1611 | Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C. <i>International Journal of Infectious Diseases</i> , 2016, 50, 1-5. | 1.5 | 6 |
| 1612 | First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment. <i>Value in Health</i> , 2016, 19, 776-787. | 0.1 | 15 |
| 1613 | RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies. <i>Chromatographia</i> , 2016, 79, 1605-1613. | 0.7 | 55 |
| 1614 | Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. <i>Cytokine</i> , 2016, 88, 29-36. | 1.4 | 2 |
| 1615 | Safety of direct antiviral agents in the management of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1643-1652. | 1.0 | 36 |
| 1616 | Global genotype distribution of hepatitis C viral infection among people who inject drugs. <i>Journal of Hepatology</i> , 2016, 65, 1094-1103. | 1.8 | 63 |
| 1617 | Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, e93-e99. | 0.1 | 53 |
| 1618 | Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. <i>Journal of Medical Virology</i> , 2016, 88, 94-99. | 2.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1619 | Dermatological side effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 143-146. | 1.3 | 5 |
| 1620 | Randomized comparison of daclatasvir+asunaprevir versus telaprevir+peginterferon/ribavirin in Japanese hepatitis C virus patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 14-22. | 1.4 | 44 |
| 1621 | Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. <i>Journal of Viral Hepatitis</i> , 2016, 23, 80-88. | 1.0 | 14 |
| 1622 | HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502. | 1.9 | 4 |
| 1623 | Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review. <i>European Journal of Clinical Investigation</i> , 2016, 46, 737-748. | 1.7 | 3 |
| 1624 | Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , 2016, 17, 1587-1594. | 0.6 | 10 |
| 1625 | Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 738-746. | 1.9 | 11 |
| 1626 | New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). <i>Expert Opinion on Drug Safety</i> , 2016, 15, 85-100. | 1.0 | 27 |
| 1627 | Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3108-3117. | 1.1 | 10 |
| 1628 | Diagnostics in hepatitis C: The end of response-guided therapy?. <i>Journal of Hepatology</i> , 2016, 65, S67-S81. | 1.8 | 24 |
| 1629 | Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3495-3505. | 1.3 | 24 |
| 1630 | Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV/HCV co-infected patients: final results of the Spanish BOC HIV/HCV Study. <i>International Journal of Infectious Diseases</i> , 2016, 53, 46-51. | 1.5 | 2 |
| 1631 | Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. , 2016, , 225-241. | | 0 |
| 1633 | Hepatocellular Carcinoma and Hepatitis C Virus. , 2016, , 109-136. | | 1 |
| 1634 | Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening. <i>Antiviral Therapy</i> , 2016, 21, 567-577. | 0.6 | 5 |
| 1635 | The era of first direct-acting antiviral agents: What did we learn?. <i>Clinical Liver Disease</i> , 2016, 8, 72-75. | 1.0 | 1 |
| 1636 | Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 425-434. | 0.6 | 6 |
| 1637 | Serum level of interleukin-8 and interleukin-10 as predictors for response to interferon+ribavirin combined therapy. <i>Egyptian Liver Journal</i> , 2016, 6, 7-15. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1638 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. <i>Medicine (United States)</i> , 2016, 95, e5048. | 0.4 | 32 |
| 1639 | Chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 164-172. | 0.8 | 3 |
| 1640 | The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 173-180. | 0.8 | 18 |
| 1641 | Changes in the response to treatment against chronic hepatitis C between 1999 and 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1253-1257. | 0.8 | 1 |
| 1642 | Costs and outcomes of treating chronic hepatitis C patients in routine care – results from a nationwide multicenter trial. <i>Journal of Viral Hepatitis</i> , 2016, 23, 105-115. | 1.0 | 9 |
| 1643 | Ritonavir-boosted danoprevir-based regimens in treatment-naïve and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. <i>Hepatology International</i> , 2016, 10, 478-487. | 1.9 | 3 |
| 1644 | Management of HCV Infection. , 2016, , 61-78. | | 0 |
| 1645 | A new paradigm evaluating cost per cure of HCV infection in the UK. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 2. | 1.7 | 5 |
| 1646 | Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection. <i>Gastroenterology & Hepatology</i> , 2016, 39, 377-384. | 0.2 | 0 |
| 1647 | Disparities in hepatitis C testing in U.S. veterans born 1945–1965. <i>Journal of Hepatology</i> , 2016, 65, 259-265. | 1.8 | 22 |
| 1649 | Hepatitis C virus treatment update – A new era of all-oral HCV treatment. <i>Advances in Digestive Medicine</i> , 2016, 3, 153-160. | 0.1 | 10 |
| 1650 | A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines. <i>Vaccine</i> , 2016, 34, 2821-2833. | 1.7 | 8 |
| 1651 | Telaprevir-Induced Renal Adverse Events in Japanese Patients Reported in the PMDA Adverse Drug Reactions Reporting Database. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 355-360. | 0.8 | 2 |
| 1652 | Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. <i>SpringerPlus</i> , 2016, 5, 518. | 1.2 | 4 |
| 1653 | Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. <i>Clinical Microbiology and Infection</i> , 2016, 22, 846-852. | 2.8 | 29 |
| 1654 | Real-world effectiveness of peginterferon λ -2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWER and RediPEN studies. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 597-609. | 1.3 | 1 |
| 1655 | Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1101-1107. | 1.8 | 13 |
| 1656 | New directions for protease inhibitors directed drug discovery. <i>Biopolymers</i> , 2016, 106, 563-579. | 1.2 | 26 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1657 | Effectiveness of first-generation HCV protease inhibitors. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 37-41. | 0.8 | 2 |
| 1658 | Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. <i>Hepatology Research</i> , 2016, 46, 1311-1320. | 1.8 | 8 |
| 1659 | Comparison of sleep disorders in chronic hepatitis C patients treated with interferon-based therapy and direct acting antivirals using actigraphy. <i>Hepatology Research</i> , 2016, 46, 1358-1366. | 1.8 | 17 |
| 1660 | Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. <i>Journal of Hepatology</i> , 2016, 64, 19-28. | 1.8 | 60 |
| 1661 | Approachability to the new anti-HCV direct acting antiviral agents in the Latin American context. <i>Future Virology</i> , 2016, 11, 39-46. | 0.9 | 3 |
| 1662 | How to Treat Patients with Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis. <i>Current Hepatology Reports</i> , 2016, 15, 60-66. | 0.4 | 1 |
| 1663 | Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. <i>Hepatology International</i> , 2016, 10, 258-266. | 1.9 | 9 |
| 1664 | Evaluating the current surgical strategies for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 341-357. | 1.4 | 7 |
| 1665 | New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 287-302. | 1.3 | 31 |
| 1667 | New HCV Therapies and Liver Transplantation. <i>Transplantation</i> , 2016, 100, 260-261. | 0.5 | 5 |
| 1668 | Hepatitis C Virus Genotype and Subtype Distribution in Patient Specimens Tested at the University of Texas Medical Branch, Galveston, Between January 2011 and November 2014. <i>Laboratory Medicine</i> , 2016, 47, 112-118. | 0.8 | 4 |
| 1669 | Optimum predictors of therapeutic outcome in HCV patients in Pakistan. <i>Journal of Medical Virology</i> , 2016, 88, 100-108. | 2.5 | 8 |
| 1670 | Activity-based and fraction-guided analysis of <i>Phyllanthus urinaria</i> identifies loliolide as a potent inhibitor of hepatitis C virus entry. <i>Antiviral Research</i> , 2016, 130, 58-68. | 1.9 | 54 |
| 1671 | Modeling Ribavirin-induced Anemia in Patients with Chronic Hepatitis C Virus. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 65-73. | 1.3 | 14 |
| 1672 | Optimizing HCV treatment – Moving beyond the cost conundrum. <i>Journal of Hepatology</i> , 2016, 65, 222-225. | 1.8 | 9 |
| 1673 | Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus. <i>Antiviral Research</i> , 2016, 126, 43-54. | 1.9 | 17 |
| 1674 | Personalised approaches to pharmacotherapy for schizophrenia. <i>BJ Psych Advances</i> , 2016, 22, 78-86. | 0.5 | 9 |
| 1675 | A Synthesis of a Spirocyclic Macrocyclic Protease Inhibitor for the Treatment of Hepatitis C. <i>Organic Letters</i> , 2016, 18, 1394-1397. | 2.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1676 | Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure. <i>Journal of Clinical Virology</i> , 2016, 78, 36-43. | 1.6 | 3 |
| 1677 | Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy. <i>Antiviral Research</i> , 2016, 126, 35-42. | 1.9 | 4 |
| 1678 | Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 111-116. | 1.3 | 31 |
| 1679 | A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 913-924. | 1.4 | 44 |
| 1680 | Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. <i>Journal of Hepatology</i> , 2016, 64, 301-307. | 1.8 | 147 |
| 1681 | Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 285-294. | 0.7 | 14 |
| 1682 | SUMO1 depletion prevents lipid droplet accumulation and HCV replication. <i>Archives of Virology</i> , 2016, 161, 141-148. | 0.9 | 10 |
| 1683 | Telaprevir-based therapy in patients coinfecting with chronic hepatitis C virus infection and HIV: INSIGHT study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 244-250. | 1.3 | 2 |
| 1684 | Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 58-66. | 0.6 | 14 |
| 1685 | Predictive factors for 24-weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. <i>Hepatology International</i> , 2016, 10, 158-168. | 1.9 | 2 |
| 1686 | Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 203-212. | 0.7 | 2 |
| 1687 | Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. <i>Health Care Management Science</i> , 2017, 20, 16-32. | 1.5 | 14 |
| 1688 | Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 229-236. | 1.4 | 61 |
| 1689 | 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. <i>United European Gastroenterology Journal</i> , 2017, 5, 69-75. | 1.6 | 10 |
| 1690 | Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection. <i>Journal of Pharmacy Practice</i> , 2017, 30, 154-161. | 0.5 | 6 |
| 1691 | Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. <i>Journal of Gastroenterology</i> , 2017, 52, 94-103. | 2.3 | 38 |
| 1692 | Cost-Effectiveness of the Hepatitis C Self-Management Program. <i>Health Education and Behavior</i> , 2017, 44, 113-122. | 1.3 | 6 |
| 1693 | IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. <i>Hepatology Research</i> , 2017, 47, E5-E13. | 1.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1694 | Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. <i>Journal of Advanced Research</i> , 2017, 8, 131-137. | 4.4 | 15 |
| 1695 | Hepatitis C: efficacy and safety in real life. <i>Liver International</i> , 2017, 37, 26-32. | 1.9 | 43 |
| 1696 | Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. <i>Clinical Transplantation</i> , 2017, 31, e12941. | 0.8 | 25 |
| 1697 | Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 593-601. | 1.4 | 6 |
| 1698 | Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies. <i>Clinical Drug Investigation</i> , 2017, 37, 647-657. | 1.1 | 4 |
| 1699 | Oxidative Deaminations and Deisatinylation of Ugi-Azide and Ugi-3CR Products: A Two-Step MCR-Oxidation Protocol toward Functionalized β -Ketoamides and β -Ketotetrazaoles. <i>Organic Letters</i> , 2017, 19, 2238-2241. | 2.4 | 17 |
| 1700 | Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study. <i>Infectious Diseases and Therapy</i> , 2017, 6, 265-275. | 1.8 | 5 |
| 1701 | ITPA gene polymorphism (<i>rs10980</i>) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2017, 89, 1823-1829. | 2.5 | 6 |
| 1702 | A fixed-dose combination of ledipasvir and sofosbuvir \pm ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 348-360. | 0.3 | 0 |
| 1703 | Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review. <i>BMC Infectious Diseases</i> , 2017, 17, 260. | 1.3 | 20 |
| 1704 | Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 635-642. | 2.5 | 13 |
| 1705 | Hepatitis B and C. <i>Pediatric Clinics of North America</i> , 2017, 64, 641-658. | 0.9 | 31 |
| 1706 | Hepatitis C infection. <i>Nurse Practitioner</i> , 2017, 42, 14-23. | 0.2 | 1 |
| 1707 | Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, S1-S23. | 0.5 | 29 |
| 1708 | The Management of Anemia in Patients with HCV Treated with DAA. <i>ARS Medica Tomitana</i> , 2017, 23, 62-65. | 0.0 | 0 |
| 1709 | Direct catalytic enantioselective Mannich-type reaction of β , β -dithioacetonitriles with imines using chiral bis(imidazoline)-Pd complexes. <i>Chemical Communications</i> , 2017, 53, 6776-6779. | 2.2 | 18 |
| 1710 | HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. <i>HIV Clinical Trials</i> , 2017, 18, 126-134. | 2.0 | 31 |
| 1711 | Evaluation of the Abbott RealTime HCV genotype II plus RUO (PLUS) assay with reference to core and NS5B sequencing. <i>Journal of Clinical Virology</i> , 2017, 90, 26-31. | 1.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1712 | Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. <i>Scientific Reports</i> , 2017, 7, 45605. | 1.6 | 20 |
| 1713 | Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems. <i>Virus Research</i> , 2017, 235, 37-48. | 1.1 | 7 |
| 1714 | Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 583-594. | 1.3 | 33 |
| 1715 | Prevalence of Sofosbuvir Resistance-Associated Variants in Brazilian and Worldwide NS5B Sequences of Genotype-1 HCV. <i>Antiviral Therapy</i> , 2017, 22, 447-451. | 0.6 | 13 |
| 1716 | Protease Inhibitor Resistance. , 2017, , 21-40. | | 0 |
| 1717 | Treatment optimization for HIV/HCV co-infected patients. <i>Therapeutic Advances in Infectious Disease</i> , 2017, 4, 18-36. | 1.1 | 13 |
| 1718 | Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 559-567. | 1.4 | 10 |
| 1719 | Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. <i>Hepatology Research</i> , 2017, 47, 1147-1154. | 1.8 | 2 |
| 1720 | Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 853-861. | 1.3 | 4 |
| 1721 | The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 103-113. | 1.4 | 6 |
| 1722 | Tolerability and efficacy of pegylated consensus interferon- α in the treatment of chronic hepatitis C. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 9-16. | 0.8 | 2 |
| 1723 | Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. <i>Journal of Clinical Microbiology</i> , 2017, 55, 504-509. | 1.8 | 15 |
| 1724 | Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease. <i>Oncology</i> , 2017, 92, 3-9. | 0.9 | 12 |
| 1725 | A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (<i>S</i>)-1-((<i>R</i>)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-<i>N</i>-((4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 228-247. | | |
| 1726 | Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 470-479. | 0.6 | 9 |
| 1727 | Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. <i>Clinical Medicine Insights: Cardiology</i> , 2017, 11, 117954681771320. | 0.6 | 9 |
| 1728 | Direct-acting antivirals for chronic hepatitis C. <i>The Cochrane Library</i> , 2017, 2017, CD012143. | 1.5 | 56 |
| 1730 | Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2017, 40, 433-446. | 0.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1731 | Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. <i>Clinical Immunology</i> , 2017, 183, 82-90. | 1.4 | 0 |
| 1732 | Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 433-446. | 0.2 | 16 |
| 1733 | Publicâ€Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. <i>Gastroenterology</i> , 2017, 153, 626-631. | 0.6 | 20 |
| 1734 | Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective. <i>Value in Health Regional Issues</i> , 2017, 13, 7-15. | 0.5 | 14 |
| 1735 | Direct-acting antivirals for chronic hepatitis C. <i>The Cochrane Library</i> , 2017, 6, CD012143. | 1.5 | 74 |
| 1736 | Singleâ€Dose and Multipleâ€Dose Pharmacokinetics of Vaniprevir in Healthy Men. <i>Clinical and Translational Science</i> , 2017, 10, 480-486. | 1.5 | 1 |
| 1737 | Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1149-1154. | 0.8 | 7 |
| 1738 | Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 789-795. | 1.4 | 20 |
| 1739 | Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare. <i>Journal of Racial and Ethnic Health Disparities</i> , 2017, 4, 1147-1158. | 1.8 | 16 |
| 1740 | Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. <i>BMC Health Services Research</i> , 2017, 17, 288. | 0.9 | 1 |
| 1742 | Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. <i>European Journal of Health Economics</i> , 2017, 18, 1001-1011. | 1.4 | 22 |
| 1743 | Hemoglobin during ribavirinâ€based HCV therapy is closely related to circulating levels of DHEA. <i>Journal of Medical Virology</i> , 2017, 89, 1033-1039. | 2.5 | 2 |
| 1744 | Emerging Antivirals in the Future. , 2017, , 63-75. | | 0 |
| 1745 | Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017, 45, 103-106. | 2.3 | 11 |
| 1746 | Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 65-82. | 0.6 | 8 |
| 1747 | Spending on Hepatitis C Antivirals in the United States, 2009â€2015. <i>Pharmacotherapy</i> , 2017, 37, 65-70. | 1.2 | 8 |
| 1748 | Drugs to Treat Viral Hepatitis. , 2017, , 1327-1332.e1. | | 3 |
| 1749 | Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1-14. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1750 | Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocytic Inhibitor of the Hepatitis C Virus NS3 Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 4 |
| 1751 | Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. <i>Lancet, The</i> , 2017, 389, 1268-1272. | 6.3 | 35 |
| 1752 | Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 645-650. | 1.4 | 11 |
| 1753 | Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 548-557. | 1.4 | 13 |
| 1754 | Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 45-52. | 1.4 | 20 |
| 1755 | Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 527-539. | 1.1 | 13 |
| 1756 | Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. <i>Clinical Infectious Diseases</i> , 2017, 64, 92-99. | 2.9 | 18 |
| 1757 | Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection. <i>Hepatology Research</i> , 2017, 47, 773-782. | 1.8 | 3 |
| 1758 | Identification of novel inhibitors of HCV NS3 protease genotype 3 subtype B through molecular docking studies of phytochemicals from <i>Boerhavia diffusa</i> L. <i>Medicinal Chemistry Research</i> , 2017, 26, 327-334. | 1.1 | 2 |
| 1759 | Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 859-863. | 1.4 | 21 |
| 1760 | Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 504-511. | 2.3 | 16 |
| 1762 | Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 1525-1529. | 0.6 | 0 |
| 1763 | Viral and host factors associated with outcomes of hepatitis C virus infection. <i>Molecular Medicine Reports</i> , 2017, 15, 2909-2924. | 1.1 | 25 |
| 1764 | Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , 2017, 16, 312-317. | 0.6 | 1 |
| 1765 | Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. <i>Annals of Hepatology</i> , 2017, 16, 366-374. | 0.6 | 3 |
| 1766 | Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C Infections. , 2017, , . | | 0 |
| 1767 | Approaches and Considerations for the Successful Treatment of HCV Infection. , 2017, , . | | 0 |
| 1768 | Hepatitis C treatment: where are we now?. <i>International Journal of General Medicine</i> , 2017, Volume 10, 39-52. | 0.8 | 86 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1769 | Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. International Journal of Medical Sciences, 2017, 14, 403-411. | 1.1 | 21 |
| 1770 | CONTEXTUALIZAÇÃO E AVANÇOS NO TRATAMENTO DA HEPATITE C: UMA REVISÃO DA LITERATURA. Visão Acadêmica, 2017, 18, . | 0.1 | 3 |
| 1771 | Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS ONE, 2017, 12, e0169401. | 1.1 | 25 |
| 1772 | Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS ONE, 2017, 12, e0184127. | 1.1 | 16 |
| 1773 | Perceived benefits of the hepatitis C peer educators: a qualitative investigation. Harm Reduction Journal, 2017, 14, 67. | 1.3 | 28 |
| 1774 | Potential Therapeutics: Toe Hold in the Fight against Zika Virus. Journal of Bioanalysis & Biomedicine, 2017, 09, . | 0.1 | 0 |
| 1775 | Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment. , 0, , . | | 0 |
| 1776 | Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies. , 0, , . | | 3 |
| 1777 | The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 595-607. | 0.7 | 3 |
| 1778 | Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Therapeutics and Clinical Risk Management, 2017, Volume 13, 59-64. | 0.9 | 5 |
| 1779 | Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2017, 8, 137. | 0.6 | 20 |
| 1780 | Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies. Journal of General Virology, 2017, 98, 962-976. | 1.3 | 6 |
| 1781 | Current Treatment of Chronic Hepatitis C. , 2017, , 781-789. | | 1 |
| 1782 | Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. Expert Opinion on Pharmacotherapy, 2018, 19, 451-456. | 0.9 | 3 |
| 1783 | Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients. Viral Immunology, 2018, 31, 256-263. | 0.6 | 9 |
| 1784 | Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. Internal and Emergency Medicine, 2018, 13, 775-790. | 1.0 | 4 |
| 1785 | Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection. Expert Opinion on Pharmacotherapy, 2018, 19, 749-757. | 0.9 | 6 |
| 1786 | Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 219-227. | 1.5 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1787 | Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 640-648. | 1.0 | 68 |
| 1788 | Treatment of hepatitis C virus with direct-acting antivirals: Practical aspects and current situation. <i>Revista Clínica Española</i> , 2018, 218, 29-37. | 0.3 | 1 |
| 1789 | Viral Hepatitis: Knowledge and Treatments for Hepatitis B and C Virus and Associated Transplantation and Neoplasia. <i>Gastroenterology</i> , 2018, 154, 453-456. | 0.6 | 2 |
| 1790 | Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 2-11. | 0.2 | 14 |
| 1791 | miRNAs regulate immune response and signaling during hepatitis C virus infection. <i>European Journal of Medical Research</i> , 2018, 23, 19. | 0.9 | 11 |
| 1792 | The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 50-56. | 0.4 | 6 |
| 1793 | Development of Stability Indicating HPLC-UV Method for Determination of Daclatasvir and Characterization of Forced Degradation Products. <i>Chromatographia</i> , 2018, 81, 785-797. | 0.7 | 25 |
| 1794 | Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, 132-137. | 0.5 | 3 |
| 1795 | Neutralizing activity and safety of human monoclonal antibodies against hepatitis C virus. <i>Human Antibodies</i> , 2018, 26, 127-134. | 0.6 | 1 |
| 1796 | Extrinsic Nonimmune Hemolytic Anemias. , 2018, , 663-672. | | 2 |
| 1797 | Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2018, 90, 907-918. | 2.5 | 15 |
| 1798 | Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual. <i>Revista Clínica Española</i> , 2018, 218, 29-37. | 0.2 | 4 |
| 1799 | Management of Chronic Hepatitis C in End-stage Renal Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 287-294. | 1.1 | 2 |
| 1800 | Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. <i>Hepatology</i> , 2018, 67, 847-857. | 3.6 | 55 |
| 1801 | Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. <i>Annals of Hepatology</i> , 2018, 17, 18-32. | 0.6 | 28 |
| 1803 | Design and Analysis of a Novel 6-URS Self-Reconfigurable All-Dimensional Walking Robot. , 2018, , . | | 0 |
| 1804 | Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance. <i>Current Drug Metabolism</i> , 2018, 19, 215-223. | 0.7 | 5 |
| 1806 | Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881235. | 1.4 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1807 | The Short- and Long-Term Outcomes in Elderly Patients with Hepatocellular Carcinoma after Curative Surgery: A Case-Controlled Study with Propensity Score Matching. <i>European Surgical Research</i> , 2018, 59, 380-390. | 0.6 | 12 |
| 1808 | The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 580. | 1.3 | 2 |
| 1809 | Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 14-20. | 0.4 | 2 |
| 1810 | Epidemiology and Elimination of HCV-Related Liver Disease. <i>Viruses</i> , 2018, 10, 545. | 1.5 | 48 |
| 1811 | Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602. | 0.8 | 12 |
| 1812 | Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 73-85. | 0.9 | 2 |
| 1813 | Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. <i>Anticancer Research</i> , 2018, 38, 5513-5520. | 0.5 | 2 |
| 1814 | First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 146-154. | 0.4 | 2 |
| 1815 | Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. <i>Internal Medicine</i> , 2018, 57, 1101-1104. | 0.3 | 4 |
| 1816 | Regulation of interferon signaling and HCV RNA replication by extracellular matrix. <i>International Journal of Molecular Medicine</i> , 2018, 42, 957-965. | 1.8 | 6 |
| 1817 | Consenso Mexicano para el Tratamiento de la Hepatitis C. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2018, 83, 275-324. | 0.4 | 9 |
| 1818 | Transmission genetics of drug-resistant hepatitis C virus. <i>ELife</i> , 2018, 7, . | 2.8 | 7 |
| 1819 | Applications of gold nanoparticles in virus detection. <i>Theranostics</i> , 2018, 8, 1985-2017. | 4.6 | 256 |
| 1820 | Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling. <i>Frontiers in Microbiology</i> , 2018, 9, 1546. | 1.5 | 61 |
| 1821 | Pharmacogenetics and the treatment of HIV/HCV-coinfected patients. <i>Pharmacogenomics</i> , 2018, 19, 979-995. | 0.6 | 2 |
| 1822 | Clinico-Pathological Importance of TGF- β ² /Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis. <i>Cancers</i> , 2018, 10, 183. | 1.7 | 56 |
| 1823 | Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2018, 41, 2-11. | 0.0 | 0 |
| 1824 | Hepatitis C Virus: Viral Quasispecies and Genotypes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 23. | 1.8 | 53 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1825 | Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life. <i>Internal Medicine</i> , 2018, 57, 1959-1966. | 0.3 | 5 |
| 1826 | Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 986-993. | 0.6 | 23 |
| 1827 | Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. <i>BMC Infectious Diseases</i> , 2018, 18, 74. | 1.3 | 23 |
| 1828 | The Mexican consensus on the treatment of hepatitis C. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2018, 83, 275-324. | 0.1 | 0 |
| 1829 | Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2018, 60, e29. | 0.5 | 2 |
| 1830 | Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 649-657. | 1.5 | 4 |
| 1831 | Clinical Aspects of Liver Transplantation. , 2018, , 605-627. | | 0 |
| 1832 | Pathology of Liver Transplantation. , 2018, , 629-662. | | 1 |
| 1833 | Current Trends in Macrocyclic Drug Discovery and beyond -Ro5. <i>Progress in Medicinal Chemistry</i> , 2018, 57, 113-233. | 4.1 | 21 |
| 1834 | Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. <i>Health Information and Libraries Journal</i> , 2019, 36, 318-340. | 1.3 | 3 |
| 1835 | Prevention Strategies for Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 255-289. | 0.4 | 2 |
| 1836 | <p>Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2565-2577. | 2.0 | 20 |
| 1838 | Antiviral Consideration for Transplantation Including Drug Resistance. , 2019, , 953-975. | | 2 |
| 1840 | â€œHere Today, Gone Tomorrowâ€-or â€œHere Today, Stay a Long Whileâ€: The Divergent Paths of Two Host Factors Important in Viral Infections. <i>Clinical Therapeutics</i> , 2019, 41, 1907-1911. | 1.1 | 3 |
| 1841 | Epidemiology, Use of resources, and Costs of Medical Management of Hepatitis C in Argentina, Colombia, Uruguay, and Venezuela. <i>Value in Health Regional Issues</i> , 2019, 20, 180-190. | 0.5 | 1 |
| 1842 | Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A singleâ€centre experience. <i>Haemophilia</i> , 2019, 25, 1028-1034. | 1.0 | 8 |
| 1843 | The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir. <i>Topics in Medicinal Chemistry</i> , 2019, , 389-413. | 0.4 | 9 |
| 1844 | The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. <i>Topics in Medicinal Chemistry</i> , 2019, , 97-113. | 0.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1845 | The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®). Topics in Medicinal Chemistry, 2019, , 237-280. | 0.4 | 1 |
| 1846 | Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)â€Viremic Donors Into HCVâ€Negative Recipients: Outcomes Following Liver Transplant of HCVâ€Viremic Donors. Hepatology, 2019, 69, 2381-2395. | 3.6 | 103 |
| 1847 | Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transplantation, 2019, 25, 598-609. | 1.3 | 70 |
| 1848 | Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Annals of Hepatology, 2019, 18, 137-143. | 0.6 | 1 |
| 1849 | Development and Marketing of INCIVEK (Telaprevir; VX-950): A First-Generation HCV Protease Inhibitor, in Combination with PEGylated Interferon and Ribavirin. Topics in Medicinal Chemistry, 2019, , 261-291. | 0.4 | 1 |
| 1850 | Viral Hepatitis: Chronic Hepatitis C. , 2019, , . | | 1 |
| 1851 | Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients. , 2019, , 65-95. | | 0 |
| 1852 | Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. Value in Health Regional Issues, 2019, 20, 95-102. | 0.5 | 2 |
| 1853 | A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. Journal of Chemotherapy, 2019, 31, 274-283. | 0.7 | 1 |
| 1854 | 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry. Scientific Reports, 2019, 9, 7288. | 1.6 | 6 |
| 1855 | O olho na hepatite C: uma revisÃ£o. Arquivos Brasileiros De Oftalmologia, 2019, 82, 161-167. | 0.2 | 3 |
| 1856 | Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact. Statistics in Medicine, 2019, 38, 2505-2523. | 0.8 | 13 |
| 1857 | Equivalent Outcomes With Retransplantation and Primary Liver Transplantation in the Direct-acting Antiviral Era. Transplantation, 2019, 103, 1168-1174. | 0.5 | 9 |
| 1858 | Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 700-706. | 0.7 | 6 |
| 1859 | Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. Antiviral Therapy, 2019, 24, 371-381. | 0.6 | 5 |
| 1860 | Review on chemogenomic approaches towards hepatitis C viral targets. Journal of Cellular Biochemistry, 2019, 120, 12167-12181. | 1.2 | 4 |
| 1861 | Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals â€ a retrospective cohort study. Transplant International, 2019, 32, 854-864. | 0.8 | 13 |
| 1862 | Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. Cells, 2019, 8, 317. | 1.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1863 | A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. <i>BMC Nephrology</i> , 2019, 20, 36. | 0.8 | 7 |
| 1864 | <i>In Vitro</i> Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir. <i>Journal of Clinical Microbiology</i> , 2019, 57, . | 1.8 | 10 |
| 1865 | Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach. <i>PLoS ONE</i> , 2019, 14, e0209587. | 1.1 | 7 |
| 1866 | A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 245-268. | 2.6 | 5 |
| 1868 | Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy. <i>Annals of Internal Medicine</i> , 2019, 170, 594. | 2.0 | 103 |
| 1870 | The Evolution of Clinical Trials for Hepatitis C. <i>Topics in Medicinal Chemistry</i> , 2019, , 187-235. | 0.4 | 0 |
| 1872 | Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. <i>PLoS ONE</i> , 2019, 14, e0218759. | 1.1 | 15 |
| 1873 | Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region. <i>Pathogens</i> , 2019, 8, 236. | 1.2 | 9 |
| 1874 | Treatment of Hepatitis C Virus. <i>Orthopaedic Nursing</i> , 2019, 38, 273-277. | 0.2 | 0 |
| 1875 | Weight loss changed gait kinematics in individuals with obesity and knee pain. <i>Gait and Posture</i> , 2019, 68, 461-465. | 0.6 | 33 |
| 1876 | HCV genotype 6 prevalence, spontaneous clearance and diversity among elderly members of the Li ethnic minority in Baisha County, China. <i>Journal of Viral Hepatitis</i> , 2019, 26, 529-540. | 1.0 | 8 |
| 1877 | Evolution of efficacious pangenotypic hepatitis C virus therapies. <i>Medicinal Research Reviews</i> , 2019, 39, 1091-1136. | 5.0 | 13 |
| 1878 | A longitudinal study assessing depression in hepatitis C: Does gender play a role in the new-onset depression during interferon-alpha treatment?. <i>Women and Health</i> , 2019, 59, 181-195. | 0.4 | 3 |
| 1879 | Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 4-12. | 0.4 | 8 |
| 1880 | Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 569-577. | 1.5 | 18 |
| 1881 | Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440. | 1.8 | 30 |
| 1882 | Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. <i>Digestive Diseases</i> , 2020, 38, 137-142. | 0.8 | 19 |
| 1883 | Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction. <i>Frontiers in Genetics</i> , 2020, 11, 577387. | 1.1 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1884 | Management of Hepatitis C in Children and Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 785-790. | 0.6 | 2 |
| 1885 | Hepatocellular carcinoma: old friends and new tricks. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1898-1907. | 3.2 | 154 |
| 1886 | Screening for Hepatitis C Virus: How Universal Is Universal?. <i>Clinical Therapeutics</i> , 2020, 42, 1434-1441. | 1.1 | 7 |
| 1887 | Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. <i>Journal of Infectious Diseases</i> , 2020, 222, S745-S757. | 1.9 | 9 |
| 1888 | <p>Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: StructureâActivity Relationships<p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 757-771. | 2.0 | 3 |
| 1889 | A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era. <i>South African Medical Journal</i> , 2020, 110, 106. | 0.2 | 4 |
| 1890 | Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia. <i>Value in Health Regional Issues</i> , 2020, 21, 164-171. | 0.5 | 1 |
| 1891 | Factors influencing treatment outcome in hepatitis C virus minority patients at an inner-city hospital. <i>Medicine (United States)</i> , 2020, 99, e19505. | 0.4 | 2 |
| 1892 | Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 1030. | 1.0 | 20 |
| 1893 | Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients. <i>Digestion</i> , 2021, 102, 453-461. | 1.2 | 1 |
| 1894 | Viral Hepatitis in pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 256, 287-296. | 0.5 | 25 |
| 1895 | Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 185-198. | 2.3 | 9 |
| 1896 | Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 139-157. | 0.8 | 5 |
| 1897 | Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era. <i>Transplantation</i> , 2021, 105, 2482-2489. | 0.5 | 2 |
| 1898 | Current Management of HCV Genotype 3 Infection. , 2021, , 97-117. | | 0 |
| 1899 | Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line. <i>Anais Da Academia Brasileira De Ciencias</i> , 2021, 93, e20200632. | 0.3 | 2 |
| 1900 | Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City. <i>Harm Reduction Journal</i> , 2021, 18, 38. | 1.3 | 7 |
| 1901 | Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. <i>Minerva Medica</i> , 2021, 112, 162-174. | 0.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1902 | Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emtasvir. Organic Process Research and Development, 2021, 25, 838-848. | 1.3 | 6 |
| 1903 | Blinding in Clinical Trials for Chronic Liver Diseases. Seminars in Liver Disease, 2021, 41, 163-171. | 1.8 | 1 |
| 1904 | Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. Kidney360, 2021, 2, 1316-1325. | 0.9 | 0 |
| 1905 | Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 701-711. | 1.8 | 1 |
| 1906 | Impact of IL28B Polymorphism on the Response to Treatment of Hepatitis C with Interferon Based Therapy or Direct Acting Antivirals. Medical Journal of the University of Cairo Faculty of Medicine, 2021, 89, 1333-1340. | 0.0 | 1 |
| 1907 | Current therapeutics against HCV. VirusDisease, 2021, 32, 228-243. | 1.0 | 14 |
| 1908 | Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. Cells, 2021, 10, 1626. | 1.8 | 5 |
| 1909 | The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. Journal of Viral Hepatitis, 2021, 28, 1452-1463. | 1.0 | 10 |
| 1910 | Viral hepatitis: Milestones, unresolved issues, and future goals. World Journal of Gastroenterology, 2021, 27, 4603-4638. | 1.4 | 21 |
| 1911 | An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. Expert Opinion on Pharmacotherapy, 2021, 22, 1839-1846. | 0.9 | 0 |
| 1913 | Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. Methods in Molecular Biology, 2019, 1911, 3-32. | 0.4 | 80 |
| 1914 | Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results in Cancer Research, 2021, 217, 107-140. | 1.8 | 2 |
| 1915 | Neue Arzneimittel 2011., 2012., , 43-126. | | 1 |
| 1916 | Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results in Cancer Research, 2014, 193, 113-133. | 1.8 | 16 |
| 1917 | HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. , 2016., , 257-285. | | 1 |
| 1918 | Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. , 2017., , 553-627. | | 2 |
| 1919 | Viruses and Human Cancer. , 2014., , 154-168.e7. | | 1 |
| 1920 | Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. Journal of Clinical Virology, 2020, 124, 104285. | 1.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1921 | The transmissibility of hepatitis C virus: a modelling study in Xiamen City, China. <i>Epidemiology and Infection</i> , 2020, 148, e291. | 1.0 | 5 |
| 1922 | Pyridine-Enabled C–N Bond Activation for the Rapid Construction of Amides and 4-Pyridylglyoxamides by Cooperative Palladium/Copper Catalysis. <i>Journal of Organic Chemistry</i> , 2020, 85, 8045-8054. | 1.7 | 6 |
| 1924 | Hepatitis C Virus. , 0, , 1599-1616. | | 2 |
| 1925 | Chronic hepatitis C therapy: a rare complication revisited. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200514-bcr2013200514. | 0.2 | 6 |
| 1926 | Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report. <i>American Journal of Case Reports</i> , 2019, 20, 1699-1704. | 0.3 | 2 |
| 1927 | Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. <i>F1000Research</i> , 2016, 5, 367. | 0.8 | 11 |
| 1928 | Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010. <i>Universal Journal of Medical Science</i> , 2016, 4, 10-20. | 0.4 | 1 |
| 1929 | Simeprevir for the treatment of genotype 1 chronic hepatitis C virus. <i>Drugs of Today</i> , 2013, 49, 769. | 0.7 | 14 |
| 1930 | Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2011, 6, e26783. | 1.1 | 41 |
| 1931 | Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity. <i>PLoS ONE</i> , 2012, 7, e30796. | 1.1 | 78 |
| 1932 | HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors. <i>PLoS ONE</i> , 2012, 7, e39652. | 1.1 | 78 |
| 1933 | Inhibition of Both Protease and Helicase Activities of Hepatitis C Virus NS3 by an Ethyl Acetate Extract of Marine Sponge <i>Amphimedon</i> sp. <i>PLoS ONE</i> , 2012, 7, e48685. | 1.1 | 7 |
| 1934 | Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. <i>PLoS ONE</i> , 2012, 7, e52048. | 1.1 | 23 |
| 1935 | Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e52158. | 1.1 | 12 |
| 1936 | Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. <i>PLoS ONE</i> , 2013, 8, e55285. | 1.1 | 91 |
| 1937 | Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil. <i>PLoS ONE</i> , 2013, 8, e67734. | 1.1 | 6 |
| 1938 | Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?. <i>PLoS ONE</i> , 2013, 8, e70319. | 1.1 | 21 |
| 1939 | Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e71262. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1940 | Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results. PLoS ONE, 2013, 8, e80528. | 1.1 | 13 |
| 1941 | Inhibitory Effects of Caffeic Acid Phenethyl Ester Derivatives on Replication of Hepatitis C Virus. PLoS ONE, 2013, 8, e82299. | 1.1 | 31 |
| 1942 | HCV Genotypes, Characterization of Mutations Conferring Drug Resistance to Protease Inhibitors, and Risk Factors among Blood Donors in São Paulo, Brazil. PLoS ONE, 2014, 9, e86413. | 1.1 | 30 |
| 1943 | Impact of Donor and Recipient Single Nucleotide Polymorphisms of IL28B rs8099917 in Living Donor Liver Transplantation for Hepatitis C. PLoS ONE, 2014, 9, e90462. | 1.1 | 4 |
| 1944 | Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS ONE, 2014, 9, e94542. | 1.1 | 33 |
| 1945 | Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 6: A Meta-Analysis. PLoS ONE, 2014, 9, e100128. | 1.1 | 14 |
| 1946 | HCV Genome-Wide Genetic Analyses in Context of Disease Progression and Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e103748. | 1.1 | 3 |
| 1947 | Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience. PLoS ONE, 2014, 9, e110284. | 1.1 | 5 |
| 1948 | Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. PLoS ONE, 2014, 9, e110857. | 1.1 | 15 |
| 1949 | Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. PLoS ONE, 2014, 9, e112592. | 1.1 | 20 |
| 1950 | Influence of Genes Suppressing Interferon Effects in Peripheral Blood Mononuclear Cells during Triple Antiviral Therapy for Chronic Hepatitis C. PLoS ONE, 2015, 10, e0118000. | 1.1 | 8 |
| 1951 | Serum Interferon-Related MicroRNAs as Biomarkers to Predict the Response to Interferon Therapy in Chronic Hepatitis C Genotype 4. PLoS ONE, 2015, 10, e0120794. | 1.1 | 14 |
| 1952 | 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLoS ONE, 2015, 10, e0140853. | 1.1 | 2 |
| 1953 | Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. PLoS ONE, 2015, 10, e0141660. | 1.1 | 13 |
| 1954 | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE, 2015, 10, e0144004. | 1.1 | 5 |
| 1955 | Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PLoS ONE, 2016, 11, e0145409. | 1.1 | 6 |
| 1956 | Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PLoS ONE, 2016, 11, e0150299. | 1.1 | 2 |
| 1957 | Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS ONE, 2016, 11, e0156731. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1958 | Drug Pricing Evolution in Hepatitis C. PLoS ONE, 2016, 11, e0157098. | 1.1 | 16 |
| 1959 | Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study. PLoS ONE, 2016, 11, e0159976. | 1.1 | 7 |
| 1960 | Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS ONE, 2016, 11, e0161821. | 1.1 | 8 |
| 1961 | Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands. PLoS ONE, 2016, 11, e0163488. | 1.1 | 38 |
| 1962 | Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS ONE, 2016, 11, e0163884. | 1.1 | 7 |
| 1963 | A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C. PLoS ONE, 2016, 11, e0164563. | 1.1 | 7 |
| 1964 | Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. PLoS ONE, 2016, 11, e0166631. | 1.1 | 5 |
| 1965 | Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PLoS ONE, 2017, 12, e0170667. | 1.1 | 2 |
| 1966 | Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus. PLoS Pathogens, 2016, 12, e1005610. | 2.1 | 71 |
| 1967 | On Chinese and Western Family Trees: Mechanism and Performance. Advances in Distributed Computing and Artificial Intelligence Journal, 2016, 5, 11-22. | 1.1 | 2 |
| 1968 | Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. Journal of Clinical and Translational Hepatology, 2014, 2, 1-6. | 0.7 | 20 |
| 1969 | Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. Journal of Clinical and Translational Hepatology, 2014, 2, 124-33. | 0.7 | 17 |
| 1970 | Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. Journal of Clinical and Translational Hepatology, 2014, 2, 65-73. | 0.7 | 3 |
| 1971 | Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies. Journal of Clinical and Translational Hepatology, 2015, 3, 36-41. | 0.7 | 8 |
| 1972 | Therapeutic Response of Triple Drug Therapy in Hepatitis C Infection. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, . | 0.2 | 1 |
| 1975 | EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION – UNDER REAL LIFE – CONDITIONS. Medicinos Teorija Ir Praktika, 2014, 21, 23-32. | 0.0 | 1 |
| 1976 | HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. , 2017, , 45-66. | | 18 |
| 1977 | Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: A meta-analysis of randomized trials. Revista Espanola De Enfermedades Digestivas, 2015, 107, 591-7. | 0.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1978 | Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1. <i>Journal of Gastroenterology and Hepatology Research</i> , 2014, 3, 1335-1339. | 0.2 | 6 |
| 1979 | The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. <i>Oncotarget</i> , 2017, 8, 41764-41777. | 0.8 | 28 |
| 1980 | Treating hepatitis C "what's new?". <i>Australian Prescriber</i> , 2015, 38, 191-197. | 0.5 | 7 |
| 1981 | Annexin A1 negatively regulates viral RNA replication of hepatitis C virus. <i>Acta Medica Okayama</i> , 2015, 69, 71-8. | 0.1 | 7 |
| 1982 | Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , 2017, 30, 327-343. | 0.4 | 6 |
| 1983 | Safety of Telaprevir for Chronic Hepatitis C Virus Infection. <i>Clinical Drug Investigation</i> , 2012, , 1. | 1.1 | 1 |
| 1984 | Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design. <i>Current Pharmaceutical Design</i> , 2014, 20, 694-703. | 0.9 | 10 |
| 1985 | A Primary Care-based Collaborative Hepatitis C Clinic: Clinical Structure and Virologic Outcomes with Direct Acting Antiviral Therapy. <i>Open Medicine Journal</i> , 2016, 3, 70-78. | 0.5 | 1 |
| 1986 | The Role of Physicians' Attitudes and the Provision of Hepatitis C Virus Treatment to People Who Inject Drugs. <i>Open Medicine Journal</i> , 2016, 3, 104-112. | 0.5 | 2 |
| 1987 | Development of a Flow Cytometry Live Cell Assay for the Screening of Inhibitors of Hepatitis C Virus (HCV) Replication. <i>The Open Virology Journal</i> , 2012, 6, 97-102. | 1.8 | 7 |
| 1988 | "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign. <i>JMIR Research Protocols</i> , 2015, 4, e13. | 0.5 | 6 |
| 1989 | Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia. <i>Revista Colombiana De Gastroenterología</i> , 2014, 29, 424-432. | 0.1 | 2 |
| 1990 | Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C. <i>Jurnal Infektologii</i> , 2019, 11, 65-71. | 0.1 | 1 |
| 1991 | Treatment Guidelines of Hepatitis C. <i>Acta Hepatologica Japonica</i> , 2012, 53, 355-395. | 0.0 | 2 |
| 1992 | Assessing the Population Impact of Published Intervention Studies. <i>NAM Perspectives</i> , 2015, 5, . | 1.3 | 1 |
| 1993 | Evaluation of viral heterogeneity using next-generation sequencing, end-point limiting-dilution and mass spectrometry. <i>In Silico Biology</i> , 2011, 11, 183-92. | 0.4 | 13 |
| 1994 | Current Standards in the Treatment of Chronic Hepatitis C. <i>Deutsches A&#x0308;rztblatt International</i> , 2012, 109, 352-8. | 0.6 | 20 |
| 1995 | Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-410. | 1.3 | 130 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1996 | High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 60. | 4.5 | 8 |
| 1997 | KASL clinical practice guidelines: Management of Hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 89. | 4.5 | 35 |
| 1998 | Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358. | 4.5 | 12 |
| 1999 | Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 259-266. | 4.5 | 8 |
| 2000 | Therapy Implications of Hepatitis C Virus Genetic Diversity. <i>Viruses</i> , 2021, 13, 41. | 1.5 | 32 |
| 2001 | New Antiviral Agents for Hepatitis C. <i>F1000 Biology Reports</i> , 2012, 4, 5. | 4.0 | 30 |
| 2002 | Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 239-253. | 0.6 | 9 |
| 2003 | Current treatment options and response rates in children with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 99. | 1.4 | 41 |
| 2004 | Checkmate to liver biopsy in chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2012, 18, 5514. | 1.4 | 21 |
| 2005 | Current progress in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 6060. | 1.4 | 28 |
| 2006 | Telaprevir/boceprevir era: From bench to bed and back. <i>World Journal of Gastroenterology</i> , 2012, 18, 6183. | 1.4 | 22 |
| 2007 | Factors associated with early virological response to peginterferon- α -2a/ribavirin in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2013, 19, 1943. | 1.4 | 10 |
| 2008 | Sofosbuvir and ABT-450: Terminator of hepatitis C virus?. <i>World Journal of Gastroenterology</i> , 2013, 19, 3199. | 1.4 | 23 |
| 2009 | Prevalence of hepatitis C infection among intravenous drug users in Shanghai. <i>World Journal of Gastroenterology</i> , 2013, 19, 5320. | 1.4 | 10 |
| 2010 | Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2013, 19, 6947. | 1.4 | 11 |
| 2011 | Scotomas in molecular virology and epidemiology of hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2013, 19, 7910. | 1.4 | 10 |
| 2012 | Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. <i>World Journal of Gastroenterology</i> , 2013, 19, 8940. | 1.4 | 33 |
| 2013 | Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8963. | 1.4 | 41 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2014 | Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , 2014, 20, 2839. | 1.4 | 9 |
| 2015 | Chronic hepatitis C genotype 1 virus: Who should wait for treatment?. <i>World Journal of Gastroenterology</i> , 2014, 20, 2867. | 1.4 | 6 |
| 2016 | Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. <i>World Journal of Gastroenterology</i> , 2014, 20, 2913. | 1.4 | 28 |
| 2017 | How hepatitis C virus invades hepatocytes: The mystery of viral entry. <i>World Journal of Gastroenterology</i> , 2014, 20, 3457. | 1.4 | 51 |
| 2018 | Emerging therapeutic options for the management of hepatitis C infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 7079. | 1.4 | 10 |
| 2019 | Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C. <i>World Journal of Gastroenterology</i> , 2014, 20, 7505. | 1.4 | 7 |
| 2020 | Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. <i>World Journal of Gastroenterology</i> , 2014, 20, 9245-52. | 1.4 | 10 |
| 2021 | Recurrent hepatitis C after liver transplant. <i>World Journal of Gastroenterology</i> , 2014, 20, 10668. | 1.4 | 17 |
| 2022 | Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 10984. | 1.4 | 20 |
| 2023 | Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 12722. | 1.4 | 24 |
| 2024 | <i>IL28B</i> polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 13146. | 1.4 | 20 |
| 2025 | New treatments for chronic hepatitis C: An overview for paediatricians. <i>World Journal of Gastroenterology</i> , 2014, 20, 15965. | 1.4 | 14 |
| 2026 | Management of recurrent hepatitis C virus after liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 16409. | 1.4 | 15 |
| 2027 | Management of hepatitis C in patients with chronic kidney disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 408. | 1.4 | 33 |
| 2028 | Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 10215-10223. | 1.4 | 8 |
| 2029 | Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. <i>World Journal of Gastroenterology</i> , 2015, 21, 10749. | 1.4 | 23 |
| 2030 | Impact of new treatment options for hepatitis C virus infection in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 10760. | 1.4 | 24 |
| 2031 | Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. <i>World Journal of Gastroenterology</i> , 2015, 21, 12430. | 1.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2032 | Retreatment with peginterferon and ribavirin in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 1994. | 1.4 | 2 |
| 2033 | Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. <i>World Journal of Gastroenterology</i> , 2016, 22, 3418-3431. | 1.4 | 17 |
| 2034 | Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2016, 22, 1393. | 1.4 | 24 |
| 2035 | Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model. <i>World Journal of Gastroenterology</i> , 2017, 23, 5158. | 1.4 | 3 |
| 2036 | Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. <i>World Journal of Gastroenterology</i> , 2017, 23, 8120-8127. | 1.4 | 6 |
| 2037 | Mononuclear phagocyte system in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2018, 24, 4962-4973. | 1.4 | 10 |
| 2038 | Exploring the hepatitis C virus genome using single molecule real-time sequencing. <i>World Journal of Gastroenterology</i> , 2019, 25, 4661-4672. | 1.4 | 11 |
| 2039 | Liver-related effects of chronic hepatitis C antiviral treatment. <i>World Journal of Gastroenterology</i> , 2020, 26, 2931-2947. | 1.4 | 11 |
| 2040 | Protease inhibitors: Silver bullets for chronic hepatitis C infection?. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 213-222. | 0.6 | 22 |
| 2041 | Hepatitis C virus: Here comes all-oral treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 159-172. | 0.6 | 21 |
| 2042 | Interferon-Induced Depression in Chronic Hepatitis C. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1128-1138. | 1.1 | 264 |
| 2043 | Telaprevir. <i>Journal of Postgraduate Medicine</i> , 2013, 59, 42-47. | 0.2 | 10 |
| 2044 | The new era of hepatitis C virus therapy. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 345. | 0.5 | 2 |
| 2045 | SASLT guidelines: Update in treatment of Hepatitis C virus infection. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 25. | 0.5 | 21 |
| 2046 | Hepatitis C virus infection and insulin resistance. <i>World Journal of Diabetes</i> , 2014, 5, 52. | 1.3 | 85 |
| 2047 | Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2013, 5, 332. | 0.8 | 2 |
| 2048 | Hepatitis C virus infection, microRNA and liver disease progression. <i>World Journal of Hepatology</i> , 2013, 5, 479. | 0.8 | 58 |
| 2049 | Complementary and alternative medications in hepatitis C infection. <i>World Journal of Hepatology</i> , 2014, 6, 9. | 0.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2050 | NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. <i>World Journal of Hepatology</i> , 2014, 6, 326. | 0.8 | 9 |
| 2051 | Treatment of chronic hepatitis C in liver transplant candidates and recipients: <i>Where do we stand?</i> . <i>World Journal of Hepatology</i> , 2015, 7, 1606. | 0.8 | 3 |
| 2052 | Predictive factors associated with hepatitis C antiviral therapy response. <i>World Journal of Hepatology</i> , 2015, 7, 1617. | 0.8 | 71 |
| 2053 | Era of direct acting antivirals in chronic hepatitis C: <i>Who will benefit?</i> . <i>World Journal of Hepatology</i> , 2015, 7, 2543. | 0.8 | 11 |
| 2054 | Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. <i>World Journal of Hepatology</i> , 2015, 7, 2681. | 0.8 | 12 |
| 2055 | Comparison of peg-interferon, ribavirin plus telaprevir/simeprevir by propensity score matching. <i>World Journal of Hepatology</i> , 2015, 7, 2841. | 0.8 | 5 |
| 2056 | Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. <i>World Journal of Hepatology</i> , 2015, 7, 616. | 0.8 | 28 |
| 2057 | Hepatitis C virus: <i>Is it time to say goodbye yet?</i> Perspectives and challenges for the next decade. <i>World Journal of Hepatology</i> , 2015, 7, 725. | 0.8 | 47 |
| 2058 | Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. <i>World Journal of Hepatology</i> , 2015, 7, 806. | 0.8 | 50 |
| 2059 | Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. <i>World Journal of Hepatology</i> , 2015, 7, 1133. | 0.8 | 24 |
| 2060 | Chronic hepatitis C: This and the new era of treatment. <i>World Journal of Hepatology</i> , 2016, 8, 92. | 0.8 | 69 |
| 2061 | Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. <i>World Journal of Hepatology</i> , 2016, 8, 902. | 0.8 | 5 |
| 2062 | Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. <i>World Journal of Hepatology</i> , 2016, 8, 949. | 0.8 | 5 |
| 2063 | Sofosbuvir treatment and hepatitis C virus infection. <i>World Journal of Hepatology</i> , 2016, 8, 183. | 0.8 | 15 |
| 2064 | Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. <i>World Journal of Hepatology</i> , 2017, 9, 551. | 0.8 | 2 |
| 2065 | Is the 25-year hepatitis C marathon coming to an end to declare victory?. <i>World Journal of Hepatology</i> , 2017, 9, 921. | 0.8 | 6 |
| 2066 | Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 252. | 0.8 | 2 |
| 2067 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 352. | 0.8 | 50 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2068 | Interferons and hepatitis C virus. <i>Swiss Medical Weekly</i> , 2012, 142, w13586. | 0.8 | 23 |
| 2069 | Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection. <i>Swiss Medical Weekly</i> , 2013, 143, w13793. | 0.8 | 23 |
| 2070 | Emerging Therapies for Hepatitis C. <i>Gut and Liver</i> , 2014, 8, 471-479. | 1.4 | 34 |
| 2071 | Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. <i>Gut and Liver</i> , 2017, 11, 335-348. | 1.4 | 16 |
| 2072 | Hepatitis C Virus and Antiviral Drug Resistance. <i>Gut and Liver</i> , 2016, 10, 890-895. | 1.4 | 24 |
| 2073 | Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. <i>Gut and Liver</i> , 2017, 11, 711-720. | 1.4 | 6 |
| 2074 | Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. <i>Gut and Liver</i> , 2018, 12, 694-703. | 1.4 | 18 |
| 2075 | Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. <i>Balkan Medical Journal</i> , 2015, 32, 266-272. | 0.3 | 7 |
| 2076 | Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?. <i>Turkish Journal of Gastroenterology</i> , 2016, 27, 165-172. | 0.4 | 1 |
| 2077 | Role of IL28B genotype in older hepatitis C virus-infected patients. <i>World Journal of Immunology</i> , 2013, 3, 54. | 0.5 | 3 |
| 2078 | What's new in clinical solid organ transplantation by 2013. <i>World Journal of Transplantation</i> , 2014, 4, 243. | 0.6 | 19 |
| 2079 | Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. <i>World Journal of Virology</i> , 2015, 4, 1. | 1.3 | 22 |
| 2080 | Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. <i>World Journal of Virology</i> , 2015, 4, 178. | 1.3 | 4 |
| 2081 | The changing therapeutic landscape for hepatitis C. <i>Medical Journal of Australia</i> , 2012, 196, 629-632. | 0.8 | 64 |
| 2082 | Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis. <i>Hepatitis Monthly</i> , 2014, 14, e16632. | 0.1 | 6 |
| 2083 | Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy. <i>Hepatitis Monthly</i> , 2015, 15, e28879. | 0.1 | 2 |
| 2084 | Hepatitis C Virus Treatment Revolution: Eastern European Story. <i>Hepatitis Monthly</i> , 2015, 15, e28969. | 0.1 | 9 |
| 2085 | Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. <i>Clinics</i> , 2017, 72, 378-385. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2086 | A Review of the Natural History of Chronic Hepatitis C Infection. North American Journal of Medicine & Science, 2014, 07, 001. | 3.8 | 7 |
| 2087 | Chronic Hepatitis C. , 2022, , 163-201. | | 0 |
| 2089 | Clinical Aspects of Liver Transplantation. , 2011, , 577-598. | | 0 |
| 2090 | Pathology of Liver Transplantation. , 2011, , 599-630. | | 0 |
| 2091 | Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C. Journal of the Nepal Medical Association, 2013, 51, . | 0.1 | 1 |
| 2092 | Treating Chronic HCV Without Interferon and/or Ribavirin. , 2012, , 261-269. | | 0 |
| 2096 | Viral Liver Diseases. , 2012, , 383-390. | | 0 |
| 2097 | Drug interaction (25. drug interaction of Telaprevir, a C-type viral hepatitis drug). Okayama Igakkai Zasshi, 2012, 124, 259-263. | 0.0 | 0 |
| 2098 | Treatment of chronic hepatitis C. Journal of the Korean Medical Association, 2012, 55, 1113. | 0.1 | 1 |
| 2099 | Hepatitis C therapy: now more than a coin toss to achieve the cure. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2012, , . | 0.8 | 0 |
| 2104 | Therapie der chronischen Hepatitis C. Pharma-Kritik (discontinued), 2012, 34, . | 0.0 | 0 |
| 2105 | Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction. Acta Hepatologica Japonica, 2013, 54, 731-740. | 0.0 | 0 |
| 2106 | Targeting Viral and Host Factors During the Hepatitis C Virus Replication for Efficient Antiviral Treatment. Immuno-gastroenterology, 2013, 2, 162. | 0.4 | 0 |
| 2109 | Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. Gastroenterology Research, 2013, 6, 161-170. | 0.4 | 10 |
| 2111 | Leber, Gallenwege, Pankreas. , 2013, , 144-169. | | 0 |
| 2113 | Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population. Journal of Virology & Antiviral Research, 2013, 02, . | 0.1 | 0 |
| 2118 | Management algorithm for genotype 1 hepatitis C virus. F1000prime Reports, 2013, 5, 24. | 5.9 | 1 |
| 2119 | Retransplantation for HCV-Related Liver Disease. , 2014, , 95-106. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2120 | Treatment of Hepatitis C Before Liver Transplantation. , 2014, , 1-14. | | 0 |
| 2121 | Hepatitis C and Liver Transplantation in the HIV Co-infected Patients. , 2014, , 65-76. | | 0 |
| 2122 | Treatment of Hepatitis C After Liver Transplantation. , 2014, , 45-63. | | 0 |
| 2123 | Recent Advancement in the Treatment of Chronic Hepatitis C. Korean Journal of Medicine, 2014, 86, 563. | 0.1 | 0 |
| 2124 | Real-World Virologic Response Rates and Prediction of Outcomes with Peginterferon Alfa-2a/Ribavirin in Hungarian HCV Genotype 1 Patients. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, . | 0.2 | 0 |
| 2125 | Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions. North American Journal of Medicine & Science, 2014, 07, 033. | 3.8 | 0 |
| 2126 | Prevention and Management of Infectious Complications in Kidney Transplant Recipients. , 2014, , 301-318. | | 1 |
| 2127 | Hepatitis Viruses: Hepatitis C. , 2014, , 765-783. | | 0 |
| 2128 | Liver Disease among Renal Transplant Recipients. , 2014, , 511-536. | | 0 |
| 2130 | Developments in the treatment of hepatitis C virus infection. , 2014, , 135-144. | | 0 |
| 2131 | Management of Hepatitis C in the Pre- and Post-Transplant Setting: Then and Now. Gastroenterology & Hepatology (Bartlesville, Okla), 2014, 1, . | 0.0 | 0 |
| 2132 | IL28B Genotyping: A Step towards HCV-Personalized Therapy. International Journal of Gastroenterology Research and Practice, 0, , 1-16. | 0.0 | 0 |
| 2133 | D'opister hors les murs d'™un centre de d'opistage: une exp'rience mobilisatrice pour des usagers de drogues. Sante Publique, 2015, Vol. 27, 633-639. | 0.0 | 0 |
| 2135 | Antiviral Drugs against Hepatitis Viruses. , 2015, , 563-575.e3. | | 0 |
| 2136 | Chronische Hepatitis. , 2015, , 1-10. | | 0 |
| 2137 | Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World Journal of Hepatology, 2015, 7, 2688. | 0.8 | 0 |
| 2138 | Indications for Liver Transplantation. , 2015, , 97-125. | | 1 |
| 2139 | Protease Inhibitor Resistance. , 2015, , 1-17. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2140 | Telaprevir-related DRESS syndrome complicating hepatitis C treatment. <i>Journal of Microbiology and Infectious Diseases</i> , 2015, 5, . | 0.1 | 1 |
| 2141 | Solid Organ Transplantation. , 2015, , 433-454. | | 1 |
| 2142 | HEPATITIS C VIRUS AND HEPATITIS C-INFECTION. <i>Brazilian Journal of Medicine and Human Health</i> , 2015, 3, 19-28. | 0.0 | 0 |
| 2143 | The Effect on Gastric Emptying of Telaprevir-Based Triple Therapy for Chronic Hepatitis C Patients. , 0, , 009-013. | | 0 |
| 2145 | Estradiol and/or Ibandronate Therapy Ameliorates A Case Series Describing the Outcomes of Treatment in Co-infected Patients with HIV and Hepatitis C on the United States-Mexico Border. <i>British Journal of Medicine and Medical Research</i> , 2016, 15, 1-7. | 0.2 | 0 |
| 2146 | Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. <i>Journal of Postgraduate Medicine</i> , 2016, 62, 20-25. | 0.2 | 0 |
| 2147 | Analysis of Erythrocyte Elements in Chronic Hepatitis C Patients Receiving PegIFN Monotherapy, Dual Therapy, and Triple Therapy using in-air MicroPIXE. <i>Kitakanto Medical Journal</i> , 2016, 66, 91-102. | 0.0 | 0 |
| 2148 | Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000248. | 0.2 | 0 |
| 2149 | Situation actuelle et perspectives du dÃ©pistage et du traitement curatif des hÃ©patites B et C en France. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2016, 200, 47-58. | 0.0 | 1 |
| 2150 | Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 5-11. | 0.7 | 0 |
| 2151 | Evaluation of serum iron and ferritin in different treatment regimens for chronic hepatitis C virus. <i>IOSR Journal of Pharmacy and Biological Sciences</i> , 2016, 11, 13-19. | 0.1 | 1 |
| 2152 | Chronic Hepatitis B, C, and D. , 0, , 69-95. | | 0 |
| 2153 | Prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for estimation of efficiency of therapy with the use of pegylated interferon a-2 and ribavarin in patients with chronic genotype 1 hepatitis C. <i>Klinicheskaia Meditsina</i> , 2016, 94, 224-230. | 0.2 | 1 |
| 2154 | Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. <i>Open Medicine Journal</i> , 2016, 3, 58-69. | 0.5 | 0 |
| 2155 | Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini Review. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 228-233. | 0.7 | 1 |
| 2156 | "All-oral Treatment with Daclatasvir and Asunaprevir for HCV Genotype 1 and Impact of Add-on Therapy with Lipid Modulators". <i>Advanced Research in Gastroenterology & Hepatology</i> , 2016, 2, . | 0.1 | 0 |
| 2157 | Resistance to Cyclophilin Inhibitors. , 2017, , 59-85. | | 0 |
| 2158 | Quasispecies and Drug Resistance. , 2017, , 123-147. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2159 | Molecular Evolution of Hepatitis C Virus: From Epidemiology to Antiviral Therapy (Current Research) Tj ETQq0 0 0 rgBT /Overlgck 10 Tf 5 | | |
| 2160 | Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients. ARS Medica Tomitana, 2017, 23, 47-52. | 0.0 | 0 |
| 2161 | The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. Journal of Clinical and Translational Hepatology, 2017, 5, 59-66. | 0.7 | 14 |
| 2163 | Chronic Viral Hepatitis. , 2017, , . | | 0 |
| 2164 | Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon in Management of Egyptian Chronic Hepatitis C Patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2017, 7, 155-158. | 0.1 | 0 |
| 2165 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World Journal of Virology, 2017, 6, 59-72. | 1.3 | 7 |
| 2166 | The Curative HCV Treatments in China. Journal of Biosciences and Medicines, 2018, 06, 42-59. | 0.1 | 0 |
| 2167 | Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Experimental and Clinical Transplantation, 2018, 16, 182-190. | 0.2 | 2 |
| 2168 | Scientific and Ethical Considerations for Increasing Minority Participation in Clinical Trials. , 0, , . | | 0 |
| 2169 | GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo. Acta Pharmacologica Sinica, 2018, 39, 1746-1752. | 2.8 | 2 |
| 2170 | Antiviral therapy of hepatitis C with 1 genotype after liver transplantation. Vestnik Transplantologii I Iskusstvennykh Organov, 2018, 20, 105-115. | 0.1 | 0 |
| 2172 | Detrimental Impact of Interferon-Based Regimens for Chronic Hepatitis C on Vitamin D/Parathyroid Hormone Homeostasis. Open Rheumatology Journal, 2018, 12, 279-288. | 0.1 | 1 |
| 2173 | Hepatitis C Virus and Innate Interferon Response: Pathogen Biology, Drug Resistance, Novel Drug Targets, and Therapeutic Strategies. , 2019, , 233-249. | | 0 |
| 2174 | Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C " The TEPS Study. Russian Journal of Gastroenterology Hepatology Coloproctology, 2019, 28, 15-26. | 0.2 | 0 |
| 2175 | Management of Viral Hepatitis C in Children. , 2019, , 163-168. | | 0 |
| 2176 | Planning a Programme of Pre-authorisation Clinical Trials of Medicines for the Treatment of Chronic Hepatitis C. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2019, 9, 6-13. | 0.1 | 1 |
| 2177 | Actualizaci3n en el tratamiento de la coinfecci3n por VIH y VHC en pacientes adultos. Revista De Investigaci3n Y Educaci3n En Ciencias De La Salud (RIECS), 2019, 4, 71-83. | 0.0 | 0 |
| 2179 | Ruptured hepatocellular carcinoma in a patient with chronic hepatitis C and a sustained viral response. Akademik Gastroenteroloji Dergisi, 0, , 1-1. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2180 | Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. <i>Cadernos De Saude Publica</i> , 2020, 36, e00036619. | 0.4 | 0 |
| 2181 | Physicochemical characterization of ribavirin with spectroscopy and molecular modeling. <i>AIP Conference Proceedings</i> , 2020, . . | 0.3 | 1 |
| 2182 | Syntheses and Binding Testing of N1-Alkylamino-Substituted 2-Aminobenzimidazole Analogues Targeting the Hepatitis C Virus Internal Ribosome Entry Site. <i>Australian Journal of Chemistry</i> , 2020, 73, 212. | 0.5 | 0 |
| 2183 | Diagnosis and management of telaprevir-associated rash. <i>Gastroenterology and Hepatology</i> , 2011, 7, 469-71. | 0.2 | 4 |
| 2184 | Hepatitis C virus treatment complicated by rheumatoid arthritis. <i>Gastroenterology and Hepatology</i> , 2011, 7, 774-6. | 0.2 | 0 |
| 2185 | Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex. <i>Biotechnology Healthcare</i> , 2011, 8, 26-8. | 0.2 | 1 |
| 2186 | Advances in the treatment of hepatitis C virus infection. <i>Gastroenterology and Hepatology</i> , 2012, 8, 91-101. | 0.2 | 8 |
| 2187 | Management of anemia in patients receiving protease inhibitors. <i>Gastroenterology and Hepatology</i> , 2012, 8, 254-6. | 0.2 | 1 |
| 2188 | Hepatitis C virus infection and nonalcoholic steatohepatitis. <i>Gastroenterology and Hepatology</i> , 2012, 8, 305-12. | 0.2 | 23 |
| 2189 | Anemia management in the era of triple combination therapy for chronic HCV. <i>Gastroenterology and Hepatology</i> , 2012, 8, 1-16. | 0.2 | 9 |
| 2190 | Hepatitis C virus and its renal manifestations: a review and update. <i>Gastroenterology and Hepatology</i> , 2012, 8, 434-45. | 0.2 | 25 |
| 2192 | New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2013, 72, 6-13. | 0.4 | 4 |
| 2193 | The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents. <i>European Gastroenterology & Hepatology Review</i> , 2012, 1, 33-39. | 0.0 | 2 |
| 2194 | Recurrence of hepatitis C after liver transplantation. <i>Annals of Gastroenterology</i> , 2013, 26, 304-313. | 0.4 | 38 |
| 2195 | Direct-acting antiviral agents in patients with hepatitis C cirrhosis. <i>Gastroenterology and Hepatology</i> , 2012, 8, 727-65. | 0.2 | 4 |
| 2196 | Protease inhibitor-based therapy for hepatitis C virus infection-why wait?. <i>Gastroenterology and Hepatology</i> , 2012, 8, 674-6. | 0.2 | 0 |
| 2197 | Management of anorectal symptoms associated with telaprevir. <i>Gastroenterology and Hepatology</i> , 2012, 8, 839-40. | 0.2 | 0 |
| 2198 | Syphilis negatively influences the response to hepatitis C virus treatment in an HIV-infected patient. <i>Topics in Antiviral Medicine</i> , 2012, 20, 134-8. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2199 | Frontiers in the treatment of hepatitis C virus infection. <i>Gastroenterology and Hepatology</i> , 2014, 10, 90-100. | 0.2 | 7 |
| 2200 | HCV infection treatment: a future full of hope. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, 1-5. A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL | 0.6 | 65 |
| 2201 | 2012: The 47th Annual Meeting of the European Association for the Study of the Liver April 18-22, 2012 – Barcelona, Spain Special Reporting on: Safety of Telaprevir or Boceprevir in Combination with Peginterferon α 2/Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS C020-CUPIC) SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Re-treatment with Bocepre. <i>Gastroenterology and Hepatology</i> , 2012, 8, 1-20. | 0.2 | 21 |
| 2202 | Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. <i>P and T</i> , 2014, 39, 345-52. | 1.0 | 12 |
| 2206 | Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. <i>Annals of Gastroenterology</i> , 2015, 28, 55-65. | 0.4 | 39 |
| 2207 | Hepatitis C screening. <i>Ochsner Journal</i> , 2014, 14, 664-8. | 0.5 | 13 |
| 2210 | Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. <i>P and T</i> , 2015, 40, 256-76. | 1.0 | 40 |
| 2211 | Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics. <i>Annals of Hepatology</i> , 2015, 14, 234-42. | 0.6 | 11 |
| 2213 | Is response-guided therapy being applied in the clinical setting? The hepatitis C example. <i>American Health and Drug Benefits</i> , 2015, 8, 22-8. | 0.5 | 2 |
| 2215 | Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. <i>International Journal of Organ Transplantation Medicine</i> , 2016, 7, 38-45. | 0.5 | 19 |
| 2216 | Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Mono-infection Treatment. <i>Gastroenterology and Hepatology</i> , 2014, 10, 706-715. | 0.2 | 0 |
| 2217 | Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. <i>Topics in Antiviral Medicine</i> , 2014, 22, 685-9. | 0.1 | 1 |
| 2218 | Complications of HIV disease and antiretroviral therapy. <i>Topics in Antiviral Medicine</i> , 2012, 20, 48-60. | 0.1 | 10 |
| 2219 | Update of the past year: a review from IDSA 2011. <i>Topics in Antiviral Medicine</i> , 2011, 19, 187-92. | 0.1 | 1 |
| 2220 | Managing adverse effects and complications in completing treatment for hepatitis C virus infection. <i>Topics in Antiviral Medicine</i> , 2012, 20, 125-8. | 0.1 | 11 |
| 2221 | The history of the Department of Internal Medicine at Saint Louis University. <i>Missouri Medicine</i> , 2012, 109, 115-8. | 0.3 | 0 |
| 2222 | Advances in the treatment of hepatitis C virus infection. <i>Topics in Antiviral Medicine</i> , 2012, 20, 5-10. | 0.1 | 26 |
| 2223 | Hepatitis C virus therapeutics: at the end of the beginning. <i>Topics in Antiviral Medicine</i> , 2012, 20, 17-9. | 0.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2224 | Changing Treatment Landscape of Hepatitis C Virus Infection Among Penitentiary Inmates. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 14S-17S. | 0.6 | 0 |
| 2225 | Management of Hepatitis C in Patients With HIV. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 15S-19S. | 0.6 | 0 |
| 2226 | Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon- α 2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Iranian Journal of Public Health, 2018, 47, 1845-1853. | 0.3 | 1 |
| 2227 | Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. Gastroenterology and Hepatology, 2018, 14, 687-705. | 0.2 | 2 |
| 2228 | Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastro-Enterologica Belgica, 2021, 84, 633-652. | 0.4 | 10 |
| 2230 | Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14. | 1.9 | 9 |
| 2231 | Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy. Journal of Infection and Public Health, 2022, 15, 277-281. | 1.9 | 5 |
| 2232 | Present and future management of viral hepatitis. World Journal of Gastroenterology, 2021, 27, 8081-8102. | 1.4 | 2 |
| 2233 | Reusable Cu ²⁺ -xS-modified masks with infrared lamp-driven antibacterial and antiviral activity for real-time personal protection. Chemical Engineering Journal, 2022, 441, 136043. | 6.6 | 13 |
| 2239 | Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor. Acta Medica Okayama, 2014, 68, 17-22. | 0.1 | 7 |
| 2249 | PEG-Interferon- α 2b ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study. Farmacia Hospitalaria, 2015, 39, 29-43. | 0.6 | 1 |
| 2250 | Gestion des effets secondaires de la trithérapie en pratique libérale. HEGEL - HEpato-GastroEntérologie Libérale, 2012, N° 4, 27-29. | 0.0 | 0 |
| 2251 | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. World Journal of Hepatology, 2022, 14, 985-992. | 0.8 | 0 |
| 2252 | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. World Journal of Hepatology, 2022, 14, 984-991. | 0.8 | 1 |
| 2253 | Breakthroughs in hepatitis C research: from discovery to cure. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 533-550. | 8.2 | 62 |
| 2254 | Hepatitis C "Cure and Prevention. Annals of the Academy of Medicine, Singapore, 2014, 43, 341-342. | 0.2 | 0 |
| 2255 | Treatment of Hepatitis C Virus Prior to Posterior Lumbar Fusion. Clinical Spine Surgery, 0, Publish Ahead of Print, . | 0.7 | 0 |
| 2257 | Natural inhibitors of SARS-CoV-2 main protease: structure based pharmacophore modeling, molecular docking and molecular dynamic simulation studies. Journal of Molecular Modeling, 2022, 28, . | 0.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2258 | Applications of covalent chemistry in targeted protein degradation. <i>Chemical Society Reviews</i> , 2022, 51, 9243-9261. | 18.7 | 14 |
| 2259 | The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2023, 12, . | 0.8 | 1 |
| 2260 | Hepatitis C: epidemiology, natural history, and diagnosis. , 2023, , 229-250. | | 0 |
| 2261 | Chronic Hepatitis C. <i>Medical Clinics of North America</i> , 2023, 107, 423-433. | 1.1 | 3 |
| 2262 | Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 0, 29, 949-966. | 1.4 | 3 |
| 2263 | Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , . | 1.4 | 0 |
| 2264 | Hepatitis C: treatment. , 2023, , 251-279. | | 0 |
| 2266 | Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study. <i>Balkan Medical Journal</i> , 0, , . | 0.3 | 1 |